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Introduction
1. Hematopoiesis
Hematopoiesis, or blood cell formation, is the process in which a limited set of
hematopoietic stem cells is able to give rise to all types of functional blood cells
via commitment to specific hematopoietic lineages (Figure 1.1). The majority of
the stem cells are quiescent, leaving only a small population of actively cycling
hematopoietic stem cells (181). When a stem cell divides, it again generates a
stem cell, a proces called self-renewal, and a cell that is committed to develop
into either a myeloid or lymphoid restricted stem cell (120). Differentiation is the
process in which a hematopoietic stem cell matures into a functional blood cell.
This process is irreversible and the more differentiated a progenitor cell is, the
less blood cells it can produce (175). Blood cells can be classified into three
groups. Red cells, or erythrocytes, which constitute about 45% of the blood
volume. They are responsible for transport of oxygen (O2) from the lungs
throughout the organism, and of CO2 from the tissues to the lungs. Platelets,
which are important in blood clotting, constitute 0.1 % of the blood volume
whereas white blood cells have a role in defense against infections and
constitute less than 0.1% of the total blood volume. 
During murine embryonic development, hematopoiesis starts in the
blood islands of the yolk sac 7-11 days post coitum (69). Yolk sac hematopoiesis
is referred to as primitive hematopoiesis. It is believed that definitive
erythropoiesis starts in the aorta-gonad-mesonephros region (AGM-region),
where the first definitive hematopoietic stem cells develop (55, 68, 171, 200).
From the AGM, the hematopoietic stem cells migrate to the fetal liver and to a
lesser extent to the fetal spleen, where definitive hematopoiesis continues at
about day 11 of development. In neonates, hematopoiesis is finally established
in the bone marrow. Hematopoiesis is a tightly regulated process that has to
respond and adjust to a variety of conditions such as blood cell turnover, infection
and blood loss (168, 174, 175). Hematopoiesis is regulated by a variety of factors
presented by stromal cells or present in the extracellular matrix. However,
regulation by hematopoietic growth factors is a dominant and certainly the best
studied aspect of hematopoiesis.
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Figure 1.1. Schematic picture of hematopoiesis. Stem cells are capable of self-renewal and differentiation. Upon
differentiation into the common myeloid or lymphoid progenitor the self-renewal capability is lost. During
hematopoiesis differentiation is assumed to be irreversible. Via distinct progenitor stages, multipotent progenitor
cells differentiate in mature, fuctional blood cells. Differentiation into the separated hematopoietic lineages requires
the presence of certain hematopoietic growth factors and cytokines. SCF (Stem cell factor), IL3 (Interleukin 3), FT3L
(Fms-like tyrosine kinase-3 ligand), Epo (erythropoietin), GM-CSF (granulocyte/macrophage-colony stimulating
factor), G-CSF (granulocyte -colony stimulating factor), M-CSF (macrophage-colony stimulating factor), TPO
(thrombopoietin), CFU-GEMM (colony forming unit-granulocyte-erythroid-monocyte-megakaryocyte), CFU-Bas
(colony forming unit-basophilic granulocyte), CFU-Mast (colony forming unit-mast cell), CFU-Eo(colony forming
unit-eosinophilic-granulocyte), BFU-MK (burst forming unit-megakaryocyte), BFU-E (burst forming unit-erythroid).
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1.1. Regulation of Hematopoiesis by hematopoietic growth factors
Many extrinsic and intrinsic factors determine lineage commitment, expansion
and survival of hematopoietic stem cells. Two models have been proposed for
regulation of hematopoiesis. The stochastic model (267, 288) implies that
commitment is a random process in which growth factors only determine the
outgrowth of certain committed progenitors. The instructive model claims a
deterministic role in lineage commitment for extracellular factors, such as
hematopoietic growth factors (270, 282). For example, certain transcription
factors which determine commitment of hematopoietic stem cells, are regulated
by growth factors (326). Although additional research is needed to address the
validity of these models in its full scope, hematopoietic growth factors such as
cytokines are of great importance for regulation of the differentiation process (60,
266). Hematopoietic growth factors are produced by stromal cells in the bone
marrow and by monocytes, macrophages, endothelial cells, and various organs
such as the pancreas, kidney and liver. In general, the receptors for the
hematopoietic growth factors can be classified in two groups: the tyrosine kinase
family with an intrinsic kinase domain (276), and the cytokine family lacking an
intrinsic kinase domain (44). Members of the latter family couple to the Janus
kinase family members, which phosphorylate the receptor and downstream
targets (113).  
As shown in Figure 1.1, certain growth factors and cytokines have a
broad target cell specificity and act on a wide variety of hematopoietic progenitor
cells, including multilineage progenitors. Examples of this category are stem cell
factor (SCF; 169), Interleukin-3 (IL-3; 162), and Fms-like tyrosine kinase-3 ligand
(FLT3-L; 229). The target cell spectrum of other growth factors is more restricted.
They regulate the proliferation and differentiation of particular, committed subsets
of hematopoietic cells only, as exemplified by erythropoietin (Epo; 98, 106, 141),
thrombopoietin (TPO; 166), and granulocyte-colony stimulating factor (G-CSF;
59). Hematopoietic growth factors may also act in concert to support proliferation
of a certain hematopoietic cells. For example, SCF cooperates with GM-CSF, G-
CSF, IL-3 or Epo to stimulate the proliferation of myeloid and erythroid progenitor
cells (169). In addition, a series of growth inhibiting  factors have been described.
Examples of cytokines with a negative effect on growth are transforming-growth
factor-β (124, 125), and tumor necrosis factor-α (29).
1.2. Regulation of hematopoiesis by transcription factors
Transcription factors are important intrinsic factors that regulate hematopoiesis.
This is shown by the fact that deregulation of the transcription factors PU-1,
GATA-1, AML-1 or C/EBPα contributes to development of human acute myeloid
leukemia (259). Transcription factors in the hematopoietic system can be
classified in two categories: (1) general factors, which play a role in multiple
hematopoietic lineages and mostly in multipotent progenitors, e.g. GATA-2 (273),
AML-1 (196), or SCL (223), and (2) specific transcription factors, which are
expressed in distinct lineages, such as PAX5, involved in early B-cell
development (194), and erythroid Krüppel-like factor, involved in erythroid
development (193). Except for lineage specific gene expression, some lineage-
specific transcription factors play a deterministic role in lineage commitment. A
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typical example is GATA-1. This factor is required for erythroid and
megakaryocytic differentiation (189, 241, 292) and has been shown to regulate
lineage commitment at two different levels. First, the ratio GATA-1 versus PU-1,
a transcription factor required for development of early multipotent myeloid
progenitors (30, 57), determines development of the myeloid progenitor into
either the myeloid or the erythroid lineage. Second, differential binding to friend
of GATA (FOG) to GATA-1 regulates megakaryocytic versus erythroid
commitment (37). A similar role in lineage choice has been proposed for C/EBPα
and PU-1 in granulocytic/macrophage progenitors (215, 218).
These examples highlight the importance of transcriptional regulation in
normal hematopoietic development. Interestingly, a category of transcription
factors is regulated by hematopoietic growth factors. Because hematopoietic
growth factors are dominant in the regulation of hematopoiesis, they may exert
their function at least in part through transcriptional interference.
1.3. Signaling regulated gene expression
Transcription factors and growth factors act in concert to determine commitment,
expansion, survival and differentiation of hematopoietic cells. Several classes of
transcription factors have been described that integrate growth factor signaling
with regulation of gene transcription in the hematopoietic system. By doing so,
signaling regulated transcription factors change the gene expression profile to
allow adaptation of a certain hematopoietic cell to its environment. This group of
transcription factors comprises Signal transducers and activator of transcription
(Stats), Forkhead box containing transcription factors sub class O (Foxo), cAMP
response element binding proteins and the NFκB family. Stats are activated upon
cytokine induction via Janus kinases (128), and mice lacking Stat5a and Sta5b
suffer from severe anemia during fetal liver erythropoiesis (46, 245). Foxo family
members are inactivated upon cytokine or growth factor treatment via direct
phosphorylation by protein kinase B (PKB; 30).
2. Erythropoiesis
Erythropoiesis is the process by which erythrocytes are produced. As outlined in
Figure 1.1, the earliest known progenitor cell with the potential to form
erythrocytes, the CFUGEMM, originates from the common, multipotent progenitor
cell, and differentiates via multiple intermediate stages (BFUE, CFUE, see below)
into a functional erythrocyte.
2.1. Erythroid development 
Progenitors can be measured by various in vivo and in vitro methods. Often used
in vivo tests are the colony forming unit-spleen assay (CFUS) and repopulation
assays, whereas colony cultures in semi-solid medium, liquid cultures, flow
cytometry and cytology represent commonly used in vitro tests. These methods
have been used to study the multipotency and the proliferative capacity of
erythroid progenitor cells and have contributed to the identification of discrete
stages of erythroid development. The in vivo colony forming Unit-spleen assay
(CFUS) was for a long time the leading assay for studying stem cells (265). In this
assay, bone marrow progenitor cells that are transplanted in irradiated mice
Chapter 1
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produce colonies on the surface of the mouse spleen 7 to 13 days after
transplantation. The assay identifies multipotent progenitors (CFUS) from which
erythrocytes can be grown (172). This multipotent progenitor also showed
similarities towards the burst forming unit-erythroid (BFUE, described later; 161).
A very early erythroid progenitor can be identified using an in vitro erythroid
colony assay in semisolid medium. This progenitor is called CFUGEMM for colony-
forming-unit granulocytes, erythrocytes, megakaryocytes, and macrophages
(173). An immature, fully erythroid committed progenitor is the burst forming unit-
erythroid (BFUE). In vitro, when grown in the presence of Epo, SCF and
interleukin-3 (IL-3), the BFUE is able to form a colony consisting of about 5000
erythrocytes in about 10 days (176, 310). A more mature, phenotypically distinct,
erythroid progenitor is the colony forming unit-erythroid (CFUE). In vitro, this
progenitor is able to give rise to colonies containing 8 to 64 erythrocytes in the
presence of Epo (309). The CFUGEMM, BFUE, and CFUE can be discriminated in
the same culture by analyzing colony size, color and morphological
characteristics. SCF has been shown to act mainly on the BFUE stage and has
little effect on the CFUE progenitor. Epo however, is required and sufficient for
survival and proliferation from the CFUE stage towards the mature erythrocytes
(98, 106, 115). During maturation of a CFUE, several morphological distinctive
stages can be discriminated (108). The first is the pro-erythroblast. In humans
this cell has a size of 14 - 19 µm, contains visible nucleoli, and is able to store
iron required for hemoglobin synthesis later on in differentiation. The basophilic
erythroblast represents the next morphological distinctive stage and can be
characterized by disappearing nucleoli, a cell size of 12 - 17 µm, the start of
hemoglobin synthesis and condensation of DNA. It is called basophilic because
of large amount of alkaline ribosomal and globin mRNA molecules present in the
cytoplasm. Further differentiation gives rise to the polychromatic erythroblast.
This progenitor has already high levels of the hemoglobin protein, and has
decreased its size to 12 - 15 µm. Further condensation of the DNA then yields
the orthochromatic erythroblast (8 - 12 µm). Extrusion of the nucleus results in a
reticulocyte. From this stage it takes about 1 day for the reticulocyte to terminally
differentiate into a 7 - 8 µm, donut-shaped, mature erythrocyte that lost its
ribosomes and mitochondria. In mice, the pro-erythroblast measures about 12
µm in diameter, and finally reaches a diameter of 4 µm as a mature erythrocyte.
The erythrocyte has an average life span of 120 days in humans and 55 days in
mice. Worn-out erythrocytes are phagocytosed by macrophages in the liver and
the spleen, whereas nuclei extruded during differentiation are phagocytosed by
macrophages in the bone marrow.
3. The major factors that regulate erythropoiesis
3.1. Erythropoietin is required for erythroid expansion and differentiation
In the hematopoietic system, the receptor for erythropoietin (EpoR) is selectively
expressed in the erythroid lineage resulting in a lineage specific Epo response.
Epo and its receptor are both essential from the CFUE stage of erythroid
differentiation; mice lacking Epo (Epo) or the Epo-receptor (EpoR) die at day 12.5
of gestation from a lack of fetal erythrocytes (313). CFUE can be isolated from
Introduction
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Epo null fetal livers and do form mature erythrocytes when supplemented with
exogenous Epo in vitro (152, 313). Erythropoietin (Epo) is produced in the kidney
in response to low oxygen levels (hypoxic conditions), but also by BFUE in an
oxygen-independent way (251). Under normal physiological conditions Epo
levels are suboptimal, leading to homeostasis of red cell production with about
20% of erythroid progenitors going in apoptosis (107, 240). This suggests that
Epo functions as a survival factor (77, 100, 115, 139). This is further established
in experiments showing that ectopic expression of the GM-CSF, G-CSF or
prolactin receptor rescues erythroid colony formation in absence of Epo signaling
(97, 244, 246, 302). However, it is of note that Epo has also been shown to be
essential for induction of erythroid expansion in cooperation with SCF, as will be
discussed later.
3.1.1. EpoR signaling
The EpoR is a type I cytokine receptor characterized by the presence of four
conserved cysteines (C), a WSXWS motif, a group of aromatic residues in its
extracellular domain, the absence of intrinsic tyrosine kinase activity and its
constitutive association with Janus kinase-2 (Jak2; 141, 264, 307). When Epo
binds to the EpoR homodimer, the receptor conformation changes resulting in
activation of Jak2 and phosphorylation of the EpoR (220, 257, 297) on 8 tyrosine
motifs (48, 307). Receptor phosphorylation results in the recruitment and
activation of various proteins that bind direct or indirect to the receptor (Figure
1.2) (48, 235). I will give a brief overview on the main pathways activated.
Stat5 is the main Stat-family member involved in EpoR signaling, and is
recruited to Y343 and Y403 (51, 293). After phosphorylation by Jak2, Stat5
dimerizes and translocates to the nucleus to regulate target gene transcription
(51, 113). Several Stat5 target genes have been identified. Bcl-XL is up-regulated
in differentiation in a Stat5-dependent way, and substitutes for Epo-induced
survival during differentiation (65). Activation of the Stat5 targets cytokine-
inducible protein (Cis), suppressor of cytokine signaling (SOCS), and Pim-1
serves as a negative feedback loop for Epo receptor signaling via multiple
mechanisms (165, 186, 320). SOCS1 binds Jak2 and inhibits its catalytic activity
(71, 186), whereas Cis has been shown to bind directly to phosphorylated
tyrosines on the receptor, thereby competing with Stat5 for binding (165). Pim-1
causes reduced tyrosine phosphorylation of the receptor, probably through
stabilization of the SOCS proteins (204).
Activation of the Ras/Raf/Mitogen-activated protein kinase (MAP kinase)
pathway by the Epo receptor occurs via several steps. Epo stimulation results in
complex formation between growth factor receptor-bound protein 2 (Grb-2) and
Shc, and recruitment to tyrosine 464 of the EpoR (49, 50), upon which the
guanine nucleotide exchange factor Son of sevenless (Sos-1) is recruited to the
complex. Sos-1 than converts the inactive Ras-GDP into the active Ras-GTP
form, resulting in the activation of the downstream target molecules Raf/MAP
kinase (67, 70, 262, 263). 
The p85α subunit of Phosphoinositide-3-OH kinase (PI3K) is recruited to
Y481 (51, 130). The associated catalytic subunit (p110) phosphorylates
phospholipids in the membrane, producing phosphatidylinositol-3,4-phosphate
Chapter 1
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(PIP2) and PI-3,4,5-phosphate (PIP3) from PI-4-phosphate and PI-4,5-
phosphate, respectively. These PI3K lipid products act as signaling-dependent
anchors to recruit multiple signaling molecules that contain a pleckstrin homology
domain. Examples are protein kinase B (PKB), Phosphoinositide-dependent
kinase-1 (PDK1) and Bruton's tyrosine kinase (Btk), as well as docking
molecules such as Adaptor protein-2 (AP-2) and Grb-2 associated binding
protein-1 and 2 (Gab-1, Gab-2) (109, 146, 268, 305, 318). In turn, proteins like
Gab-1 and 2 serve as docking molecules for many other signaling molecules like
SH2-containing protein Shc, SH2-containing inositol phosphatase (SHIP), Grb2,
Phospholipase C (PLC) and PI3K (156, 304). Since PIP3-dependent Gabs are
able to recruit PI3K, they serve as a positive feedback-loop for PI3K activity
(225). 
Recently the tyrosine kinase RON was also implicated in EpoR signaling.
Ron has been shown to associate with Gab-1 and to activate the PI3K/PKB and
the MAP kinase pathways (1, 78, 191, 324),  Ron is phosphorylated by Jak2 in
response to Epo (279) and Epo-induced phosphorylation of Gab-1 appeared to
be critically dependent on Ron kinase activity (279). Direct activation of Ron
results in the activation of the MAP kinase and PI3K/PKB pathway, but not the
Jak/Stat pathway (279).  
Since many of the signaling molecules can dock to several sites in the
signaling complex, signal transduction pathways may be initiated in various
ways. Notably, transduction of erythroid progenitors derived from EpoR -/- fetal
livers with distinct EpoR mutants suggested that only tyrosine 479 of the EpoR is
essential erythroid colony formation (131, 312). However, mice expressing a
truncated EpoR lacking all tyrosines exhibit a normal erythropoiesis (321).
Introduction
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3.2. Stem cell factor is required for erythroid expansion
The receptor c-Kit is a growth factor receptor with ligand-dependent tyrosine
kinase activity, classified as a type III receptor kinase family member together
with Fms-like tyrosine kinase-3 (Flt-3), the receptors for colony-stimulating factor-
1 (CFS-1), and the platelet-derived growth factor receptor (PDGF). Common
features of this family are the extracellular part with five immunoglobulin-like
domains, and the cytoplasmic part with a kinase domain which is interrupted by
a insert of variable length (10, 25). c-Kit was originally identified as the viral
oncogene (v-kit) responsible for the transforming activity if the Hardy-Zuckerman
IV feline sarcoma virus (18). The importance of c-Kit and its ligand SCF was long
known, since two genetic mutants, mice with a homozygous White or Steel locus
were white and severely anemic at birth. The White locus appeared to encode c-
Kit, the Steel locus its ligand SCF. SCF turned out to be a growth factor with a
wide biological range. In development, SCF is not only important for migration
and proliferation of hematopietic stem cells, but also for migration and
proliferation of melanoblasts and germ cells (10). In the hematopoietic system
SCF acts on many different hematopoietic cells, starting from the pluripotent
stem cell towards more mature stages (Figure 1.1; 25, 159). SCF is produced by
various cell types (endothelial cells, fibroblasts, hematopoietic progenitor, and
marrow stromal cells) as a membrane-bound and soluble factor (25). Mice
lacking the membrane-bound form of SCF (Steel dicky mutation; Sld) suffer from
severe anemia, indicating that soluble SCF alone is not enough for normal
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Figure 1.2. Schematic representation of the signaling complexes and signal transduction pathways
activated by Epo and SCF. Ligand binding to the Epo- and c-Kit receptor triggers a cascade of downstream
signaling events. Downstream signaling molecules are recruited to the receptors or to adaptor molecules (Gab-1,
Gab-2, Dok, Grb2). The EpoR and c-Kit contribute differentially to activation of the  three main downstream signal
transduction pathways. Thick arrows indicate stronger activation of a certain pathway compared to thin arrows. The
contribution of Epo to these different pathway is indicated in gray arrows, the contribution of SCF to the different
pathways is indicated by black arrows. A more detailed representation of the PI3K pathway is shown on the right.
In addition to PTEN, the phosphatase SHIP is also involved in dephosphorylation of the membrane associated
phosphoinositol rings (PIP3).
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erythropoiesis (79). Sld mice not only have strongly reduced numbers of BFUE
and CFUE, but also have declined numbers of CFU-granulocyte-macrophage
(CFUGM) and CFUS underlining the wide activity of SCF in the hematopoietic
system (13). Also in in vitro cultures of erythroid progenitors, membrane bound
SCF appeared to be more potent than soluble SCF to inhibit differentiation and
promote expansion (122, 198). This could be due to the fact that membrane
bound SCF induces prolonged c-Kit signaling (177). In addition, membrane
bound SCF may play a role in the localization and/or the migration of the
erythroid progenitors. For instance, the presence of membrane bound SCF on
spleen cells is required for expansion of erythroid cells during recovery from
hemolytic anemia in adult mice (26). In this process, BFUE from the bone marrow
travel to the spleen to support stress erythropoiesis (26, 99, 103, 190). This
suggests that membrane bound SCF on the spleen is responsible for lodging and
expansion of BFUE in the spleen. Mice with mutated, non-functional c-Kit genes
also suffer from severe anemia (28, 192, 306). Expression of c-Kit is found from
the earliest erythroid progenitor up to the stage of basophilic erythroblast (277).
This is supported by the finding that SCF is required for the in vitro expansion of
erythroid progenitors as it retards differentiation of both human and mouse
erythroid progenitor cells while stimulating proliferation (64, 184, 289, 290).
Although c-Kit or SCF homozygous null mice may suffer from an overall
decrease in blood cells, the stringent effect on the erythroid lineage indicates that
this receptor is essential for the expansion of the erythroid lineage.
3.2.1. SCF signaling
Binding of SCF to the receptor results in activation of its intrinsic kinase activity
and subsequent autophosphorylation, creating docking sites for several proteins.
PI3K binds to tyrosine 721 in human c-Kit (239), and its activation creates
docking sites for proteins containing a pleckstrin homology (PH)-domain (see
3.1.1). For example, SCF induces PI3K-dependent recruitment of a protein
complex consisting of Lyn, Tec and Dok to its receptor (281). The Src family
member Lyn associates with the juxtamembrane domain of c-Kit (Y568), and
phosphorylates the cytoplasmic tyrosine kinase Tec and the docking molecule
p62Dok-1. p62Dok-1 contains several protein-protein interaction domains, including
tyrosine residues, to recruit proteins involved in the regulation of downstream
events of c-Kit signaling. It has been suggested that p62Dok-1 serves as a negative
regulator of c-Kit signaling. In erythroid cells we have found that SOCS1 and 3,
and SHIP are recruited by p62Dok-1 (Thamar van Dijk, unpublished results), leading
to receptor down modulation. A role for p62Dok-1 in down modulation of receptor
signaling has also been shown in other systems (255, 316). Like Epo, SCF also
results in the PIP3-dependent recruitment of the docking molecule Gab-2 (279). 
SCF-induced activation of the Ras/MAP kinase pathway requires
activation of Lyn, which in turn recruits and phosphorylates Shc. Both Shc and
phosphorylated residues in c-Kit recruit Grb2/Sos, which subsequently activates
the Ras-Raf-MAP kinase cascade (24, 117, 147). 
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3.3. Cooperation between SCF and Epo signaling
The cooperation of Epo and SCF in erythroid expansion is shown by increased
erythroid colony numbers in the presence of both factors (131). The cooperation
is confirmed at the molecular level. We showed co-immunoprecipitation of the
EpoR and cKit in murine primary fetal liver cells and in the erythroblasts cell line
I/11 (278). Several domains have been shown to be important for this interaction.
The tyrosine kinase receptor c-Kit interacts with the extended box-2 region in the
cytoplasmic domain of the EpoR (313). In addition, we showed an interaction of
the extracellular domain of both receptors in a yeast two hybrid assay
(unpublished data). These data show that the Epo and SCF receptors can
function in the same signaling complex.
Signal transduction pathways activated by Epo and SCF overlap to a
large extent (Figure 1.2; and paragraph 3.1.1 and 3.2.1). In general, Epo and
SCF stimulation lead to activation of the Ras/MAP kinase and PI3K pathway, and
of downsteam targets such as the adapter molecule Gab-2 (279) and Bruton's
tyrosine kinase (Btk; 237). However, there are also differences in downstream
target activation. The most obvious difference relates to Epo-induced activation
of the Jak/Stat pathway. Recruitment of adapter molecule Gab-1 by Ron, and its
activation in response to Epo treatment (279), is another Epo-specific event.
Other targets are phosphorylated in response to both Epo and SCF but appear
to have stimulus-specific effects. Btk activation protects primary cells from Trail-
induced apoptosis only when induced by SCF (237), whereas Epo-induced Btk
phosphorylation acts as a positive regulator of EpoR signaling (237). Activation
of Btk in response to SCF may affect SCF-induced gene expression, but it is
equally possible that Btk mediates the cellular localization of specific proteins
such as those involved in TRAIL-induced apoptosis. Since not all downstream
pathways need to affect target gene expression, it will be revealing to profile SCF
target genes e.g. in Btk-deficient cells. In addition, other differentially regulated
targets of both receptors may be discovered in future experiments as well.
In conclusion, the partial overlap between Epo and SCF signaling
explains why both receptors are required for erythroid expansion. Since the
combined activation of common Epo/SCF signal transduction cascades results in
a more enhanced and prolonged signal (135, 253), the strength of the Epo/SCF
induced signal may also be essential for full support of erythroid expansion. 
3.4. In vitro expansion of erythroid progenitors reflects stress-
erythropoiesis
The cooperative effect of Epo and SCF on erythroid expansion has been shown
in erythroid progenitors derived from different tissues and organisms. Erythroid
progenitors derived from human neonatal cord blood and adult bone marrow,
from mouse fetal liver and adult bone marrow, or from chicken bone marrow, can
be expanded in the presence of Epo, SCF, and Dex (290, 291, 301, 303). Epo
and SCF have also been reported to cooperate in expansion of human erythroid
colony-forming cells (185), and in colony formation of erythroid progenitors
isolated from murine fetal livers (112).
As mentioned above, the glucocorticoid receptor (GR) is also implicated
in expansion of erythropoiesis. Dexamethasone, an artificial ligand of the GR,
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does support erythroid colony formation of primary cells (19, 47, 275), but also
supports erythroid expansion in in vitro cultures (219, 290, 291, 301, 303).
Notably, mice expressing a GR mutant lacking transactivation activity (GRdim),
are viable and show normal erythropoiesis. However these mice fail to induce
stress erythropoiesis in response to hypoxia (14). This shows that the GR, and
particularly its transactivation activity, is required for erythroid expansion under
hypoxic stress (219). This and the fact that erythroid progenitors derived from
GR-/- and GRdim/dim mice cannot be expanded in vitro (14, 43), suggests that in vitro
erythropoiesis reflects stress erythropoiesis. The role of the GR in stress
erythropoiesis is underscored by strongly increased release of glucocorticoids
under anemic stress conditions (11, 271).
In addition to glucocorticoids, SCF also plays an important role in stress
erythropoiesis. Mice in which c-Kit is mutated respond poorly to anemic stress
(104). SCF levels are not affected under anemic conditions (145, 308), but SCF
is responsible for the lodging of BFUE from the marrow to the spleen, where
murine stress-erythropoiesis takes place (26, 103, 199, 219). Treatment of
hypoxic mice with a neutralizing antibody for c-Kit almost completely inhibited
splenic erythropoiesis, and only modestly affected erythropoiesis in the bone
marrow (26). This explains why the acute expansion of erythroid cells in
response to hypoxia is at least in part due to migration of BFUE from the bone
marrow to the spleen, but also due to higher proliferation rates of CFUE in the
spleen (99, 103, 190). Finally, hypoxia immediately up-regulates Epo (228). Epo
levels are known to be required for increased survival, proliferation and
differentiation of erythroblasts. We showed that Epo-induced activation of PI3K-
dependent signaling pathways as well as Epo-induced activation of the MAP
kinase pathway is important for the expansion of erythroid progenitors in
presence of SCF (279). These data suggest that the combined action of Epo,
SCF and Dex is essential in stress-erythropoiesis. 
Interestingly, we found that murine, fetal liver or bone marrow derived
erythroid progenitors could be cultured indefinitely when derived from mice
lacking p53 (237, 290). This resulted in e.g. the I/11 and R10 cell lines. These
lines retain (1) the ability to differentiate synchronously to hemoglobinised,
enucleated erythrocytes, (2) full factor dependence and (3) a normal diploid
karyotype when maintained properly. Notably, development of murine
erythroleukemia induced by spleen focus forming virus (SFFV) is critically
dependent on loss of p53 (213), and p53 was shown to antagonize
glucocorticoid-induced proliferation of erythroid progenitors (89).
4. The cyclic-AMP pathway
In addition to Epo, SCF and Dex, many additional factors modulate
erythropoiesis. Among them TGF-β family members (322), Interleukin-3 (85),
GM-CSF (74), or ligands for serpentine receptors coupled to trimeric G-proteins.
One mechanism via which Serpentine receptor mediate erythropoiesis is via
regulation of intracellular levels of cyclic-AMP (cAMP). This paragraph discusses
the role of the cAMP pathway.
Hormones such as adrenaline (epinephrine), calcitonin, and
prostaglandins induce an increase of the second messenger cAMP upon binding
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to their receptor (Figure 1.3). The receptors are associated with guanine
nucleotide-binding protein (G-protein), which consists of three subunbits, α (45
kD), β (35 kD), and γ (7 kD). Hormone binding to the receptor stimulates the
exchange of GDP for GTP to the receptor bound Gα protein. The G-protein then
falls apart into the three subunits. Gα subunits come in 3 functionally different
subtypes: Gαq, which activates phospholipase activity; Gαs, which activates
adenylate cyclase to generate cAMP; Gαi, which inhibits adenylate cyclase. In
addition, the heterodimer of Gβ,γ and or Gαi may activate kinases (e.g. Src-family
members). The intrinsic GTPase activity of the Gαs hydrolyzes GTP to GDP and
abrogates signaling (Figure 1.2; 23).
The cellular functions of cAMP are mediated through the
serine/threonine protein kinase A (PKA). PKA consists of two different subunits,
a 49 kD regulatory subunit, and a 38 kD catalytic subunit. In the absence of
cAMP, the regulatory (R-unit) and catalytic (C-unit) subunits form an
enzymatically inactive R2C2 complex. In this complex the C-unit binds a pseudo-
substrate sequence in the R-unit that mimicks a PKA phosphorylation site (94,
133). Binding of cAMP to the R-unit results in an allosteric change of the R2C2
complex, which prevents binding of the C-unit to  the pseudo-substrate, and
release of the C-units. Although PKA also phosphorylates many cytoplasmic
substrates, its nuclear localization and subsequent phosphorylation of cAMP
response element binding proteins of the Creb/ATF family constitutes a major
pathway (56, 233). In mammals at least three genes encode cAMP responsive
transcription factors: Creb, Crem and Atf-1, of which various isoforms exist, and
which are able to homo- or heterodimerize (179, 234). Serine phosphorylation by
PKA on residue 133 in Creb, 117 in Crem, and 63 in Atf-1 results in association
with Creb binding protein (Cbp)/p300, and subsequent recruitment of the basal
transcription machinery (56, 233). Creb family members belong to the basic-
domain-leucine-zipper class of transcription factors, and bind to the palindromic
sequence TGACGTCA, first identified in the somatostatin promoter, and called
the cyclic AMP responsive element (CRE; 179, 234).
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4.1. The cAMP pathway and regulation of erythropoiesis
The cAMP pathway is involved in many physiological processes, such as
memory and long term potentiation (242), circadian rhythms (82, 83), pituitary
functions (252) spermatogenesis (233), and hematopoiesis. Activation of the
cAMP pathway is associated with differentiation of many cell types, including
hematopoietic cells (157, 164). For instance, increased cAMP levels inhibit
growth and induce differentiation of leukemic blasts (101, 197, 231).
Some studies have pointed to a role for the cAMP pathway in regulation
of erythropoiesis. Increased cAMP levels have been associated with growth
suppression (105, 274), and cAMP was shown to promote chemically induced
differentiation of mouse erythroleukemia cells, whereas inhibition of adenylyl
cyclase suppresses differentiation (142). Furthermore, knock-down of the cAMP
downstream target protein kinase A (PKA) impairs erythroid differentiation of
mouse erythroleukemia cells (210) and reduces heme and hemoglobin synthesis
(209, 254, 285). The latter was suggested to be caused by an impaired
transcriptional activity of the erythroid specific transcription factor NF-E2 which is
activated in differentiation (9, 91).
Physiologically, increased cAMP levels in erythroid cells are at least
partially induced by prostaglandins. Stimulation of erythroid cells with
prostaglandins promotes hemoglobin synthesis (52), which most likely is
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Figure 1.3. Schematic representation of the cAMP signal transduction pathway. A G-protein coupled receptor
is activated upon ligand binding at the cell surface resulting in dissociation of the Gα unit from the Gβ and Gγ units.
Gα binds adenylyl cyclase (AC) which triggers the conversion of adenosine tri-phosphate (ATP) into cyclic-AMP
(cAMP). cAMP binds the regulatory subunit (R) of the protein kinase A (PKA) complex, inducing the release of the
catalytic subunit of PKA. PKA is tranported to the nucleus where it is able to mediate transcription by
phosphorylation of cyclic-AMP response element (CRE) binding proteins of the Creb family proteins (serine 133 for
Creb).
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regulated via PKA (209). Interestingly, the prostaglandin E2 receptor is more than
30-fold up-regulated during terminal erythroid differentiation (64), which may
explain the more potent growth suppression of cAMP in differentiating cells (274).
Interestingly, PGE2 has been shown to cooperate with the Epo-induced
transcriptional activation Stat5 enhancing the expression of SOCS2, SOCS3 and
Bcl-XL (22).
The data show the involvement of the cAMP/PKA pathway in regulating
gene expression in erythroid cells, and suppressing erythroid growth. However,
the exact role of this pathway and its regulation in erythropoiesis is largely
unknown.
5. Erythropoiesis and disease
Various erythroid malignancies have been reported. In polycythaemia vera an
excess of erythrocytes is caused by hypersensitivity to Epo, or by EpoR
mutations leading to hyper-responsiveness of the receptor (140).
Erythroleukemia is a variant of acute myeloid leukemia with significant
involvement of the erythroid  lineage (226). Anemia is caused by a lack of
functional erythrocytes. Anemia can occur when hemoglobin synthesis is
disturbed (thalassemia and sickle cell disease; 114), or when reduced numbers
of progenitors are present (e.g. Josephs-Diamond-Blackfan anemia and Fanconi
Anemia; 295). If the defect is in the production, survival or differentiation of CFU-
E, the anemia may be refractory to increased Epo levels. If mature erythrocytes
are instable, increased Epo levels will increase the survival and proliferation of
CFU-E, generating more erythrocytes. This results in the increased numbers of
reticulocytes in the peripheral blood, a condition known as reticulocytosis.
6. The PI3K pathway
6.1. The PI3K pathway is required for erythroid expansion 
As mentioned before, Phosphatidyl Inositol-3 kinase (PI3K) is activated both by
the EpoR and c-Kit. PI3K is a heterodimeric complex consisting of 85- and 110
kD subunits (p85 and p110; 121). The p85 subunit contains two Src homology 2
(SH2) domains, which bind to phosphorylated tyrosines. The domain in between
the two SH2 domains is required to bind to the catalytic p110 subunit (132).
Active PI3K phosphorylates the 3'-OH group of the phosphatidylinositol (PI) ring
present in the plasma membrane, resulting in phosphoinositol-3-phosphate
PI(3)P1,  PI(3,4)P2, or PI(3,4,5)P3. This results in recruitment and activation of
pleckstrin-homology (PH)-domain containing proteins (283). Downstream
effector molecules can have a  preferential affinity for the distinct phosphoinositol
rings. For instance, Btk and general receptor for phosphoinositides (Grp1)
specifically bind PI(3,4,5)P3 (217). The pleckstrin homology (PH) domain of PKB
was shown to have highest affinity to PI(3,4)P2, and somewhat lower for
PI(3,4,5)P3 (84). Tapp1 and Tapp2 (tandem PH-domain-containing protein) only
bind PI(3,4)P2 and not PI(3,4,5)P3, whereas phosphatidylinositol-three-
phosphate-binding PH-domain protein-1 (Pepp-1), Pepp-2, Pepp-3, ATPH1, and
the FYVE finger domain protein preferentially bind PI(3)P1 (66, 217). PI3K is
implicated in regulation of survival, cell cycle progression, differentiation, and
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intracellular trafficing (81, 283, 284). Oncogenic transformation and growth factor
stimulation result in increased levels of phospholipids in the membrane (35, 121,
249).
The PI3K pathway is essential for Epo and SCF induced erythroid
expansion. Inhibition of the PI3K pathway by the inhibitor LY294002 (7.5 and 15
µM) strongly suppresses erythroid expansion in favor of differentiation (290,
291). This appears to be specific for the PI3K pathway because inhibition of the
Ras/MAP kinase pathway also suppressed erythroid expansion but does not
enhance differentiation (290, 291). The role of PI3K in erythroid expansion has
also been shown in vivo using p85α-/- mice. Deletion of the p85α subunit of PI3K
in mice does not result in death (86). However, the colony forming ability of
erythroid progenitors in E14,5 fetal livers of  p85α-/- embryo's was 2-3 fold
decreased when the progenitors were cultured in the presence of Epo and SCF.
Colony numbers were less drastically decreased when grown in the presence of
Epo alone (112). This also suggests that PI3K is most important for expansion of
early erythroid progenitors, but not for Epo-dependent survival and
differentiation. Notably, p85α-/- mice display a transient fetal anemia, a temporary
shortage of red cells which becomes apparent when maximal expansion is
required during fetal liver erythropoiesis (112).
In vivo studies using transgenic mice expressing mutant EpoR or c-Kit,
lacking the PI3K docking sites do not show a requirement for PI3K in normal
erythropoiesis. These transgenic mice are viable and have a normal definitive
erythropoiesis (21, 321). However, stress erythropoiesis has not been examined
in these mice. In addition, other PI3K docking sites present in the EpoR-/c-Kit
signaling complex (e.g. on Gab-1, Gab-2 docking molecules) might substitute for
PI3K activation (278).
6.2. Negative regulators of the PI3K pathway
The PI3K pathway is negatively regulated in several ways. The phosphatase
protein PTEN was identified as a tumor suppressor (150, 260), and was shown
to dephosphorylate the 3' position of phosphoinositol phosphates (160). PTEN-
null embryonic fibroblasts have higher PIP3 levels, and constitutive PKB activity
(248), which can be converted by re-expression of PTEN in PTEN deficient cells
(149). Another down-regulator of PIP3 signaling is the SHIP family of
phosphatases. These SH2-domain-containing inositol phosphatases (SHIP)
have been shown to dephosphorylate PIP3 at the 5' position (227). To date, two
SHIP proteins have been identified: SHIP1/SHIP and SHIP2. Whereas SHIP is
predominantly restricted to the hematopoietic system, SHIP2 is more
ubiquitously expressed (155, 206). Various studies have shown that SHIP and
SHIP2 negatively downregulate the PKB activity (7, 154, 258). However, since
PTEN dephosphorylates the 3' position, it is the direct and complete antagonist
of PI3K. Therefore, activation of PKB, which preferentially binds PI(3,4)P2 above
PI(3,4,5)P3, is probably most affected by PTEN, and to a lesser extent by SHIP,
whereas FYVE-domain containing proteins which bind specifically to PI(3)P1
which can only be repressed by PTEN (92, 203).
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7. Protein Kinase B (PKB/Akt-1) 
PKB was cloned independently by two groups (42, 119). Because the gene
showed similarity to the kinase domains of protein kinase C and protein kinase
A, it was named protein kinase B (16, 42, 119) Three PKB isoforms exist:
PKBα/Akt-1, PKBβ/Akt-2 and PKBγ/Akt-3, sharing more than 80% homology on
amino acid level. All three isoforms share an NH2-terminal pleckstrin homology
domain (about 100 amino acids (aa)), followed by a kinase domain
(approximately 250 aa), and the COOH-terminal regulatory domain. PKB has two
phosphorylation residues: threonine 308 (T308, situated in the kinase domain),
and serine 473 (S473, present in the regulatory domain) which are important
determinants for its activity.
The pleckstrin homology (PH) domain of PKB was shown to have
highest affinity to PI(3,4)P2, and somewhat lower for PI(3,4,5)P3 (84). Once
recruited to the plasma membrane, PKB is phosphorylated at two sites.
Threonine 308 is phosphorylated by the serine/threonine kinase
phosphoinositide-dependent-kinase-1 (PDK1), a protein that is also recruited to
PI(3,4)P2 and PI(3,4,5)P3 via its PH-domain. T308 phosphorylation regulates
substrate access to the catalytic site (5, 250), whereas subsequent
phosphorylation of S473 is required for full activation (4). Phosphorylation of
S473 is performed by the DNA-dependent protein kinase (DNA-PK; 327). Once
activated, PKB translocates from the plasma membrane to the cytosol or to the
nucleus where it phosphorylates its substrates.
PKB mediates a variety of cellular functions. It has been implicated in
regulation of insulin uptake, glucose metabolism, protein synthesis and
regulation of survival (41, 137, 283). PKB mediated survival and proliferation is
regulated via multiple mechanisms. First, regulation of protein synthesis is
established through phosphorylation of 4E-binding protein (4E-BP). It is thought
that the signal is transduced from PKB, through mTOR to 4E-BP (17, 76).
Phosphorylation of 4E-BP by mTOR results in its dissociation from eukaryotic
initiation factor 4E (eIF4E), thereby initiating translation (33, 95). The role of PKB
in stimulation of protein synthesis has clearly been shown in skeletal muscle,
adipose tissue, and in erythroid cells (Blazquez-Domingo and Grech, in
preparation; 126). In addition, overexpression of eIF4E in erythroblasts results in
erythroid expansion (M. Blazquez-Domingo and G. Grech, in preparation). 
PKB mediated inhibition of the apoptotic machinery is another way to
support growth. This has been confirmed in a wide variety of cells (45, 75, 317).
PKB up-regulates the anti-apoptotic factor Bcl-2, which bind and inhibits the pro-
apoptotic factors Bcl-Xs, Bax, Bad and Bak. In addition, PKB inactivates the pro-
apoptotic factor Bad directly via phosphorylation resulting in the association to
14-3-3 proteins (53, 58, 315). Furthermore, PKB stimulates cell cycle progression
by direct phosphorylation of the cell cycle inhibitor p27KIP. Phosphorylation of the
nuclear localization motif of p27KIP impaired its nuclear import resulting in as
release of cyclin dependent kinase-2 and stimulation of cell cycle progression
(151, 287).
Studies in the hematopoietic system indeed have shown a proliferation-
inducing role for PKB. In the myeloid cell line 32D, PKB is implicated in IL-3
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induced proliferation. Both in T-cells and in the pre-B cell line Ba/F3, cytokines
activate PKB, which results in inhibition of apoptosis and cell cycle progression
through induction of Bcl-2 and c-Myc expression. In 1999, PKB was shown to
regulate cell survival via regulation of a subfamily of forkhead transcription
factors. 
8. The Forkhead family of transcription factors
The first member of the forkhead family was identified in Drosophila
melanogaster in 1989. Mutations in this gene resulted in homeotic transformation
of gut structures into head-derived elements, therefore the gene was called fork
head (299). About two years later, mammalian family members were found and
described as a small family of hepatocyte enriched DNA-binding transcription
factors, the hepatocyte nuclear factors, which showed homology to the
Drosophila fork head gene (144, 298). But it was the characterization of the
forkhead DNA binding domain that led to the identification of the forkhead family
of transcription factors (143). The winged helix DNA-binding domain
encompasses about 110 amino acids and is conserved in a wide range of
species. Since than, more than 100 forkhead family members have been
identified in organisms ranging from yeast to humans (123).
8.1. The Foxo subfamily of Forkhead transcription factors
The first member of the O subclass of forkhead family members (Foxo) was
identified in Caenorhabditis elegans and was named Daf-16. Daf-16 was shown
to regulate dauer formation. Dauer formation is a developmental stage in the 15
weeks life span of the worm, which ensures survival under nutrient poor
conditions through closing its mouth and anus and by lowering its metabolism.
This developmental arrest can be reversed upon improving conditions (261).
After the identification of Daf-16 the mammalian homologues were investigated.
Daf-16 showed a large degree of homology to the mammalian forkhead
transcription factors AFX (Foxo4), FKHR (Foxo1), and FKHR-L1 (Foxo3a) and
was negatively regulated by the insulin receptor (Daf-2) and PI3K (Age-1; 8, 127,
153, 182, 195). All Foxo family members contain three PKB phosphorylation sites
(RXRXX(S/T)X) (Figure 1.4; 3, 294). PKB was shown to phosphorylate the Foxo
family members on these three PKB motifs: a NH2-terminal threonine (T32), a
forkhead box serine (S253), and a COOH-terminal serine (S315; Figure 1.4). T32
and S253 are required for nuclear export and binding to 14-3-3 proteins (27, 30).
Phosphorylation of S315 was shown to enhance nuclear export (Figure 1.5; 32,
222).
Other kinases regulate Foxo proteins as well. These are: Casein kinase
1 (CK1), dual specificity tyrosine phosphorylated and regulated group of kinase
(Dyrk1a), and serum and glucocorticoid regulated kinase (SGK). CK1 recognizes
serine or threonine phosphorylated protein motifs. PKB phosphorylation of the C-
terminal PKB site is essential for CK1 phosphorylation of the two downstream
serines (Figure 1.4; 222). CK1 can be activated upon DNA damage (232).
Dyrk1a is activated by an as yet unknown kinase, and its cellular function is still
unclear (311). One Dyrk1a phosphorylation site is present in the Foxo family
members. This site (S325) is located adjacent to the two CK1 phosphorylation
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sites (S318, S321) and is constitutively phosphorylated (222, 311). Mutation of
the S325 Dyrk1a site decreased nuclear localization and transcriptional activity,
suggesting that it is functional (311). SGK is regulated at the transcriptional level
and on protein level by serum, glucocorticoids and stress factors (148). Activation
of SGK is induced in a PI3K- and PDK1-dependent way (134, 201). Because
PKB and SGK have identical substrates it is difficult to distinguish between their
activity (134, 201). However, the fact that SGK is activated by a much broader
range of stimuli, that it lacks a pleckstrin homology domain, and that it prefers a
serine as a phospho-acceptor, probably determine their differential role in vivo
(32, 134). Although both kinases phosphorylate the NH2-terminal PKB site, SGK
preferentially phosphorylates the COOH-terminal phosphorylation site whereas
PKB preferres the serines in the forkhead box (32). Finally, Foxo3a was shown
to interact with and to be phosphorylated by IκB kinase (Ikk), independent of
PI3K activity (110). Serine 644, present in a Ikk target sites (DSX (hydrophobic
amino acid)XX(S/T)) appeared to be the Ikk target site in Foxo3a.
Phosphorylation of this site repressed transcriptional activity and induced nuclear
exclusion of a PKB phosphorylation deficient Foxo3a mutant, indicating that Ikk
phosporylation serves as an alternative pathway that regulates Foxo activity
(110).
Taking all possible phosphorylation events into account, there seems to
be a certain order in these phosphorylation events. Phosphorylation of the PKB
site in the forkhead box (S253) is a prerequisite for phosphorylation of the N-
(T32) and C-terminal (S315) PKB sites (221). Namely, mutation of S253
abolished insulin induced phosphorylation of Foxo1 whereas mutation of the
NH2- or COOH-terminal PKB sites did not (187). Since phosphorylation of the
CK1 sites is again dependent on phosphorylation of the COOH-terminal S315
PKB site, phosphorylation of S253 by PKB site can be regarded as the triggering
event leading to Foxo phosphorylation.
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Figure 1.4. Allignment of murine Foxo family members. (A) Common elements (boxed) and known
phosphorylation sites (S and T) are indicated. Stress induced Acetylation and phosphorylation sites are indicated as
Ac-stress and p-stress respectively (Brunet et al., 2002). Two domains have been identified to bind 14-3-3 proteins:
the indicated N-terminal site, and the Forkhead box PKB phosphorylation site. The positions of the phosphorylation
sites are numbered according to the positions in Foxo3. Ac-CBP: Lysines known to be target of the acetylase
CBP/P300. Caspase and protease cleavage sites are also indicated (see text). (B) Schematic drawing of Foxo
proteins. Several domains are indicated, and positions of the phosphorylation sites in all family members are given
for the murine Foxo proteins. Figures adapted from Birkenkamp et al. (2003) Biochem Soc Trans., 31, 292-297, and
Van der Heide et al. (2004) Biochem J., 380, 297-309.
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8.2. Regulation of Foxo transcriptional activity
Transcriptional activity of subfamily O of forkhead transcription factors is
regulated at three levels: I) cellular translocation, II) DNA binding and III) protein
degradation (34, 280), as will be discussed below (Figure 1.5).
(I) The nuclear membrane forms a physical barrier between the cytosol
and the nucleus. Transport between these compartments takes place through the
nuclear pore complex. Small molecules (<50 kD or < 9 nm) are able to diffuse
freely through this complex, whereas larger complexes require active transport
(136). Foxo's depend on active transport mechanisms. Foxo1, 3, and 4 contain
a nonclassical nuclear localization signal (NLS) consisting of three arginines next
to the forkhead box PKB site (S253) and three lysine residues located 19
residues downstream of the arginines (Figure 1.4; 27, 158). Whereas a basic
domain is required for NLS function, phosphorylation of the PKB site (S253) and
the adjacent CK1 sites establishes a negative charge inhibiting nuclear
translocation (27). Recently, a second NLS was identified in Foxo1 (325).
Nuclear import of Foxo3a requires binding to importin and shuttling from the
cytosol to the nucleus in a Ran-dependent manner (136, 280, 319). 
Essential factors in nuclear/cytoplasmic localization of Foxo proteins are
the 14-3-3 proteins. 14-3-3 proteins exist in seven isoforms. They consist of
acidic dimeric subunits of about 27 kD (296). The 14-3-3 dimer binds tightly to
single molecules containing tandem repeats of phosphoserine motifs (315). 14-
3-3 proteins are chaperone proteins able to mask or expose nuclear export or
import domains, thereby influencing the cellular distribution (31, 183, 224). Foxo
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Figure 1.5. The PI3K/PKB
represses transcriptional activity
of the Forkhead family of
transcription factors subclass O
(FoxO). Binding of SCF to c-Kit
induces the tyrosine kinase activity
of c-Kit, which leads phosphorylation
of the receptor and downstream
targets such as PI3K. Active PI3K
phosphorylates inotisol rings (at the
3-position) present in the
plasmamembrane. Proteins
containing a pleckstrin homology
domain (PDK1, PKB) are recruited
by these phospholipids
(PI(3,4,5)P3). Once PKB is activated
through phosphorylation by PDK1
and DNA-PK, it translocates to the
nucleus where it phosphorylates
Foxo transcription factors on three
different PKB phosphorylation sites.
Once phosphorylated, DNA binding
of Foxo's is disrupted and Foxo
nuclear export is enhanced. PI3K
activation thus inhibits Foxo
transcriptional activation of Foxo
target such as the cell cycle inhibitor
p27KIP.
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proteins contain one optimal 14-3-3 binding site which overlaps with the NH2-
terminal PKB site (T32). Mutation of this site disrupts 14-3-3 binding, resulting in
nuclear localization (30, 187). Since Foxo binding to conserved exportin 1 (Crm1)
is independent of the Foxo phosphorylation status (280), it can be concluded that
the nuclear localization of the T32 mutant is caused by the inability of Foxo
proteins to bind the cytoplasmic anchoring protein 14-3-3 and not by impaired
nuclear export. 14-3-3 proteins can also bind to degenerate binding sites (314).
It was shown that both phosphorylation of residues in the NH2-terminus (T32)
and the Forkhead box (S253) are essential for optimal 14-3-3 binding, suggesting
the presence of an additional 14-3-3 binding site in the Forkhead box (30, 325).
Since S253 is a prerequisite for phosphorylation of the other sites (see 7.1), and
its phosphorylation also masks the NLS, phosphorylation of S253 is a key event
in the control of Foxo proteins.
Non-DNA bound Foxo is exported from the nucleus dependent on
exportin 1 (Crm1) and Ran-GTP (27, 116, 222). Mutation of the COOH-terminal
phosphorylation site (S315), which also inhibits phosphorylation of the CK1 sites,
greatly increased nuclear localization (27, 222). In addition, insertion of the
stretch of 4 COOH-terminal serines in Foxo6 restored nuclear export (Figure 1.4;
116). Because S315 is not important for 14-3-3 and nuclear export, its
phosphorylation may disrupt DNA binding. This may indirectly promote its nuclear
export and cytoplasmic retention.
(II) It was initially thought that Foxo nuclear export was the major
determinant for inhibition of Foxo function. However, phosphorylation of Foxo's
appeared to block Foxo transcriptional activity as well. Phosphorylation of S253
in the forkhead box by PKB inhibits Foxo1 transactivation without affecting its
cellular distribution (167, 205, 221, 323). Furthermore it was shown that
phosphorylation of S253 disrupts DNA binding (158). These data were confirmed
after the identification of Foxo family member 6. Foxo6 lacks the C-terminal
stretch of phosphorylation sites, and also one of the two nuclear export
domains,(116) both crucial for nuclear export (Figure 1.4) (31). By consequence,
growth factor stimulation only slightly induced nuclear export of Foxo6 but
potently inhibited Foxo6 transactivation activity (116). These data show that
transcriptional activity of Foxo proteins can be suppressed without nuclear
exclusion. 
(III) Foxo proteins are relatively stable proteins. The half-life of Foxo4 is
more than 10 hours (34), However, insulin stimulation of a murine pro-B cell line
decreased the Foxo1 and 3 protein levels by proteolytic degradation (211).
Insulin stimulation induced Foxo1 ubiquitination and subsequent degradation by
the proteosome system in a PI3K-dependent way (167), which required
cytoplasmic localization. Another pathway involved in degradation of Foxo
proteins is the IκB kinase (Ikk) regulated pathway. Ikk, is also activated upon
growth factors stimulation (62), and induced Foxo3a nuclear localization and
subsequent ubiquitination and protein degradation via the proteosome (110).
Finally, Foxo3a can be cleaved by caspase-3-like proteases, yielding an
NH2-terminal, and a COOH-terminal domain. The cleavage site was also present
in Foxo1 and 4, but not in Foxo6 (38). Furthermore it is shown that Foxo1 is
negatively regulated by androgens in a proteolytic-dependent way (111). 
Introduction
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8.3. Transcriptional regulation by Foxo proteins
Two elements have been identified to which Foxo-members bind preferentially:
the insulin response element (IRE), and the Daf-16 binding element (DBE). The
DBE was defined as TTGTTTAC (87), which overlaps with the IRE:
CACTAGCAAAACAAACTTATTTTGAACAC (256).  These domains have in
common the core forkhead binding sequence which has been identified in the
promoter of a variety of forkhead targets: (G/A)(T/C)(C/A)AA(C/T)A (123, 230).
However, this core sequence alone is not enough for DNA binding. Probably,
flanking DNA sequences are important for target specificity (123, 207, 230).
Forkhead transcription factors in general have been described to bind DNA as
monomers, through helix 3 of the winged helix domain (40, 118), and Foxo family
members were shown to bind DNA similarly (300). Mutation of an essential
histidine to an arginine in helix 3 disrupted DNA binding of Foxo1 (HRAAA
mutant). Importantly, this mutation blocked regulation of only part of the Foxo1
target genes and retained the ability to repress growth (216). This observation
indicated that Foxo1 transcriptional regulation might in part be independent of
DNA binding. DNA-binding independent control of gene expression may occur
through the interaction of Foxo's with several co-regulators such as,
CCAAT/enhancer binding protein β, p300 and Creb/binding protein (CBP),
several steroid and non-steroid nuclear receptors, and Smads (20, 238, 280).
The examples outlined above suggest diverse mechanisms via which Foxo's
regulate transcription.
8.4. Functions of Foxo proteins
At present, Forkhead transcription factors of the subclass O have been
implicated in regulation of a variety of cellular processes in response to different
stimuli. Among the first identified Foxo targets were the proapoptotic gene Fas
ligand (Tnfsf6; 30), Insulin growth factor binding protein-1 (Ifgbp-1; 102), and the
cell cycle inhibitor Cdkn1b (p27KIP; 170), which indicated a role for Foxo family
members in regulation of apoptosis, cell cycle progression and metabolism. Foxo
proteins were shown to regulate the cell cycle through regulation of p27KIP (137)
and Ccng2 (Cyclin G2; 163), by downregulation of D-type cyclins (216, 236), and
via regulation of cyclin B and polo-like kinase (Plk) (6). Foxo-mediated induction
of apoptosis involves transcription of pro-apoptotic factors such as Fas ligand
(Tnfsf6; 30), Bim (63), and Trail (93, 178). And in response to oxidative stress and
DNA damage, Foxo transcription factors regulate Gadd45 (269), whereas Mnsod
and p66shc are up-regulated in response to oxidative stress only (138, 188). Foxo
transcription factors also mediate cellular metabolism via upregulation of Igfbp-1
(102), glucose-6-phosphatase (G6pc; 12), and pyruvate dehydrokinase-4 (Pck1;
214).
In conclusion, Foxo family members control growth rate via diverse
mechanisms. In C. elegans, nutrient depletion leads to a developmental arrest
that increases life span, whereas in mammalian cells Foxo's are also activated in
response to nutrient and growth factor depletion, but also in response to
oxidative stress and DNA damage. Dependent on the stimuli Foxo’s induce
growth arrest, senescence or apoptosis. 
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9. The PI3K/Foxo pathway and neoplastic transformation
In this introduction we first introduced SCF as a growth factor able to delay
differentiation and promote expansion of erythroid progenitors. We argued that
activation of the PI3K/PKB pathway is important for this function of SCF and that
inhibition of Foxo's is an important function of PKB. Accumulating evidence
shows that the regulation of the PI3K/PKB/Foxo3a pathway is important to
control the balance of expansion and differentiation in many cell types and that
disrupted control is involved in leukemogenesis. 
First, mutations in cKit that render the receptor constitutively active occur
approximately in one third of all inv(16) and t(8;21) AML (15, 90). Expression of
constitutively active cKit mutant in factor-dependent cell lines renders these cells
factor independent (129), and exogenous expression of mutant cKit in mouse
marrow cells caused leukemia in transplanted mice (129). Notably, PI3K activity
is critical for the transforming ability of the D816V cKit mutant (39). Furthermore,
autocrine loops of cKit activation may be important in many other types of
leukemia (208). 
Second, constitutive activation of PI3K is widespread in many types of
tumors. This can be caused by the breakpoint-cluster-region-abelson (Bcr-Abl)
fusion protein in CML, which is a kinase that strongly activates PI3K (243). The
BCR/ABL kinase resulting from a chromosomal translocation plays an essential
role in the pathogenesis of chronic myelogenous leukemia and Philadelphia
positive acute myeloid leukemia. The importance of PI3K/PKB pathway for the
transforming potential of BCR/ABL has been supported by the observation that a
kinase-dead PKB mutant was able to inhibit BCR/ABL-induced bone marrow
transformation. It also suppressed outgrowth of leukemia in severe combined-
immunodeficiency (SCID) mice transduced with the BCR/ABL kinase.
Conversely, addition of an active PKB mutant enhanced leukemia development
in SCID mice infected with a defective BCR/ALB mutant (2). Because PKB has
been shown to regulate apoptosis and cell cycle progression, the transforming
capacity is thought to occur at least partially through deregulation of these
processes. PI3K activity can also be increased due to PTEN inactivation, which
was observed in a variety of tumors (36). PTEN heterozygous mice may develop
a progressive lymphoproliferative disorder (61, 212), whereas PTEN
heterozygosity contributed to the development of myelodysplasia in SHIP
deficient mice (180).
Third, a general hallmark of cancer is loss of growth control. In many
tumors this results from activation of a growth promoting gene (proto-oncogene),
and loss of a growth-suppressing tumor suppressor gene. The importance of
tumor suppressor genes in tumorigenesis is underlined by the fact that
inactivation of one of the two copies of the gene already contributes to cancer
progression (80, 272, 286). Foxo transcription factors may function as tumor
suppressor genes. They suppress cell growth and are able to induce apoptosis
or cellular senescence through transcriptional activation of genes such as the cell
cycle inhibitor p27KIP and the pro-apoptotic factor Bim (20, 34). Inactivation of
Foxo function has been associated with tumorigenesis and poor survival in
breast cancer (FOXO3a; 110). Inactivation may be the consequence of
chromosomal translocation. In acute lymphoblastic leukemia a chromosomal
Introduction
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abnormality was identified that involved a fusion between the MLL gene on
chromosome 11, and FOXO4 on the X-chromosome (202). Due to X-inactivation
in females and the single copy of the X-chromosome in males , FOXO4
disruption results in the complete inactivation of Foxo4. Chromosomal fusion
between FOXO1 and PAX3 or PAX7 in translocations t(2,13) and t(1,13),
respectively, has been demonstrated in pediatric alveolar rhabdomyosarcoma
(54, 88). In this case the fusion products exhibit stronger transactivation activity
compared with PAX3 and PAX7 alone (72). This results in a stronger inhibition of
myogenic differentiation, thereby presumably contributing to the tumorigenic
phenotype. Notably, the PAX3-FOXO1 fusion gene up-regulates two tyrosine
kinase receptors: the platelet derived growth factor receptor (PDGFR) and MET,
which are not regulated by FOXO1 or PAX3 alone (73, 96). Because these
receptors are potent activators of the PI3K pathway, the intact FOXO1 protein
might be repressed as well. This potent FOXO1 inactivation may contribute to
tumorigenesis.
Growth advantage through Foxo inactivation is not the only mechanism
contributing to tumorigenesis. Foxo proteins are also activated in responses to
oxidative stress and DNA damage indicating that suppression of Foxo activity
does not only contribute to cell proliferation, but also to a cell's resistance to DNA
damage and oxidative stress. Therefore it will be important to understand the
mechanism of Foxo function not only as regulators of cell growth, but also as
regulators of the cellular response to chemotherapeutics.
Chapter 1
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10. Scope of the thesis
A proper balance between cell expansion and differentiation is a central feature
of normal hematopoiesis and deregulation of this balance may lead to
development of leukemia. In the studies presented in this thesis we set out to
investigate mechanisms that are involved in regulation of the
expansion/differentiation balance in erythropoiesis and concentrated on the
PI3K/PKB pathway. It had become clear that the PI3K pathway plays a role in
erythropoiesis, but the impact of the downstream events remained largely
elusive. Because inhibition of the PI3K/PKB pathway induces erythroid
differentiation without affecting apoptosis, we were interested to sort out PKB
mediated cellular mechanisms different from apoptosis. In a series of
experiments we addressed the role of the PI3K/PKB-dependent Foxo forkhead
transcription factors in controlling erythropoiesis (Chapter 2). We explored to
what extent Epo and SCF regulate Foxo proteins and how the different Foxo
family members are regulated during terminal erythroid differentiation. To test
whether Foxo3a controls the balance between erythroid expansion and
differentiation, erythroblast clones, stably expressing a tamoxifen-inducible, PKB-
phosphorylation deficient Foxo3a(A3):ER mutant were obtained and tested. In
additional approaches to explore the mechanisms via which Foxo3a controls
erythropoiesis, we performed mRNA profiling studies to identify erythroid specific
Foxo3a targets. We concentrated on a novel Foxo3a target identified in these
studies, Btg1, and examined whether and how Btg1 is involved in regulation of
the balance between erythroid expansion and differentiation (Chapter 2). A
pathway different from the PI3K pathway that is implicated in regulation of
erythropoiesis is the cAMP pathway. The cAMP pathway was also found to
regulate Btg1 transcription. Therefore, the transcriptional cooperation of Foxo3a
and the cAMP pathway on this target was investigated in expanding and
differentiating erythroblasts (Chapter 3). To identify other Foxo3a target genes,
erythroblast clones were used that stably express a tamoxifen inducible, PKB-
phosphorylation deficient Foxo3a(A3):ER mutant, in combination with a general
17K EST cDNA array (Chapter 4). The profiling results were compared with
profiling data obtained from the identical arrays on which Epo and SCF controlled
transcription was analyzed, to sort out the overlap between Foxo3a and Epo/SCF
targets. Because the PI3K pathway is most potently activated by the combined
stimulation of Epo and SCF in expanding erythroblasts, and is downregulated
during differentiation we wished to know whether expression of selected Foxo3a
targets is dependent on PI3K and how these genes are regulated in expanding
and differentiating erythroblasts (Chapter 4). Since a large number of Foxo3a
target genes did not show the expected transcriptional regulation by Epo and
SCF, we finally set out to investigate whether this may caused by cooperation
with additional transcription factors (Chapter 4).
In Chapter 5 we present both a summary and a discussion of the
experimental observations of this thesis with emphasis on their relevance for
understanding the molecular mechanism regulating erythropoiesis, as well as
their impact on future scientific research concerning the cellular functions and
mechanisms of Foxo proteins, and on hematopoiesis in general.
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Abstract
Erythropoiesis requires tight control of expansion, maturation, and survival of
erythroid progenitors. Since activation of phosphatidylinositol-3-kinase (PI3K) is
required for erythropoietin/stem cell factor-induced expansion of erythroid
progenitors, we examined the role of the PI3K-controlled Forkhead box, class O
(Foxo) subfamily of Forkhead transcription factors. Foxo3a expression and
nuclear accumulation increased during erythroid differentiation, whereas
untimely induction of Foxo3a activity accelerated differentiation of erythroid
progenitors to erythrocytes. We identified B cell translocation gene 1
(Btg1)/antiproliferative protein 2 as a Foxo3a target gene in erythroid progenitors.
Promoter studies indicated Btg1 as a direct target of Foxo3a. Expression of Btg1
in primary mouse bone marrow cells blocked the outgrowth of erythroid colonies,
which required a domain of Btg1 that binds Protein Arginine Methyl Transferase
1. During erythroid differentiation, increased arginine methylation coincided with
Btg1 expression. Concordantly, inhibition of methyl transferase activity blocked
erythroid maturation without affecting expansion of progenitor cells. We propose
Foxo3a-controlled expression of Btg1 and subsequent regulation of protein
arginine methyl transferase activity as a novel mechanism controlling erythroid
expansion and differentiation.
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Introduction
Homeostasis of the hematopoietic system requires tight control of expansion,
differentiation and survival of progenitor cells, which is exerted by numerous
cytokines and growth factors acting on specific cell types, e.g. erythropoietin
(Epo), or on multiple types of progenitors, e.g. stem cell factor (SCF). The role of
SCF in hematopoiesis is mainly to stimulate expansion and delay differentiation
of hematopoietic progenitors in cooperation with more cell type specific factors
(reviewed by 7).
Erythroid progenitors can be expanded in presence of Epo, SCF and
dexamethasone (Dex), whereas they differentiate into enucleated,
hemoglobinized erythrocytes in presence of Epo alone (18, 55). Differentiation
involves four differentiation specific cell divisions with altered cell cycle
regulation, until a terminal G1-arrest is reached. SCF considerably delays
differentiation, eventually yielding ~20-fold increased numbers of mature
erythrocytes. Erythroid differentiation is thought to be an autonomously regulated
cascade of events in which Epo-signaling is mainly required for survival and
constitutive BCL-XL expression is sufficient to allow erythroid differentiation in
defined medium lacking any factors (19, 45). SCF, a potent activator of PI3K in
erythroid progenitors, is unable to induce cell survival in absence of Epo (18, 55).
Instead, SCF signaling is required to delay differentiation, which is abrogated by
PI3K-inhibitor LY294002 (55). Both Epo and SCF activate PI3K and its target
Protein Kinase B (PKB or c-AKT; 1). However, compared to Epo, SCF is much
more potent in inducing PKB phosphorylation (55).
Phosphorylation and activation of the serine/threonine kinase PKB
controls fundamental processes such as cell cycle progression, apoptosis and
mRNA-translation (6, 9, 12, 14, 41). The Forkhead box, class O (FoxO) subfamily
of Forkhead transcription factors is an important effector of PKB in regulating
apoptosis and cell cycle progression. Members of this subfamily, Foxo4 (AFX),
Foxo1 (FKHR) and Foxo3a (FKHR-L1), are directly phosphorylated by PKB,
leading to cytoplasmic retention and inhibition of their transcriptional activity (8,
28, 47). In absence of phosphorylation, these transcription factors induce
expression of genes encoding proteins that inhibit the cell cycle such as p27KIP
(17, 35), p130Rb2 (27), and Cyclin G2 (40), or pro-apoptotic proteins such as Bim
(15, 16) and the transcriptional repressor BCL-6, which inhibits expression of the
anti-apoptotic factor BCL-XL (49). Whether Foxo activation results in cell cycle
arrest, induction of apoptosis, or other cell fates will depend on the cellular
context.
We investigated the potential role of Foxo family members during
expansion and differentiation of erythroid progenitors. Foxo3a expression
increases during differentiation resulting in nuclear accumulation 48 h after
induction of differentiation. Activation of a phosphorylation-insensitive Foxo3a
mutant accelerated differentiation under conditions favoring renewal. DNA micro-
array screens identified B cell translocation gene 1/anti-proliferative protein 2
(Btg1/Apro2) as a novel Foxo3a target. Ectopic expression of Btg1 inhibited the
expansion of mouse erythroid progenitor cells, which was dependent on the
Protein Arginine Methyl Transferase 1 (Prmt1) binding domain of Btg. We present
Foxo3a regulates erythroid differentiation and induces Btg1
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data that suggest that modulation of protein arginine methylation activity by Btg1
may present a new Foxo-dependent mechanism regulating erythroid
differentiation.
Results 
Foxo3a expression and activity increase during erythroid differentiation
In search of PI3K-dependent pathways involved in maintenance of erythroid
progenitor renewal, we analyzed expression and function of the PI3K/PKB-
regulated Forkhead family members Foxo4, Foxo1, and Foxo3a during
expansion and differentiation of the p53-deficient I/11 erythroid cell line. After
induction of differentiation, expression of Foxo1 and Foxo4 increased for 24 h,
but then rapidly declined to levels lower than those observed under renewal
conditions (Figure 2.1A). In contrast, Foxo3a expression sharply increased 12-24
h after differentiation induction (Figure 2.1B), reaching maximal expression at 48
h and remaining high until completion of differentiation at 72 h (Figure 2.1A, B).
Essentially the same results were obtained with primary erythroid progenitors
expanded from E12.5 fetal livers, except that these cells express maximal levels
of Foxo3a at 24 h and complete differentiation in 48 h (unpublished data).
Foxo3a function is regulated by phosphorylation. In factor-deprived and
re-stimulated erythroblasts, SCF induced a strong transient phosphorylation of
Foxo3a serine-residue 253, whereas Epo only weakly induced phosphorylation
of Foxo3a (Figure 2.1C). In Figure 2.1C, the unidentified protein X is
phosphorylated in factor deprived cells and dephosphorylated following Epo or
SCF stimulation. Phosphorylation of protein X is equally strong at time 0 in both
panels, the much more pronounced signal in the Epo-stimulation experiment is
due to an accordantly longer exposure of the blot. Upon induction of
differentiation, phosphorylation of Foxo3a reached maximum levels after 36 h,
and decreased thereafter, whereas total Foxo3a expression still increased
(Figure 2.1D, the band detected at 72 h by the phospho-specific antibody may be
the same protein X detected in Figure 2.1C). Foxo3a phosphorylation coincided
with reduced expression and phosphorylation of PKB (Figure 2.1D, middle
panels). By consequence, unphosphorylated Foxo3a, and thus Foxo3a mediated
transcription increased from 36 h onwards as monitored by expression of the
Foxo3a target gene p27KIP (Figure 2.1D, third panel). This is accompanied by
increased nuclear localization of Foxo3a (Figure 2.1E; 72 h after induction of
differentiation the cells are enucleated, hence no nuclear localization can be
detected). Together, Foxo3a is upregulated early in differentiation and is
transcriptionally active ~36-48 h after induction of differentiation as indicated by
its phosphorylation status and the expression of its target p27KIP. 
Physiological effects of Foxo3a in erythroid differentiation
Although Foxo1, Foxo3a and Foxo4 may control cell cycle progression and cell
survival of renewing cells, the expression pattern of Foxo3a suggests an
additional role in erythroid differentiation. To investigate the role of Foxo3a we
Chapter 2
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used an inducible, phosphorylation-insensitive Foxo3a(A3):ER fusion construct,
in which three serine- phosphorylation sites are mutated to alanines. Fusion of
this mutant to an estrogen receptor domain allows induction of nuclear
translocation of Foxo3a(A3):ER by 4-hydroxytamoxifen (4OHT; 16). The
Foxo3a(A3):ER protein was expressed in I/11 erythroid progenitors by retroviral
transduction. Exposure of Foxo3a(A3):ER expressing cells to 50 nM 4OHT
induced p27KIP protein levels in eight out of ten clones, which did not occur in
empty vector transduced cells (unpublished data). To test whether activation of
Foxo3a regulates erythroid differentiation and induces Btg1
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Figure 2.1. Foxo3a expression and activity increases during erythroid differentiation. (A) Western blots of
differentiating I/11 cells (samples taken every 12 h) were analyzed with antibodies recognizing Foxo1, Foxo3a and
Foxo4. ERK protein levels do not change during differentiation (loading control). (B) Western blot analysis of Foxo3a
total protein levels during the first 24 h of differentiation (ERK expression serves as loading control). (C) I/11 cells
were factor deprived and stimulated with Epo (5 U/ml) and SCF (1 µg/ml) for increasing time-periods as indicated.
Blots were analyzed with phosphospecific Foxo3a antibodies (S253) and antibodies recognizing total Foxo3a. An
unidentified, cross-hybridizing protein (X) is dephoshorylated in response to Epo and SCF. Its signal is comparable
at t 0’ in the Epo and SCF panel when equally exposed. (D) Western blots of differentiating I/11 cells (samples taken
every 12 h) were analyzed with antibodies recognizing Foxo3a and S253-phosphorylated Foxo3a, PKB and S473-
phosphorylated PKB, p27KIP and Erk. The protein recognized by Ser253-Foxo3a antibodies at t 72 h is unknown and
may be the same background band X detected by this antibody in (C). (E) Cytoplasmic and nuclear protein extracts
of differentiating I/11 cells were analyzed with antibodies recognizing Foxo3a, STAT3 and ERK. Under these
conditions STAT3 is only present in the cytoplasm, indicating minimal contamination of nuclear extracts with
cytoplasmic proteins. ERK expression serves as a loading control.
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Foxo3a(A3):ER could counteract SCF-induced delay of Epo-dependent
differentiation, Foxo3a(A3):ER clones and empty vector control clones were
cultured in Epo or in Epo plus SCF, both in presence or absence of 50 nM 4OHT.
Cell numbers, cell size, hemoglobin levels and cell morphology were monitored
daily. 4OHT did not affect proliferation or differentiation of control clones,
whereas it slightly decreased proliferation and enhanced hemoglobinization of
Foxo3a(A3):ER clones in presence of Epo (Figure 2.2A). In presence of Epo and
SCF, proliferation was impeded which was accompanied with enhanced
differentiation as analyzed by hemoglobinization (Figure 2.2B) and cell
morphology (Figure 2.2C). 4OHT increased the number of partially mature and
mature hemoglobinized cells, but cytospins showed no evidence for increased
cell death (Figure 2.2C). We did not observe an increase in apoptotic cells upon
Foxo3a(A3):ER activation, using a TUNEL assay (Figure 2.2D). This indicated
that exogenous, active Foxo3a accelerates differentiation of erythroid
progenitors. Also, in presence of Epo, SCF and Dex, activation of Foxo3a(A3):ER
abrogated renewal and induced differentiation. However, the presence of Dex
interferes with hemoglobin synthesis and precludes the use of this parameter to
monitor differentiation accurately. Using siRNA, we examined whether
underexpression of Foxo3a impaired or delayed erythroid differentiation. An
siRNA that fully blocked Foxo3a in a transient assay (Figure 2.2E, FOXi2)
resulted in a considerable, but not complete, reduction of Foxo3a expression
upon stable expression in erythroid progenitors (Figure 2.2F). After induction of
differentiation, reduced Foxo3a expression attenuated differentiation as
measured by hemoglobinization (Figure 2.2G). Thus, activation of Foxo3a
accelerated differentiation, and reduced levels of Fox3a suppress maturation
during differentiation.
Chapter 2
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Figure 2.2. Foxo3a induces erythroid differentiation. All Foxo3a(A3):ER clones used had similar expression
levels of the mutant Foxo3a protein and treatment of all clones induced rapid up-regulation of p27KIP (not depicted).
(A and B) A vector transduced clone (EV1) and Foxo3a(A3):ER expressing clones F5 and F6 were seeded in
differentiation medium containing Epo (A) or Epo plus SCF (B), in absence (open diamonds) or presence (closed
squares) of 50 nM 4OHT. Cumulative cell numbers (upper panel) and hemoglobin content per cell volume (lower
panel) was determined at daily intervals. (C) At day 4 of the experiments, cell morphology and hemoglobin content
was analyzed in cytospins. Hemoglobinized cells are smaller and darker (D). The vector control clone (EV1) and
two Foxo3a(A3):ER clones (F10, F12) were cultured in presence of Epo, SCF, Dex in presence or absence of 4OHT.
As a control, parental I/11 cells were seeded in medium lacking factors. After 24 h, the percentage of apoptotic cells
was determined by a TUNEL assay. Values represent mean ± SD of apoptotic cells counted in five fields of a
cytospin preparation (100 cells/field) in two independent experiments. (E) Phoenix E cells were transfected with
Foxo3a wild-type alone or in combination with RNAi constructs FOXi1 to 4 (see material and methods). Transient
expression of Foxo3a was determined by western blot (Erk serves as a loading control). (F) I/11 clones, transduced
with pSuper-retro vector as a control (ev1 and ev2) or pSuper-retro FOXi2 (clone numbers indicated) were tested
for Foxo3a on Western blot. (G) Two empty vector (ev1, ev2) and four FOXi2 clones (clone numbers indicated) were
differentiated in the presence of Epo. The hemoglobin content of the cells was measured at 0, 48 and 72 hours in
differentiation. Values represent mean ± SD of three experiments.
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Foxo3a target genes in erythroid cells
Although the Foxo3a target p27KIP can induce cell cycle arrest and differentiation
in some cell types, overexpression of p27KIP induced apoptosis in erythroblasts,
whereas erythroid differentiation was normal in p27KIP-deficient cells (23). In
addition to known targets that cause apoptosis or cell cycle arrest, Foxo3a could
induce so far unknown targets that function in erythroid differentiation. To identify
such target genes, cDNA derived from a Foxo3a(A3):ER expressing clone and a
control clone exposed to 4OHT (50 nM) for 0, 2 or 6 h, were hybridized to
custom-made 'hematopoietic' DNA microarrays containing ~9000 cDNAs derived
from SSH libraries enriched for transcripts of expanding erythroblasts (I/11 cells)
and mature T-cells (26). These microarrays contained multiple copies of
abundant erythroid-specific cDNAs (up to a few hundred for ß-globin). The
complete array results are available as supplementary data (Table S1, available
at http://www.jcb.org/cgi/content/full/jcb.200307056/DC1). Upon 4OHT treatment
of Foxo3a(A3):ER-expressing cells for 2 h, seven transcripts in the array were
up-regulated >1.75 fold compared with no treatment, whereas no up-regulated
genes were detected in similarly treated control cells. Five out of those seven
transcripts represented Btg1, with an average up-regulation of 1.9 ± 0.14 (Figure
2.3A). Upon 6 h of 4OHT treatment, 98 transcripts indicated a >1.75 fold increase
compared to no treatment. Eleven of these represented Btg1. Their average fold
up-regulation was 2.9 ± 0.33 (Figure 2.3A,B). None of these transcripts was
detected in the control experiment.
The same arrays were also screened for genes up- or down-regulated in
I/11 cells that were factor depleted and subsequently restimulated with Epo
and/or SCF (26). Among the Foxo3a targets up-regulated after 6 h, only the
transcripts representing Btg1 were down-regulated by Epo and SCF-signaling as
expected for genes primarily regulated by Foxo3a (Figure 2.3C and unpublished
data). Therefore, we concentrated on Btg1 as a novel putative Foxo3a target.
Two additional Foxo3a(A3):ER clones were treated for 2 h with 50 nM 4OHT, and
Btg1 transcript levels were determined by real-time PCR. In both clones, Btg1
expression was two-fold up-regulated, whereas control clones showed no
change in Btg1 expression (Figure 2.3D). Cyclohexamide treatment of I/11 cells
strongly up-regulated Btg1, which precluded its use to determine whether protein
synthesis is required for Btg1 up-regulation.
Together, we identified Btg1 as a prominent Foxo3a target in this screen.
We also show that mitogenic signaling suppresses Btg1 expression, which is in
accordance with the observed Epo- and SCF-induced phosphorylation of
Foxo3a.
Chapter 2
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Btg1 is a direct Foxo3a target
To examine whether Btg1 is a direct target of Foxo3a, we analyzed the Btg1
promoter region for putative Foxo-binding sites. Among the sequences submitted
to the public database, mouse cDNA clone L16846 contained the longest 5'UTR
sequence. A comparison with genomic sequences in the CELERA database
showed that the start of cDNA L16846 (designated +1) is located 40 nt
downstream of a conserved TATA-box sequence (Figure 2.4A). We found four
potential forkhead binding sites (Daf-16 binding element (DBE)) at position -219,
-454, -826 and -922 (Figure 2.4B), allowing a 1-bp mismatch compared with the
consensus sequence TTGTTTAC (21). outside the TGTT core sequence. Only
DBE1 (position -219) completely matched the consensus sequence, and an
alignment between the mouse and human Btg1 promoter sequence (BAC
AC025164) revealed that only DBE1 was 100% identical between mouse and
human (Figure 2.4A). 
To determine which part of the Btg1 promoter mediates Foxo3a-induced
expression, genomic fragments containing all 4 DBEs (-1033/+82), DBE1 (-
314/+82) or no DBE-sites (-67/+82) were tested for basal promoter activity in
Ba/F3 (hematopoietic, pro-B cells), COS (monkey kidney cells) and NIH3T3
(fibroblasts; Figure 2.4B, C). The activity of the different reporter constructs was
similar in all cell types. The promoter activity of the -1033/+82 and the -314/+82
fragments was equally high, whereas the promoter activity of the -67/+82 Btg1
promoter fragment was almost reduced to background levels, indicating the
presence of a crucial regulatory element between -314 and -67. 
Foxo3a regulates erythroid differentiation and induces Btg1
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Figure 2.3. Btg1, a Foxo3a target gene. Labeled cDNA
from Foxo3a(A3):ER clone F14 and vector clone EV1,
exposed to 50 nM 4OHT for 0, 2 and 6 h in presence of Epo,
SCF and Dex, was hybridized to a 9K cDNA micro-array
enriched for hematopoietic transcripts. (A) The number of
spots that detected a >1.75 fold increase in signal upon
treatment with 4OHT compared to nontreated cells is
indicated for both clones after 2 and 6 h of treatment. Btg1
transcripts were represented at least 11 times on these
arrays, 5 of these Btg1-spots showed >1.75 fold up-
regulation after 2 h induction with 4OHT. (B and C) The
average regulation on the 11 Btg1 spots is calculated after 2
and 6 h 4OHT treatment (B) and after 2 h Epo-, SCF- or Epo
plus SCF-induction of factor-deprived cells (C), 1 meaning
no regulation. Error bars indicate SD. (D) Control clone EV1
and Foxo3a(A3):ER clones F10 and F15 were treated with
50 nM 4OHT for 2 h and relative Btg1 expression was
determined by real-time PCR (Taqman), using expression of
RNAse-inhibitor to normalize the values. Values represent
mean ± SD of three independent experiments.
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To investigate the role of DBE1, the TGTT core was mutated to AAAT in
the -1033/+82 and -314/+82 constructs. This mutation caused a significant loss
of basal promoter activity in both fragments (Figure 2.4D), indicating that DBE1
is a critical element in the Btg1 promoter. Cotransfection of Foxo3a(A3) with the
wild-type and mutant -314/+82 promoter induced wild-type but not mutant
314/+82 Btg1 promoter activity (Figure 2.4E). Together these data suggest that
Foxo3a is able to activate transcription of Btg1 via the DBE1 element in the Btg1
promoter. 
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Figure 2.4. Regulation of Btg1 promoter activity by Foxo3a. (A) Sequence of the promoter region (plain) and
part of the first exon (bold, italics) of Btg1. Top sequence is derived from the mouse CELERA database and cDNA
clone L16846, the bottom sequence is derived from the human BAC AC025164. The start of mouse cDNA L16846
was assigned as position +1. A potential TATA-box and FoxO-binding site (DBE) are indicated. (B) Schematic
drawing of the Btg1 promoter fragments used in reporter assays. Four potential FoxO-binding sites, DBE1-4, were
found in the -1033/+ 82 promoter fragment. (C) Basal Btg1 promoter activity of these fragments was tested in COS,
NIH3T3 and Ba/F3 cells and compared with a vector control (pGL3). Luciferase activity is represented as arbitrary
units. Values represent mean ± SD of three measurements. (D) Both -1033/+82 and -314/+82 fragments with either
a wild-type or a mutated DBE1 were tested for basal promoter activity in COS cells. The -67/+82 fragment, serves
as a negative control. (E) COS cells were cotransfected with Foxo3a(A3) and the -314/+82 Btg1 promoter with either
a wt or a mutated DBE1. Luciferase activity presented as fold induction on the horizontal axis. Values represent
mean ± SD of three measurements.
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Btg1 is up-regulated in erythroid differentiation
If Btg1 is a Foxo3a target, its mRNA expression should follow Foxo3a activity
during differentiation of erythroid progenitors. We determined Btg1 transcript
levels during erythroid differentiation by Northern blot and real-time PCR (Figure
2.5), using mRNA prepared from I/11 cells harvested at 12-hour intervals after
differentiation induction. Btg1 mRNA expression was low until 36 h after induction
of differentiation when cells still proliferate. Btg1 transcript levels strongly
increased 48 h after differentiation induction when cells become postmitotic, and
remained high until the final stages of erythroid differentiation (Figure 2.5). Thus,
Btg1 is expressed upon appearance of active Foxo3a during differentiation,
suggesting a role of Btg1 in late erythroid differentiation. 
Btg1 may act via protein arginine methylation during differentiation
Btg1 is one of six family members, all sharing two highly homologous domains
(BoxA and B; Figure 2.6A). It shares a third region of homology with Btg2 (BoxC),
which associates with Prmt1 (2, 31). Overexpression of the Btg1 BoxC domain
has been shown to inhibit differentiation of PC12 cells (2). We expressed Btg1 in
the I/11 erythroid progenitors, but only obtained small, differentiated clones that
could not be expanded (unpublished data). Btg1:ER fusion constructs as used for
Foxo3a were not regulated tight enough. Because bone marrow is transduced
with much higher efficiencies than I/11 cells, we next transduced murine primary
bone marrow to examine proliferation and differentiation in suspension cultures
and in colony assays, using retroviral expression vectors containing Btg1 wild-
type or a Btg1 construct lacking boxC (Btg1-∆BoxC). Colony formation of
transduced cells was determined in serum-free semisolid medium supplemented
Foxo3a regulates erythroid differentiation and induces Btg1
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Figure 2.5. Btg1 is transcriptionally
upregulated during erythroid differen-
tiation. (A) Total RNA was isolated from
differentiating erythroid progenitors at
12-h intervals. Btg1 transcript levels
were detected using a Sma1/BamH1
211 bp fragment as a probe (top).
Ethidium bromide staining (bottom)
indicated equal loading. (B) Real-time
PCR on the RNA samples confirmed the
kinetics in a quantitative way, using
SYBR green in Taqman-analysis and
normalizing to the expression of the
RNAse-inhibitor RI. Values represent
mean ± SD of three measurements.
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with granulocyte-macrophage colony-stimulating factor (GM-CSF; myeloid
colonies), or with a combination of Epo, SCF and Dex (producing exclusively
erythroid colonies as Dex inhibits outgrowth of SCF-dependent, nonerythroid
colonies; controlled by cytospins (unpublished data). Addition of puromycin
selected for the outgrowth of transduced cells only. Bone marrow was infected
with supernatants containing equal numbers of virus as controlled by dot-blot
experiments (unpublished data; 20). Colonies were counted 7 days after plating.
Ectopic expression of Btg1 drastically reduced both the size and the number of
erythroid colonies (Figure 2.6B: smallest, average and largest colonies are
shown), whereas it only slightly reduced the number of myeloid colonies (Figure
2.6C). In contrast, erythroid colonies expressing Btg1-∆BoxC were normal in size
and only slightly reduced in number compared with the vector-control colonies
(Figure 2.6B,C). Though the total number of colonies obtained differed between
experiments (between 95 and 266 colonies in the vector control), the relative
number of colonies obtained upon transduction of the various constructs was
constant. Therefore colonies are given as a percentage of control. Essentially the
same results were obtained in suspension cultures (Figure 2.6D). This result
indicates that Btg1 abrogates proliferation, and that this effect depends on the
presence of the Prmt1 interaction domain in boxC.
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Figure 2.6. Btg1 inhibits proliferation of erythroid
progeni-tors. (A) Schematic drawing of the 171
amino acid Btg1 protein, indicating the conserved
domains A-C. (B-D) Density-purified murine bone
marrow progenitors were transduced with an empty
vector, and retroviral expression vectors encoding
Btg1 or Btg1(∆BoxC). Transduced cells were selected
with puromycin in serumfree semisolid medium
supplemented with 2 U/ml Epo, 100 ng/ml SCF and 
10-6 M Dex or with 10 ng/ml GM-CSF. Cytospins
showed that all colonies grown with Epo, SCF, Dex
contain erythroid cells, whereas GM-CSF allows
colony formation by various myeloid progenitors (not
depicted). 7 days after plating, the morphology of
erythroid colonies was photographed with a CCD
camera (B, left to right: smallest, average, largest
colony) and colonies were counted (C). Values
represent mean ± SD of three independent
experiments each counted in triplo. Transduced cells
were also grown in suspension cultures under
conditions favoring expansion of erythroid progenitors
and total cell numbers were determined daily. An
antisense Btg1 construct is added as a control (D).
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Because boxC of Btg1 interacts with Prmt1, we investigated whether
protein arginine methylation is associated with Btg1 expression. Two different
antibodies (7E6, recognizing mono- and dimethyl-arginine, and ASYM24,
recognizing only asymmetrical dimethyl-arginine) were used to
immunoprecipitate arginine-methylated proteins from lysates of cells at different
stages of differentiation. Concurrent with the activation of Foxo3a and the up-
regulation of Btg1, the 7E6 antibody detected a prominent protein of 100 kD
(Figure 2.7A top panel). The ASYM24 antibody detected proteins of 45, 40 and
37 kD, which appeared after up-regulation of Btg1 (Figure 2.7A, second panel).
ASYM24 also detects abundant proteins that are methylated at all stages of
differentiation. In contrast, the overall Prmt1 protein levels in the same lysates
remained constant during differentiation (Figure 2.7A, lower panel). 
To examine whether inhibition of methylation affects the balance
between expansion and differentiation of erythroid progenitors, I/11 erythroblasts
were seeded in differentiation medium containing Epo or Epo plus SCF to
analyze differentiation. Aliquots were exposed to the methyl-transferase inhibitor
5'-deoxy-5'-methylthioadenosine (MTA; 10 and 25 mM) or its solvent. Cell
numbers, cell volume, hemoglobinization and cell morphology were monitored
daily. In presence of Epo, I/11 cells achieve full hemoglobinization in 3 days, but
addition of MTA (both 10 and 25 mM) impairs hemoglobin accumulation (Figure
2.7B). In cytospins generated at day 3, the control cells are hemoglobinised and
enucleated, whereas MTA treated cells maintained blast morphology (Figure
2.7C). In presence of Epo and SCF, erythroblasts reduced cell size and
accumulated hemoglobin at day 8, whereas they retained blast morphology and
continued to proliferate in presence of MTA. This showed that inhibition of methyl
transferases impairs differentiation but fails to affect proliferation of erythroid
progenitors. Although the inhibitor is not specific for Prmt1, these results support
a potential role of Prmt1 in terminal erythroid differentiation. 
Foxo3a regulates erythroid differentiation and induces Btg1
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Discussion
Foxo3a expression increases sharply during erythroid differentiation, followed by
loss of phosphorylation and transcriptional activity. Inappropriate activation of
Foxo3a accelerates differentiation of erythroid progenitors to erythrocytes. Btg1
was identified as a novel target gene of Foxo3a, repressed by SCF and exerting
a negative effect on erythroid progenitor renewal. Deletion of BoxC in Btg1, a
domain known to bind protein arginine methyl transferase 1 (Prmt1), abrogated
proliferation inhibition by Btg1, suggesting that protein arginine methylation might
interfere with renewal. This is supported by the observation that inhibition of
methyl transferase activity does not interfere with progenitor expansion, but
blocks differentiation into mature erythrocytes. 
PI3K and Foxo3a control the balance between renewal divisions and
differentiation of erythroid progenitors
PI3K-dependent signaling is associated with expansion of erythroid progenitors
Chapter 2
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Figure 2.7. Protein methylation is associated with differentiation not with renewal of erythroid progenitors.
(A) Arginine-methylated proteins were immunoprecipitated and stained with two anti-methyl-arginine antibodies
(E76 and ASYM24) from cell lysates taken at 12 h intervals during differentiation of I/11 cells. The size of specific
proteins is indicated in kD. X and Y represent uncharacterized proteins detected by ASYM24 at all stages of
differentiation. The lower panels represent whole cell extract probed for total levels of Prmt1 and ERK (loading
control). (B) During differentiation of I/11 cells in presence of Epo and in absence or presence of MTA (10 and 25
mM) hemoglobin accumulation was quantified at day 2 - 4. Hemoglobin per cell volume is measured in arbitrary
units. Values represent mean ± SD of three measurements. (C) I/11 cells were seeded in differentiation medium in
the presence of Epo (top) or Epo/SCF (bottom), in absence (left) or presence (right) of the methyl-transferase
inhibitor MTA (25 mM). At day 3 (Epo) or at day 8 (Epo/SCF), cell morphology was analyzed in cytospins stained
for hemoglobin (hemoglobinized cells stain orange/brown) and histological dyes. In presence of MTA cells retained
a blast morphology and failed to accumulate hemoglobin.
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(22, 25, 36, 46, 55). Both Epo and SCF promote erythroid proliferation by
inhibition of FoxO's, whereas active Foxo3a was shown to cause cell cycle arrest
and apoptosis in erythroblasts unless inhibited by phosphorylation through PKB
(24, 33). We find Foxo1, Foxo3a and Foxo4 to be expressed in renewing
erythroid progenitors. The disappearance of Foxo1 and Foxo4 in differentiation
suggests that these FoxO-members may specifically have a role in the PI3K-
dependent control of progenitor expansion, possibly via previously reported
effector pathways (17, 27, 35, 40). Actually, the three FoxO-members may have
overlapping functions in the control of progenitor expansion. However, since not
only activation of Foxo3a, but also inhibition of PI3K activity induced
differentiation rather than apoptosis, all three FoxO-members may be able to
abrogate renewal and initiate the differentiation program. Once the differentiation
program is started, only Foxo3a is upregulated and only Foxo3a may control
gene expression in late differentiation, including Btg1. While activation of Foxo3a
enhanced differentiation, RNAi suppressing Foxo3a impaired differentiation as
monitored by reduced hemoglobinization. However, inhibition of Foxo3a did not
abrogate differentiation. Possibly, the remaining expression of Foxo3a is
sufficient to allow the differentiation process to proceed. Alternatively, the tight
control of erythroid cell numbers, evidenced by the very rare occurrence of
erythroid leukemia, has recruited several complementary mechanisms that
guarantee proper differentiation of erythroid progenitors.  The observation that
Foxo3a-deficient mice develop a compensated anemia with reticulocytosis (10).
illustrates the importance of Foxo3a in erythroid differentiation. The
reticulocytosis suggests that the anemia is caused by instability of erythrocytes
rather than by increased apoptosis of progenitors.
The role of Foxo3a in erythroid differentiation 
After induction of differentiation, erythroid progenitors undergo 3 - 4 cell divisions
whereas maturing to hemoglobinized, enucleated erythrocytes (18, 55).
Activated Foxo3a induced expression of p27KIP and p130Rb2 in erythroblasts as
has been shown for other cell types (17, 29, 35; confirmed by quantitative-PCR,
unpublished data). Forced activation of Foxo3a accelerated differentiation and
reduced the number of cell divisions. Foxo3a-induced expression of p27KIP and
p130Rb2 most likely contributed to G1-arrest. However, cell cycle arrest caused by
exogenous p27KIP fails to induce terminal differentiation of erythroid progenitors,
causing apoptosis instead (23). Furthermore, erythroid progenitors lacking p27KIP
did not show any alterations in erythroid differentiation (unpublished data). Thus,
erythroid differentiation requires more than a (p27KIP-mediated) cell cycle arrest.
In contrast to other cells, erythroid differentiation requires 3 - 4 cell divisions
without size control to mature into erythrocytes. We cannot conclude at present,
whether the newly identified Foxo3a target Btg1 contributes to differentiation
related phenotypic changes like an altered cytoskeleton organization, cell cycle
arrest, chromatin condensation and enucleation, or whether it directly contributes
to the early control of the balance between renewal and differentiation. However,
the fact that Btg1 controls protein methylation in erythroid differentiation and that
this may contribute to control of renewal versus differentiation identifies a novel
Foxo3a-dependent mechanism that may regulate many aspects of the
Foxo3a regulates erythroid differentiation and induces Btg1
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differentiation process. The importance of Btg function is underscored by the fact
that also the homologous family member Btg2 is similarly suppressed by SCF
and induced during differentiation (26), although via a distinct mechanism. This
complementary regulation underscores the biological importance of Btg
activation but precludes conclusive experiments on the requirement for Btg1 by
underexpression.
The role of Btg1 in protein methylation and differentiation
Screening of a cDNA array enriched for hematopoietic transcripts identified Btg1
as a major Foxo3a target. Others also reported Btg1 to be a potential forkhead
target (40), but so far its role and regulation were not studied in detail.
Activation of Foxo3a in expanding erythroblasts induced a >2-fold up-
regulation of Btg1 within 2 h, indicating a rapid induction. A more pronounced up-
regulation is detected during differentiation. However, Foxo3a(A3):ER protein
can only be expressed at low levels in expanding cells, resulting in
Foxo3a(A3):ER concentrations at best similar to endogenous levels. In contrast,
Foxo3a levels rise considerably during differentiation. This difference on Foxo3a
expression may explain the difference in Btg1 expression in these experimental
conditions. Expression of Btg1 is not solely regulated by Foxo3a, we also
reported Btg1 to be regulated by glucocorticoids (26). and it was shown to be a
putative vitaminD3 target (44). Moreover, preliminary data suggest that CREB
and Foxo3a have to cooperate in Btg1 induction (unpublished results). Thus,
regulation of Btg1 may be complex, suggesting an important role in cell fate
determination.
The Btg1 protein lacks enzymatic activity but contains several protein
interaction domains (Figure 2.6A), suggesting a function as an adapter molecule
for enzymes and their targets or as a regulatory cofactor. Btg1 has been shown
to interact with Prmt1 via its BoxC domain (2, 31), resulting in positive regulation
of Prmt1 activity. Thus, Btg1 may direct the associated methyl transferase activity
towards substrates binding to its NH2-terminal domains (e.g. HOXB9 and the
carbon catabolite repressor (CCR4)-associated factor-1, CAF1; 4, 38, 39, 43).
Although expression of Btg1 in mouse bone marrow cells fully blocked expansion
of erythroid progenitors, deletion of the Prmt1-associated BoxC domain largely
abolished this negative effect, indicating that recruitment of Prmt1 is essential to
the function of Btg1 in erythroid differentiation. Erythroid progenitors may be
more sensitive to this function of Btg1, since Btg1 expression only marginally
affected myeloid colony formation induced by GM-CSF. Erythroid differentiation
seemed to require arginine methylation, since its inhibition by 5'-deoxy-5-
methylthioadenosine (MTA) completely blocked terminal erythroid differentiation
without affecting the proliferation of immature erythroblasts. Despite the fact that
MTA inhibits other S-adenosyl-L-methionine-dependent methyl transferases, we
can still conclude that methylation is required for terminal differentiation and not
for renewal of erythroblasts. Similarly, global inhibitors of methylation also
inhibited differentiation in the PC12 cell line (11) and PC12 cells loaded with a
penetratin-Btg1/BoxC fusion peptide failed to differentiate, suggesting that
neuronal differentiation involves Prmt1 regulation by Btg1 (2). Overexpression of
Btg1 inhibited myoblast proliferation and induced differentiation (42). Btg2, the
Chapter 2
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closest homologue of Btg1 was shown to be upregulated in neuronal
differentiation (5, 13) and to play a role in germ cell and muscle cell differentiation
(reviewed in (51)).
It has become increasingly clear that arginine methylation functions as a
molecular switch, promoting or preventing specific protein-protein interactions
(for a review see 34). Prmt1 contributes to 90% of the total cellular methyl
transferase activity (37, 48) and mice lacking Prmt1 die at day 6.5 of
development just before gastrulation occurs (37). We showed that increased
Btg1 expression following induction of differentiation is accompanied by arginine
methylation of multiple proteins, ranging from 37 to 100 kD. The p100 detected
by 7E6 is detectable at 36 h, maximal at 48 h and not detected at later time
points, although expression of Btg1 and Prmt1 persist. Possibly its expression is
only transient, or the Btg1/Prmt1 complex is directed to other substrates in the
course of the differentiation program. Prmt1 was reported to induce methylation
of Stat1, but Stat1, Stat3 or Stat5 antibodies did not recognize the 100 kD
protein(s). So far we do not know the targets of Prmt1 in erythroid differentiation.
Interestingly, Btg1 interacts with CAF-1 and the CCR4/CAF1 complex is involved
in heterochromatin formation, gene silencing and negative regulation of mRNA
stability (4, 32, 38, 43, 50, 52, 53). In erythroid cells both Prmt1 and CAF1 are
expressed throughout differentiation at constant levels (this paper and
unpublished results), leaving the possibility that Btg1 mediated activation of
Prmt1 and CAF1 contributes to epigenetic gene regulation including
condensation of the nucleus and enucleation late in erythroid differentiation.
Materials and Methods
Cells and reagents
COS, 3T3 and ecotropic Phoenix cells were cultured in DMEM (Life Technology)
supplemented with 10% fetal calf serum (FCS; Life Technology), BA/F3 were
cultured in RPMI 1640 supplemented with 10% FCS and 10 ng/ml murine IL-3.
LY294002 was obtained from Alexis (Schwitzerland), 4-hydroxytamoxifen and 5'-
deoxy-5'-methylthioadenosine (MTA) from Sigma-Aldrich. 
Expansion and differentiation of erythroid progenitors
The erythroid cell line I/11 was cultured as described before (55). Cell numbers
and cell size were determined using a CASY1 electronic cell counter (Schärfe-
System). Cell morphology was analyzed in cytospins stained with histological
dyes and neutral benzidine (3). using an Olympus Bx40 microscope (40x
objective, NA 0.65), an OlympusDp50 CCD camera and Viewfinder Lite (1.0)
acquisition software. Images were cropped using Adobe photoshop 6.0.
Hemoglobin was measured as described previously (30). In short, 2 - 4 x104 cells
were washed in PBS, lysed in 20 ml H2O and frozen until all samples were
collected. 100 ml reagent mix (0.5 mg/ml o-phenylenediamine (Sigma), 0.03%
H2O2 in 0.1 M citrate/phosphate buffer pH 5.0) was added to thawn samples, the
reaction was stopped after 3' with 20 ml 8 N H2SO4 and the extinction of the
Foxo3a regulates erythroid differentiation and induces Btg1
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reaction product was read on an Elisa photometer at 492 nM, using the extinction
at 690 nM as a control. Extinction/cell number/cell volume was taken as a
measure for hemoglobinisation. Apoptosis was determined using the TUNEL
assay according to the manufacturer's protocol (Roche).
Generation of stable Foxo3(A3):ER or Foxo3-RNAi expressing  I/11 clones
The Foxo3(A3):ER construct (15). was cloned in the retroviral expression vector
pBABE-puro. Four RNAi constructs were cloned in pSuper-retro (kindly provided
by Anton Berns, NKI, Amsterdam, The Netherlands):
FOXi1 AATGAAGGCACGGGCAAGAGCTCTT;
FOXi2 AACCAGACACTCCAAGACCTGCTT;
FOXi3 AGTGACTTGGACCTGGACATGTT
and FOXi4 AGCCAGCTCGGCCATGGTGAT. These were transiently expressed
in Phoenix cells together with the Foxo3(A3):ER construct. Only the FOXi2
sequence suppressed Foxo3 expression and was used for stable expression in
I/11 cells. To obtain stable expression, 0.5 x 106 ecotropic Phoenix cells, seeded
in 60 mm dishes, were transfected with 16 mg plasmid DNA using calcium-
phosphate coprecipitation. 40 h after transfection, cells were treated with 10
mg/ml mitomycinC (Kyowa Hakko Kogyo, Tokyo, Japan) for 1 hour and washed
3 times with PBS, twice with an interval of > 4 h. I/11 cells (0.5 x 106 / ml) were
added and co-cultured for 24 h in StemPro-34TM plus factors. I/11 cells were
removed and grown in puromycin containing (2 mg/ml, Sigma) semisolid medium
(Methocel-containing StemPro-34TM (Invitrogen), supplemented with factors).
After 7 days, well-separated colonies were picked, expanded and analyzed for
Foxo3(A3):ER expression. 
Western blotting and antibodies
I/11 cells were growth factor deprived for 4 h in plain IMDM (Life Technology) and
stimulated at 37°C with SCF (100 ng/ml) or Epo (5 U/ml). Reactions were
stopped by addition of ice-cold PBS. Cell lysis, immuneprecipitation, SDS-PAGE
and Western blotting were performed as described previously (54). Antibodies
used in this study were: α-HA (F-7, Santa Cruz), α-Foxo4a (N-19; Santa Cruz),
α-Foxo1 (#9462, Cell Signaling Technology), α-Foxo3 (#06-951, Upstate
Biotechnology), α-phospho-Foxo3 (S-253; #06-953, Upstate Biotechnology), α-
p27KIP (#K25020, BD Transduction Laboratories), α-ERK1/2 (K-23, Santa Cruz),
α-STAT3 (C-20, Santa Cruz), α-mono- and dimethylarginine (7E6; Abcam), α-
dimethylarginine (ASYM24; Upstate) and α-Prmt1 (a generous gift from J. P.
Rouault, Hôpital Edouard Herriot, Lyon, France).
RNA isolation and Real-time quantitative PCR
After 2 h stimulation (4OHT: 50 nM; Epo: 5 U/ml; SCF: 100 ng/ml), cells were
lysed, nuclei were removed and RNA was isolated as described previously (26).
1 mg total RNA was used to synthesize cDNA, exactly as described previously
(26). The cDNA was diluted 1:10 to 1:200 prior to PCR amplification. The primer-
sequences used for the amplification of Btg1 were forward 5'-TGC AGG AGC
TGC TGG CAG-3', reverse 5'-TGC TAC CTC CTG CTG GTG A-3'; murine
ribonuclease inhibitor, forward 5'-TCC AGT GTG AGC AGC TGA G-3', reverse 5'-
Chapter 2
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TGC AGG CAC TGA AGC ACC A-3'. The real-time PCR assay involves TaqMan
technology (PE Aplied Biosystems Model 7700 or 7900 sequence detector). The
reactions were performed as described previously (26). The amplification
program consisted of 1 cycle of 50ºC with 2' hold, 1 cycle of 95 ºC with 10' hold,
followed by 40 cycles of denaturation at 95 ºC for 15'', annealing at 62 ºC for 30''
and extension at 62 ºC for 30''. The CT-values of Rnase Inhibitor were used to
normalize the Btg1 values.
cDNA array hybridisations and analysis
Total RNA was used to hybridize a custom made 'Hematopoietic' micro-array
containing approximately 9000 cDNAs, enriched for erythroid and T-cell specific
cDNAs by subtracting cDNA of expanding I/11 cells and quiescent CD4+ T-cells
from cDNAs prepared from 3T3 fibroblasts and EpH4 epithelial cells. A full
description of the array and the array hybridization is available as supplementary
data. The quality of RNA was determined with a bioanalyzer (2100 Bioanalyzer,
Agilent), according to the manufacturers instructions. For a single hybridization,
30 µg total RNA was reverse transcribed into cDNA using Cy5-UTP (CyDye,
Amersham Biosciences), whereas control total RNA was labeled with Cy3-UTP.
The micro-arrays were hybridized and analyzed as described (26). The scanning
was performed using a Genepix 400A (Axon Instruments) scanner, the analysis
using the GenePix program. 
Cloning of the Btg1 promoter and Luciferase Reporter assays
The Btg1 cDNA clone L16846 was aligned to the mouse Btg1 genomic sequence
(CELERA) and the human BAC clone AC025164. The -1033/+82 Btg1 promoter
fragment was cloned into the pGL3-Basic vector (Promega) after expansion by
PCR using a 5' oligo (5'-GTG GTG TGT ATT GCA TCT GAT GAC C-3'), a 3' oligo
(5'-CAC ATC GCT CGG ACC TCC CCA GCC-3') and the Expand High Fidelity
PCR System (Roche). The -314/+82 and the -67/+82 promoter fragments were
obtained using the internal NheI and SmaI sites, respectively. The DBE1) was
mutated using the Quickchange Site Directed Mutagenesis kit (Stratagene)
according to the manufacturers protocol with primers 5'-CGG GGG GTT TAT TTA
AAT ACA AGC AGA TTA CG-3', and its complementary sequence. For reporter
assays, COS cells were seeded at 2.5x105 cells/35mm well (Costar) and
transfected with 4 mg of DNA by calcium-phosphate co-precipitation. After 24 h
cells were washed with PBS and subsequently lysed in 25 mM Tris-phosphate
pH 7.8, 15% glycerol, 1% Triton X-100, 1 mM DTT, 8 mM MgCl2. Luciferase
activity was measured using the Steady-Glo system (Promega). LacZ
determination was used to correct for transfection efficiency.
Online supplemental material
Table S-I is an excel file that contains the data of the microarray analysis. A
MIAME compliant description of the microarray, the samples and the
hybridization and scanning procedures is given as a separate text file.
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Abstract
The transcriptional activity of forkhead transcription factor Foxo3a and
expression of its target B-cell translocation gene 1 (Btg1) are repressed by
growth factor-induced phosphatidylinositol-3-kinase (PI3K) activity. Btg1 controls
the activity of protein arginine methyl transferase 1 (Prmt1) and abrogates
expansion of erythroid progenitors. Foxo3a expression increases and PI3K
activity decreases during erythroid differentiation, resulting in increased
expression of Btg1 late in erythropoiesis. We examined regulation of Btg1
expression and found that a cAMP response element (CRE) present in the Btg1
promoter close to the Foxo3a binding site was important for Btg1 expression.
This site appeared to bind the cAMP-dependent transcription factors CREB and
ATF1, as well as ATF2 and cJun that are controlled by Jun-kinase (JNK). The
level of cAMP and phosphorylation of CREB and ATF1 strongly increased late in
differentiation, indicating that both Foxo3a and the cAMP pathway can induce
Btg1 in late erythroblasts. The prostaglandin E2 receptor, which has been shown
to activate the cAMP pathway, is strongly induced during erythroid differentiation,
and cooperates with Foxo3a on induction of erythroid differentiation.
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Introduction
Erythropoietin (Epo) is essential for expansion, survival and differentiation of
erythroid progenitors (30, 55). Stem cell factor (SCF) has an essential role in
hematopoiesis (9), but in control of erythropoiesis it is mainly involved in
expansion of erythroid progenitors under stress conditions (8, 35, 53) in
cooperation with glucocorticoids (3). The ability of erythroid progenitors to
undergo expansion in vitro in presence of Epo, SCF and glucocorticoids,
whereas they differentiate to enucleated erythrocytes in presence of Epo, reflects
stress erythropoiesis and offers a unique opportunity to study the regulation of
expansion versus differentiation of erythroid progenitors (18, 53). An important
signaling pathway in the control of this balance is the phosphatidylinositol-3-
kinase (PI3K) / protein kinase B (PKB) pathway. Inhibition of PI3K decreased
erythroid expansion and induced differentiation instead (53). Concordantly, mice
lacking the p85 subunit of PI3K display a transient fetal anemia due to decreased
progenitor expansion (24). PKB is a major effector of PI3K activity. Through direct
phosphorylation, PKB controls multiple proteins with key functions in distinct
cellular processes, among which class O forkhead transcription factors (Foxo's;
(7, 10, 28) Phosphorylation of Foxo's results in reduced DNA-binding and nuclear
exclusion (10, 28). Mutation of the 3 serine residues that are targeted by PKB into
alanine residues, renders Foxo3a constitutively active (17). Expression of this
Foxo(A3) mutant suppressed erythroid proliferation and induced erythroid
differentiation instead (2).  During differentiation, Foxo3a expression gradually
increases, whereas PKB activity is abrogated 48h after differentiation induction,
resulting in a sudden increase of Foxo3a activity concurrent with major changes
in the differentiation program such as G1 arrest of the cell cycle and chromatine
condensation. By micro-array analysis we identified B-cell translocation gene-1
(Btg1)/anti-proliferative gene-2 (Apro2) as a direct Foxo3a target (2). Expression
of Btg1 sharply increases during erythroid differentiation concomitant with
Foxo3a activity. Btg1 inhibits proliferation of erythroid progenitors, which is
dependent on its ability to bind to arginine methyl-transferase-1 (Prmt1),
suggesting that Foxo3a controls the balance between erythroid expansion and
differention thought modulation of protein arginine methylation (2).
Btg1 and its close homologue Btg2 are members of an anti-proliferative
(apro) gene family, which suppresses growth in a wide variety of cells (32, 43,
44). Btg family members are small proteins without enzymatic activity. They all
share two homologous domains (boxA and B), whereas Btg1 and Btg2 share a
third homologous region (boxC), which interacts with Prmt1 (4). Their expression
increases in the G0/G1 phases of the cell cycle and they induce differentiation in
a variety of cells. For instance, Btg2 expression is increased at the onset of early
neuronal differentiation (6, 48) and was suggested to mediate the growth arrest
that serves as a prelude to differentiation (25). Concordantly, overexpression of
boxC, which acts as a dominant negative peptide, blocked neuronal
differentiation (4). Btg1 was shown to mediate cAMP-induced differentiation of
myboblasts into myocytes (31, 42), suggesting a link between the cAMP pathway
and Btg1 function. 
The cAMP pathway, like Btg1 and Btg2, has been linked to inhibition of
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cell growth and induction of terminal differentiation. For instance, both cAMP and
Btg1 are involved in spermatid differentiation (40, 54) and cAMP was shown to
impair proliferation and induce differentiation of leukemic blasts both in vivo and
in vitro (21). In primary and transformed erythroid progenitors, cAMP impairs
proliferation (22, 29), whereas knock down of the cAMP downstream target
protein kinase A (PKA) impairs differentiation of mouse erythroleukemia cells
(37). Expression of Ala-S (5-aminolevulinate synthase), the rate-limiting enzyme
in heme-synthesis, and NF-E2 (nuclear factor erythroid 2) appeared to be
regulated by cAMP (20, 47). A major deficit of most studies concerning the role
of cAMP in erythroid differentiation is that they address the role of cAMP in
chemically induced differentiation of erythroleukemia cells, whereas little is
known about the role of cAMP in normal erythropoiesis.
Here we demonstrate that cAMP levels as well as phosphorylation of the
cAMP-responsive transcription factors CREB and ATF1 is increased during
differentiation. CREB and ATF1 appeared to cooperate with Foxo3a to induce
Btg1 expression. One of the factors able to induce cAMP in maturing erythroid
progenitors is prostaglandin E2, which enhanced Foxo3a induced erythroid
differentiation. Thus, the cAMP pathway cooperates with Foxo3a to control
terminal differentiation of erythroid progenitors and they cooperate directly in the
regulation of Btg1.
Results
A CRE site in the Btg1 promoter contributes to Btg1 expression
Analysis of the Btg1 promoter revealed the presence of cyclic-AMP responsive
element (CRE) in a highly homologous promoter region (Figure 3.1A), i.e. at
position -204, 15 basepairs downstream of the previously reported Daf-16
binding element (DBE), (Figure 3.1A) which is essential for induction of Btg1
expression by Foxo3a (2). We previously reported Foxo3a-dependent promoter
activity of both a -1030/+82 and a -314/+82 promoter fragment. To investigate the
contribution of the CRE to control of Btg1 expression, the CRE was mutated by
a two basepairs substitution (TTACGTCA to TTTGGTCA), in both the wild-type
promoter fragments and in conjunction with a mutation of the DBE (2). Promoter
activity was assayed using luciferase activity as a reporter. Deletion of the CRE
or the DBE repressed basal promoter activity to a similar extent, whereas the
promoter activity was not further repressed in the absence of both sites (Figure
3.1B). Both the longer and smaller promoter fragments are similarly regulated
confirming that the -314/+82 Btg1 promoter fragment contains the essential
elements for promoter regulation. 
The close proximity of the CRE to the DBE and the observation that
deletion of either site represses Btg1 promoter activity raises the question
whether both sites are essential for Foxo3a-induced Btg1 transcription. Co-
expression of Foxo3a and the various reporter constructs show that the DBE, but
not the CRE site is essential for Foxo3a-induced Btg1 expression (Figure 3.1C).
It was also tested whether stimulation of the cAMP pathway resulted in increased
Chapter 3
80
Chapter-3.qxd  24-Nov-04  12:05  Page 80
Btg1 expression. To this end the different Btg1 promoter constructs were
transfected to Ba/F3 cells and cultured overnight in the absence or presence of
10 mM cAMP. Cyclic-AMP stimulation increased Btg1 promoter activity of the
wild type promoter, but not of the DBE and CRE mutants, suggesting that
induction of Btg1 by cAMP is dependent on Foxo activity (Figure 3.1D). Thus,
both the DBE and the CRE site contribute to basal Btg1 promoter activity, but the
CRE-site is dispensable for Foxo3a-induced Btg1 promoter activity, whereas the
cAMP pathway has to cooperate with Foxo3a to induce Btg1 promoter activity. 
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Figure 3.1. Expression of
Btg1 is controlled by Foxo3a
and by factors binding to a
cAMP response element
(CRE) close to the Foxo
binding site (DBE). (A)
Alignment of the mouse and
human Btg1 promoter. The
transcription startsite is
indicated as +1, transcribed
sequence in bold. At +82 the
first intron is indicated by a
small dash in both sequences.
The TATA-box as well as the
Foxo binding site (DBE) and
cAMP responsive element
(CRE) are boxed. (B, C) Long 
(-1030/+82) and Short 
(-314/+82) Btg1 promoter
fragments (wild-type (wt), with
a mutated DBE (indicated as
DBE), a mutated CRE
(indicated as CRE) or both
(indicated as DBE/CRE)) were
cloned in a luciferase reporter
construct, transfected in
295HEK cells and luciferase
activity was measured 24 h
after transfection. Values were
normalized for transfection
efficiency using β-galactosida-
se activity encoded by a co-
transfected expression
plasmid. (B) Promoter activity
of mutated promoter
fragments is given as fold
repression compared to the
wild-type promoter fragment.
(C) Foxo3a expression
plasmid or empty vector has
been cotransfected with the
reporter constructs and promoter activity in presence of Foxo3a is given as fold induction compared to promoter
activity in absence of Foxo3a. Values represent mean and standard deviation of 3 experiments. (D) Btg1 reporter
constructs were transfected in Ba/F3 cells and were treated overnight with 20 mM db-cAMP, or left untreated.
Promoter activity is presented as fold induction of db-cAMP over non-treated cells (in 2log values). Values represent
mean and standard deviation of 3 experiments
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The cAMP pathway enhances Btg1 expression in erythroid progenitors
To examine whether the cAMP pathway regulates Btg1 expression in erythroid
cells, I/11 cells were treated with a stable form of cAMP (dibutyryl-cAMP; db-
cAMP, 10 µM), and ligands of the prostaglandin E2 receptor (PGE2, 10 µM) and
the adrenergic receptor (norepinephrine; NE, 100 µM), two ligands that activate
the cAMP pathway and play a role in erythropoiesis (39). Western blots
containing cytoplasmic and nuclear extracts of stimulated cells were stained with
an antibody recognizing phosphorylated serine 133 and 63 in CREB and ATF1
respectively. All three compounds induced phosphorylation of nuclear CREB and
ATF1 (Figure 3.2A). Treatment with PGE2 induced a strong, transient response,
whereas db-cAMP and NE resulted in a more prolonged activation of the cAMP
pathway. All three compounds modestly enhanced Btg1 expression (Figure
3.2B). NE and db-cAMP which both resulted in prolonged cAMP pathway
activation, also resulted in a more pronounced activation of Btg1 expression.
cAMP pathway activity during erythroid differentiation
Foxo3a is strongly up-regulated during erythroid differentiation and by
consequence also Btg1 transcript levels are elevated between 48 and 72 hours
(2), i.e. during the final stage of erythroid differentiation when the cells arrest in
the G1 phase of the cell cycle, enucleate and accumulate hemoglobin (53). The
possible involvement of the cyclic-AMP pathway in Btg1 regulation through the
CRE prompted us to investigate activity of the cAMP pathway during erythroid
differentiation. Cyclic-AMP levels increased during differentiation, reaching a
maximum between 40 and 60 h after induction of differentiation (Figure 3.3A),
concomitant with strongly increased Btg1 levels from 40 hours in differentiation
(2). Phosphorylation of CREB and ATF1 followed the levels of cAMP during
differentiation. Whereas expression of CREB and ATF1 was constant during
differentiation, phosphorylation increased from 48 hours after differentiation
induction (Figure 3.3B). Phosphorylated CREB and ATF1 are located
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Figure 3.2. Different inducers of cAMP cause phosphorylation of the transcription
factors CREB and ATF1 and increase expression of Btg1. (A) I/11 cells were factor
deprived (4 h) and stimulated with dibutyryl cAMP (db; 10 µM), prostaglandin E2 (E2;
10 µM) or norepinephirine (NE; 100 µM) for 5, 10 or 20 minutes. Cytoplasmic and
nuclear extracts were prepared and stained with an antibody recognizing
phosphorylated serine 133 and 63 in CREB and ATF1 respectively. (B) I/11 cells were
treated similarly for 2 h and Btg1 mRNA expression was quantified by realtime PCR.
Expression induced by cAMP-activators is given as fold induction compared to no
treatment. Values represent mean and standard deviation of 3 experiments.
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predominantly in the nucleus (Figure 3.3C).
The observations that cAMP can induce Btg1 expression and that the
activity of the cAMP-pathway increases during the final stages of erythroid
differentiation, strengthens the hypothesis that activation of the cAMP-pathway
contributes to Btg1 expression during erythroid differentiation.
CREB family members bind to the Btg1 promoter
We next investigated binding of CREB/ATF1 to the CRE site in the Btg1 promoter
in expanding and differentiating erythroblasts. Nuclear extracts were incubated
with a radioactively labeled oligonucleotide probe encompassing the CRE site
and tested in an electrophoretic mobility shift assay (EMSA). Two protein
complexes were found to bind the oliginucleotide probe, both in expanding
erythroblasts and 48 h after differentiation induction. Competition with wild-type
(wt), but not with a CRE mutated probe, inhibited binding of both complexes,
indicating that they bind specifically to the CRE (Figure 3.4A,B). The CRE
element in the Btg1 promoter (TTA CG TCA) is not completely similar to the
common palindromic CRE sequence identified for instance in the somatostatin
promoter (TGA NN TCA) (33, 45). Instead, it resembles the binding site identified
for the cJun/ATF2 complex (TTA CC TCA), through which the cJun/ATF2
complex regulates e.g. cJun expression (23, 50, 51). The CREB family members
CREB, CREM and ATF1 are able to form heterodimers, but they do not
heterodimerize with other bZIP classes such as AP1 family members like cJun
and cFos (15, 46). To discriminate between CREB/ATF1 and c-Jun/ATF2 binding
to the CRE-element in the Btg1 promoter, probes with an optimal CREB (TGA CA
TCA), and an optimal cJun/ATF2 binding site (TTA CC TCA) were used as
competitors for the wild-type CRE Btg1 probe. Interestingly, competition with a
CREB/ATF1 probe competed efficiently with both complexes, whereas
The cAMP pathway cooperates with Foxo3a to induce Btg1 expression 
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Figure 3.3. cAMP and phosphorylation of CREB and ATF1 is increased late in erythroid
differentiation. I/11 cells were induced to differentiate and samples were isolated at 12h intervals.
(A) Intracellular cAMP levels were determined using a cAMP enzyme-immunoassay. (B) Cell lysates were
stained with an antibody recognizing phosphorylated serine 133 and 63 in CREB and ATF1 respectively.
Cell lysates from COS, 3T3 and 293HEK cells were used as positive controls. (C) I/11 cells were induced
to differentiate, cytoplasmic and nuclear extracts were generated at 24 h intervals and stained for
phosphorylated CREB and ATF1 (see B). 
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competition with the cJun/ATF2 probe only inhibited binding of the slower
migrating complex (Figure 3.4A,B). Consistent with these findings, binding of the
faster migrating complex but not the slower migrating complex, could be
supershifted upon addition of the CREB/ATF1 antibody (Figure 3.4A,B).
In conclusion, two complexes are able to bind the CRE in the Btg1
promoter. A CREB/ATF1 complex was identified as the faster migrating complex,
whereas a cJun/ATF2 complex may be present in the slower migrating complex.
Binding of these complexes did not differ between 0 and 48 hours, but the cAMP
pathway may regulate the activity of the CREB/ATF1 complex during
differentiation to contribute to up-regulation of Btg1. 
The cAMP pathway enhances Foxo3a induced erythroid differentiation
During differentiation, the activity of the PI3K/PKB pathway decreases whereas
the activity of the cAMP pathway increases. As a result, the transcriptional activity
of both Foxo3a and CREB/ATF1 increases. To test whether both pathways
cooperate in induction of erythroid differentiation, I/11 cells were differentiated in
the presence of Epo and SCF, supplemented with 10 µM dibutyryl cAMP and /or
15 µM of the PI3K inhibitor LY294002, as indicated (Figure 3.5). Addition of
cAMP did not affect the growth of differentiating erythroblast, and LY294002
modestly reduced the number of cell divisions. However, the simultaneous
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Figure 3.4. The CRE in the Btg1
promoter binds CREB/ATF1 as well
as cJun/ATF2. Nuclear extracts from
expanding (A) and 48h differentiated
(B) I/11 cells were incubated with a
32P-labeled oligonucleotide probe
derived from the Btg1 promoter
encompassing the CRE. Binding of
protein complexes was assessed by
EMSA. To verify specific binding we
added an excess of oligonucleotide
probe: wild-type (wild-type CRE; lanes
2,3) or with a mutated CRE (mut-CRE;
lanes 4,5). To identify the protein
complexes, excess of a CREB/ATF1
specific (CREB oligo; lanes 6,7) or a
cJun/ATF2 specific (ATF2 oligo; lanes
8,9) oligonucleotide probe were
added. In supershift experiments anti-
CREB/ATF1 (lane 11) or anti-Stat5
(lane 12) were added. Arrows at the
right side indicate the mobility of
cJun/ATF2 and CREB/ATF1
complexes.
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addition of both compounds strongly suppressed growth during differentiation
(Figure 3.5A). In addition, both LY and cAMP alone did accelerate differentiation,
shown by the increased hemoglobin synthesis upon addition of LY or cAMP
alone, which was further enhanced in the presence of both compounds (Figure
3.5B), showing a cooperation between the PI3K/Foxo3a and the cAMP pathway
in the control of erythroid differentiation.
To investigate the cooperation between the PI3K/Foxo3a and cAMP pathways in
control of erythroid differentiation in more detail, it was investigated whether
stimulation of the PGE2 receptor, which is up-regulated in differentiation about
40-fold (18), could enhance Foxo3a-induced differentiation. Therefore,
erythroblast clones from the erythroid progenitor cell line I/11, stably expressing
a 4OHT-inducible, active Foxo3a mutant (Foxo3a(A3):ER; 2), were treated with
4OHT and/or PGE2. Previously we have shown that Foxo3a induced
differentiation is represented by decreased number of cell divisions and
increased hemoglobin synthesis (2). Addition of 4OHT or PGE2 in control cells
did not affect differentiation-associated proliferation, but PGE2 did enhance
hemoglobin accumulation. As expected, addition of 4OHT strongly induced
growth arrest and differentiation in clones with a high expression of Foxo(A3):ER.
Under these conditions addition of PGE2 did not enhance differentiation (data not
shown). However, in cells expressing moderate levels of Foxo(A3):ER, the
differentiation induced by 4OHT was further accelerated by PGE2 as evidenced
by decreased proliferation and increased hemoglobin accumulation (Figure 3.6).
Addition of PGE2 alone again did not affect differentiation. Therefore we
conclude that Foxo3a and the cAMP pathway cooperate on induction of erythroid
differentiation.
The cAMP pathway cooperates with Foxo3a to induce Btg1 expression 
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Figure 3.5. Cyclic-AMP enhances erythroid differentiation induced by inhibition of the
PI3K/PKB pathway. Erythroblasts (I/11 cell line) were seeded in Epo/SCF containing medium,
supplemented with the PI3K inhibitor LY294002 (15 µM), and/or 10 µM Cyclic-AMP as indicated.
(A) Growth curve of the differentition course. Cell number presented in a logaritmic scale, time
(hours) on the X-axis. (B) Hemoglobin (Hb) levels per cell volume (Y-axis, in arbitrary units (a.u.))
are shown for the timepoints 24 - 84 hours (X-axis).
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Discussion
Btg1, encoding a small adaptor molecule controlling the activity of Prmt1, was
identified as a Foxo3a target gene able to abrogate renewal divisions of erythroid
progenitors. In this study we show that Btg1 is also regulated by the cAMP
responsive transcription factors CREB and ATF1. Both the Foxo-binding site
(DBE) and the cAMP responsive element (CRE) are required for full activity of
the Btg1 promoter. The level of cAMP as well as phosphorylation of CREB and
ATF1 increases late in differentiation, concomitant with Btg1 expression. Thus,
factors activation adenylate cyclase and increasing cAMP levels can enhance
Foxo3a-mediated Btg1 expression late in differentiation. As an example we
demonstrated the cooperation of prostaglandin E2 and activation of Foxo3a in
erythroid differentiation.
Cooperation of the cAMP pathway and Foxo3a during late erythroid
differentiation
Differentiation of I/11 erythroblasts takes three days. At the onset of
differentiation, which is induced by Epo, the cells undergo 3 - 4 "differentiation
divisions", characterized by loss of size control, before they reach a terminal G1-
arrest and expel the nucleus. During this process the cells accumulate
hemoglobin, which requires the balanced expression of the globin genes and
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Figure 3.6. Prostaglandin E2 and Foxo cooperate on induction of erythroid differentiation. I/11 control
clones (EV1 and EV2) and Foxo3a(A3):ER expressing clones (F5 and F7) were induced to differentiate in
absence (diamants) or presence of 50 nM 4-hydroxy-tamoxifen (4OHT; triangles), 10 µM prostaglandin E2
(E2; squares) or both (crosses). Cells were counted at 24 h intervals to calculate cumulative cell numbers,
and hemoglobin content per cell volume was determined in arbitrary units (a.u.). 
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heme synthesis (53). Previously we have reported that Foxo3a accelerates the
erythroid maturation process that is shown by an earlier onset of the G1-arrest
and hemoglobinization (2). Here we show that the cAMP pathway, upon
activation of the prostaglandin E2 receptor, is able to accelerate the Foxo3a
induced differentiation. Cyclic-AMP and PGE2 alone did not affect differentiation
kinetics but increased hemoglobinisation.
When cells are induced to differentiate, cAMP levels rise late in
differentiation. Erythroid cells express several Gαs-coupled receptors that induce
cAMP upon activation among which the adrenergic receptor and receptors for
thrombin and PGE2 (39). The PGE2 receptor is up-regulated almost 40-fold late
in differentiation (18). In addition, gene expression profiling showed that
expression of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase
(PGDH1) is induced by dexamethasone in expanding erythroid progenitors,
whereas it is rapidly down-regulated during differentiation (27; unpublished data).
PGDH1 is the major enzyme that degrades prostaglandins and suppresses
PGE2 activity. This tight regulation of PGE2 activity suggests that PGE2 has an
important function in erythropoiesis and may also explain why PGE2 does not
affect differentiation-associated proliferation of normal erythroid cells.
The observation that PGE2 induced differentiation in clones with an
intermediate Foxo3a expression may indicate that cAMP/PKA-signaling
specifically enhances Foxo3a function. Cooperation of Foxo's and the
cAMP/PKA pathway has been observed in other cell systems as well. FoxO1-
induced expression of prolactin, a major differentiation marker in human ES cells,
was dependent on PKA, and cAMP was shown to enhance Foxo1 function in
endometrial stroma (12).
The role of cAMP in erythropoiesis
The expression of PGDH1 in expanding erythroid progenitors and the up-
regulation of the PGE2 receptor late in differentiation restrict the action of PGE2
to the final phase of erythroid differentiation. This is in agreement with the initial
observation that activation of cAMP/PKA controls hemoglobin expression (14,
36). The cAMP/PKA-dependent transcription factor CREB appeared to control at
least two key molecules in hemoglobin expression (20, 47): Ala-S, which is the
rate-limiting enzyme in heme-synthesis (38) and NF-E2, a transcription factor
binding the β-globin enhancer (1). This direct effect of CREB on heme synthesis
and globin transcription may explain the effect of PGE2 on hemoglobin
accumulation. However, the cooperation of CREB/ATF1 with Foxo3a implies that
the effect of cAMP extends beyond the regulation of hemoglobin accumulation to
the regulation of genes expressed in the final phase of erythroid differentiation.
PGE2 has also been shown to cooperate with Epo-induced Stat5 transcriptional
activation to regulate SOCS2, SOCS3 and Bcl-XL (5). Similar to Btg1, Bcl-XL is
also up-regulated late in differentiation (19).
Regulation of Btg1 transcription
Gene expression profiling studies revealed Btg1 as a Foxo1 (41) and as a
Foxo3a target (2). A conserved DBE was identified in the human and mouse Btg1
promoter, which appeared to be the target site via which Foxo3a induces Btg1
The cAMP pathway cooperates with Foxo3a to induce Btg1 expression 
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expression (2). Here we show that CREB and ATF1 bind to a CRE present in the
human and mouse Btg1 promoter to regulate its expression. Foxo3a is able to
induce Btg1 expression in the absence of the CRE, suggesting that these
pathways can act independently from each other. However, in absence of
exogenously expressed Foxo3a, both the DBE and the CRE site were required
for promoter activity and deletion of both sites did not further decrease promoter
activity. Therefore, maximal expression in erythroid differentiation likely requires
the activation of both transcription factors. This cooperation is furthermore
underlined by the observation that cAMP induction of the Btg1 promoter requires
an intact DBE. Interestingly, both induction of cAMP levels and expression of
Btg1 have been associated with cell cycle arrest in several cell types. Since the
mechanism of cAMP-induced cell cycle arrest has not been elucidated, induction
of Btg1 should be considered. 
The function of Foxo proteins is to restrict cell growth by inducing cell
cycle arrest, apoptosis, senescence or differentiation. Recently it became clear
that Foxo proteins are not only activated upon down-regulation of the PI3K/PKB
pathway, but also in response to DNA damage and oxidative stress (11, 34, 49).
These different stress conditions appeared to induce different modifications of
the Foxo protein, which affects the association with transcriptional coregulators
(11, 34). As a result, DNA damage, oxidative stress and factor deprivation may
activate different subsets of Foxo target genes. Interestingly, the CRE site in the
Btg1 promoter also recruits cJun and/or ATF2. The cJun/ATF2 complex is not
regulated by the cAMP/PKA pathway, but through Jun-kinase (JNK), a member
of the MAP kinase family. JNK is a stress-activated kinase, activated by e.g. DNA
damage. As a result, cJun/ATF2 transcriptional activity is strongly enhanced in
response to genotoxic stress (16, 26, 51). Interestingly, Btg1 expression is
induced in response to DNA-damage (13). In case of Btg1 expression, the
promoter apparently allows for potent activation of the gene under all conditions.
The DBE binds all Foxo's, allowing a potent response to factor deprivation, when
all Foxo's translocate to the nucleus (2). Binding of CREB/ATF1 to the CRE site
in the Btg1 promoter enforces Foxo3a mediated expression late in differentiation,
whereas binding of cJun/ATF2 after activation of JNK enforces Foxo-mediated
expression  in response to oxidative or genotoxic stress.
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Materials and methods
Cells and reagents
BA/F3 were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FCS
(Hyclone, PerBio) and 10 ng/ml murine IL-3 (supernatant). The erythroid cell line
I/11 was cultured in Stempro medium (Invitrogen) supplemented with 0.5 U/ml
Epo (kind gift of Ortho-Biotech, Tilburg, The Netherlands), 100 ng/ml SCF
(supernatant) and 1 mM dexamethasone (Sigma-Aldrich) (53). To activate
Foxo3aa(A3):ER 50 nM 4-hydroxytamoxifen (4OHT; Sigma-Aldrich) was added
to these expansion conditions. Stable FOXO3Aa(A3):ER expressing  I/11 clones
were generated using the retroviral expression vector pBabe as described
previously (2). LY294002 was obtained from Alexis. Prostaglandin E2, dibutyryl
cAMP and norepinephrine were obtained from Sigma.
Western blotting and antibodies
Cell lysis, SDS-polyacrylamide gel electrophoresis and Western blotting were
performed as described previously (52). Nuclear and cytoplasmic extracts were
prepared as described previously (1). Antibodies recognizing phosphorylated and
total CREB/ATF1 were obtained from Santa Cruz (sc-7978, ser-133).
Concentrated aliquots of the CREB/ATF1 (Santa Cruz, ATF-1 sc-270 X) and
Stat5 antibodies (Santa Cruz sc-835 X) were used for EMSA. 
Real-time quantitative PCR
cDNA synthesis and quantitative RT-PCR were performed using Taqman
technology and Sybr-green detection (Applied Biosystems) of dsDNA as
described (27). Murine primer sequences used:
Btg1: forward 5'-GCAGGAGCTGCTGGCAG-3',
reverse 5'-TGCTACCTC CTGCTGGTG A-3'.
Ribonuclease inhibitor: forward 5'-TCC AGT GTG AGC AGC TGA G-3',
reverse 5'-TGC AGG CAC TGA AGC ACC A-3'. The CT-values of Rnase Inhibitor
were used for normalisation.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared, and EMSA was performed as described (1). The
following oligonucleotide probes were used: 
Btg1 CRE forward 5'-AGCTGAGCAGATTACGTCAGCTCCTA;
Btg1 CRE reversed 5'-AGCTGAGGAGCTGACGTAATCTGCTA;
Btg1 CRE-mutated forward 5'-AGCTGAGCAGATTTGGTCAGCTCCTC;
Btg1 CRE-mutated reversed 5'-AGCTGAGGAGCTGACCAAATCTGCTC;
cJun forward 5'-AGCTGAGCAGATTACCTCAGCTCCTC;
cJun reversed 5'-AGCTGAGGAGCTGAGGTAATCTGCTC;
Creb forward 5'-AGCTGAGCAGATGACATCAGCTCCTC;
Creb reversed 5'- AGCTGAGGAGCTGATGTCATCTGCTC;
β-casein forward 5'-AGCTAGATTTCTAGGAATTCAATCC;
β-casein reversed 5'-AGCTGGATTGAATTCCTAGAAATCT; 
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Luciferase Reporter assays
The Btg1 reporter constructs were reported previously (2). The TTACGTCA to
TTTGGTCA mutation in the CRE was made using the Quickchange Site Directed
Mutagenesis kit (Stratagene) according to the manufacturers protocol, using the
primers: forward 5'-AGCAGATTTGGTCAGCTCCTC -3', and the opposite strand
for the reverse primer. For reporter assays 293HEK were transfected by Ca-
phosphate as described (2). Otherwise, 10x106 Ba/F3 cells were electroporated
(0.28 kV, capacitance 960 µFD) with maximum 20 mg of DNA. After recovery for
several hours in normal media, cells were washed and grown overnight in the
presence or absence of IL-3 and SCF, or cells were IL-3 deprived overnight and
next day stimulated for 7 h with IL-3. Luciferase activity was measured using the
Steady-Glo system (Promega). Transfection efficiency was determined by
cotransfecting lacZ and analyzing b-galactosidase activity.
Differentiation of I/11 cells
To differentiate I/11 cells, cells were washed and reseeded in StemPro medium
supplemented with 5 U/ml Epo and 0.5 mg/ml iron-loaded transferring. Cells and
cell size were counted electronically (Casy counter, Schärfe-systems).
Hemoglobin was measured by a calorimetric assay as described (2).
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Abstract
Stem cell factor (SCF) cooperates with erythropoietin (Epo) to sustain renewal
divisions and delay differentiation of erythroid progenitors. Activation of Foxo3a
accelerates differentiation of these progenitors. SCF-induced Protein kinase B
(PKB) inactivates Foxo3a by phosphorylation-induced translocation to the
cytoplasm. To examine how regulation of Foxo3a activity contributes to the role
of SCF in erythropoiesis, we assessed whether Foxo3a target genes correspond
to genes controlled by SCF stimulation. Expression profiling revealed a subset of
Foxo3a target genes regulated by factor deprivation and SCF restimulation.
Among these were genes involved in cell cycle control and erythroid
differentiation. Foxo3a target genes not regulated by factor deprivation included
genes involved in oxidative stress response, signal transduction and transcription
factors such as Cited2. We show Cited2 regulation by a Foxo3a/Stat5 complex,
which is sustained in the presence of Epo but inhibited by SCF. Thus, Foxo3a is
not only an effector of PKB, but integrates multiple signals to coregulate gene
expression in erythropoiesis.
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Introduction
Since the discovery of the forkhead DNA binding domain (36), about 100
members of the forkhead family have been identified and categorized in 15
subclasses (30). The subclass O of forkhead transcription factors (Foxo),
encompassing Foxo1, 3, 4, and 6 (8, 29), is phosphorylated by Protein Kinase B
(PKB; 13, 33, 54), which results in transcriptional inactivation through nuclear
export and cytosolic retention by binding to 14-3-3 proteins (11, 13). Only Foxo6,
which lacks the COOH-terminal PKB site important for nuclear export, shows a
predominant nuclear localization independent of PKB activity (29).
Initial studies on Foxo proteins in hematopoiesis pointed to a role for
Foxo's in the regulation of the cell cycle and apoptosis (9, 16). Foxo's were
shown to induce the cell cycle inhibitor p27KIP and the pro-apoptotic Bcl-2 family
member Bim in Ba/F3 cells (18), and Fas-ligand in Jurkat T-cells (13). On the
other hand, Foxo1 was suggested to induce survival and maturation in
thymocytes (37) and we showed that activation of Foxo3a in erythroid
progenitors induces differentiation instead of apoptosis (4). Together the data
suggest that the role of Foxo proteins in hematopoiesis is diverse, and possibly
cell type specific.
The induction of differentiation by Foxo3a is consistent with the role of
the PI3K/PKB pathway in erythropoiesis. Major factors regulating erythropoiesis
are erythropoietin (Epo) and stem cell factor (SCF) (12, 40, 58). Expansion of
erythroid progenitors can be achieved in vitro using serum free medium
supplemented with Epo, SCF and glucocorticoids (19, 56), which reflects in vivo
expansion of erythroid progenitors under stress conditions (5, 10). Both Epo and
SCF activate the PI3K/PKB pathway, but SCF activates PKB most potently (56).
Inhibition of PI3K abrogates Epo/SCF-induced expansion of in vitro cultures,
suggesting that pathways downstream of PI3K/PKB are required to expand
erythroid progenitors (56). Notably, mice lacking the PI3K subunit p85 display a
transient fetal liver anemia (28), caused by a reduced number of BFUE and
CFUE. Lack of p85 did not increase the rate of apoptosis in erythroid progenitors
and mast cells but decreased proliferation (24, 28, 42). Foxo3a-/- mice suffered
from a mild compensated anemia associated with reticulocytosis, suggesting
normal expansion but defects in erythrocyte maturation (17). Together these data
indicate an important role for the PI3K/PKB/Foxo pathway in regulating the
balance between erythroid expansion and differentiation.
Recently, we screened a hematopoietic cDNA array enriched for
erythroid specific cDNA's for Foxo3a target genes. We identified Btg1, an
activator of protein arginine methyl transferase 1 (Prmt1) as a direct Foxo3a
target, and showed that Btg1 repressed expansion of erythroid progenitors (4). In
this study we extended our search for Foxo3a targets using a 17K EST cDNA
array, which we previously screened for Epo and SCF target genes (32). We
identified several differentially regulated clusters of Foxo3a target genes and
analyzed two clusters of Foxo3a upregulated genes that are differentially
regulated by Epo and SCF in erythroblasts. One cluster encompasses target
genes are repressed by SCF and upregulated in differentiation (Cdkn1b, Btg1,
Ccng2, Ulk1), whereas the other cluster contains genes that are hardly affected
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by SCF or differentiation (Dcn, Sesn1, and Cited2). To investigate how Foxo3a
targets escape negative control by SCF-induced PKB activation, we focused on
the regulation of the transcriptional regulator Cited2. We present a novel
mechanism of transcriptional control in which an alleged growth stimulatory
transcription factor, Stat5, cooperates with an assumed growth inhibitory
transcription factor, Foxo3a, to control expression of Cited2. Our data implicate
that Foxo3a is not only an effector of PKB, but that it functions to integrate and
transmit multiple signals which cooperate to regulate the gene expression
program of erythroid progenitors.
Results
Identification of Foxo3a targets in the erythroblasts
To identify Foxo3a target genes activated in erythroid progenitors we used I/11
erythroblast clones stably expressing an inducible, active Foxo3a mutant
(Foxo3a(A3):ER). This Foxo3a mutant was constructed by mutating the three
inhibitory PKB phosphorylation sites to alanine residues, and by fusing it to the
ligand binding domain of the estrogen receptor to render it inducible upon
addition of 4-hydroxy-tamoxifen (4OHT; 4, 18). cDNAs derived from a
Foxo3a(A3):ER-expressing erythroblast clone and an empty vector control clone
induced by 4OHT under expansion conditions were hybridized to 17k EST cDNA
arrays (32). Potential Foxo3a target genes were selected using an arbitrary
threshold of >1.75 fold change (positive or negative) comparing the ratio
plus/minus 4OHT in Foxo3a(A3):ER clones and <1.3 for the same genes in the
vector control clone, to exclude nonspecific effects of 4OHT. This yielded 299
potential target genes. The ratio of 1.75 was set previously using the same arrays
to obtain the 1% genes most strongly regulated by Epo and SCF (32). Regulation
of the potential Foxo3a target genes was clustered with available data on the
regulation of these genes by Epo-, SCF- and dexamethasone detected on the
same arrays (32) (Figure 4.1 and supplementary data). Hierarchical clustering
indicated that cluster A (22 genes) is the first outstanding cluster, containing
genes upregulated by Foxo3a and downregulated by Epo and SCF. Cluster A
contains all genes already known to be Foxo targets such as p27KIP, Btg1 and
Cyclin G2 (Table I). Remaining Foxo3a target genes were split in 4 additional
clusters. Clusters B and C contain all Foxo3a downregulated genes, of which
cluster B genes (191 genes) are not or hardly regulated by Epo/SCF signaling,
whereas cluster C genes (38 genes) are upregulated by Epo/SCF signaling.
Cluster D and E contain the remaining Foxo3a upregulated genes that are either
not regulated by Epo/SCF signaling (cluster D, 42 genes) or also upregulated by
Epo/SCF signaling (cluster E, 5 genes). Because phosphorylated Foxo3a is
excluded from the nucleus, we expected Foxo3a target genes to be counter
regulated by Epo/SCF signaling as seen in clusters A and C. However, these
clusters appeared to contain only 60 (20%) of the 299 selected genes (Figure
4.1). 
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Figure 4.1. Dendogram of Foxo3a target genes and their regulation by Epo, SCF and Dex. Erythroid
progenitors (I/11) expressing Foxo3a(A3):ER  or a control vector were treated with or without 4OHT (50 nM) for 6h
under expansion conditions (Epo/SCF/Dex). cDNAs were hybridized to 17k EST arrays in pairs using dual labeling
with fluorochromes. Genes were selected when induced or repressed by 4OHT more than 1.75 fold in
Foxo3a(A3):ER expressing cells (ratio +4OHT/-4OHT: 'Foxo3a') and less than 1.3 fold in control cells (ratio +4OHT/-
4OHT 'EV'). These genes were clustered with data on the regulation of these genes by Epo (E), SCF (S), Epo/SCF
(ES), Epo/SCF/Dex (ESD), Dex (D) and Epo/SCF/Zk (3 X 10-6 M glucocorticoid antagonist Zk1123.993 (ZK)) by
Spotfire software using Euclidean distance and average linkage to assess distance. I/11 cells were factor deprived
and induced for 2 h with the respective ligand (ratio +/- ligand). Five major clusters of target genes are indicated at
the left side. Black ovals indicate the branches of the distinct clusters. Dark-grey bars (as shown in the Foxo3a
column, cluster A) indicate upregulation, light-grey bars (as shown in the Foxo3a column, cluster B) indicate
repression by 4OHT or growth factors. Black bars indicate non-regulated sequences.
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Differential regulation of Foxo3a targets by starvation/stimulation,
corresponds with their differential regulation in differentiation
Because only 20% of the potential Foxo3a target genes were regulated as
expected, we investigated the regulation of selected Foxo3a upregulated genes
from cluster A (downregulated by Epo/SCF as expected) and cluster D (no
regulation by Epo/SCF) to assess the reliability of the array hybridization and
clustering. These included Btg1 (B-cell translocation gene 1), Ulk1 (Unc-51-like
kinase) and Ccng2 (Cyclin G2) to represent cluster A and the surface molecule
Dcn (Decorin), the anti-proliferative gene Sesn1 (Sestrin 1), and Cited2
(CBP/p300-interacting transactivator, with glu/asp-rich C-terminal domain) to
represent cluster D.
First, Foxo3a-dependent expression of the selected targets was
assessed in two independent Foxo3a(A3):ER clones (F17 and F18) and a control
clone using a short induction time (Figure 4.2A). All targets were induced
between 2- and 4-fold within 2 h in both Foxo3a(A3):ER expressing clones but
not in the control cells. Next, regulation of selected targets was examined in
factor depleted and restimulated erythroid progenitors in the presence or
absence of the PI3K inhibitor LY294002 (LY) to determine PI3K/PKB
dependence. Cluster A targets Btg1, Cyclin G2 and Ulk1 were strongly repressed
by Epo, SCF and Epo/SCF (Figure 2B, between 2-fold for Ulk1 and 30-fold for
Cyclin G2), which was abrogated upon inhibition of PI3K, indicating repression
through PI3K/PKB-mediated phosphorylation of Foxo3a. In contrast, cluster D
targets Decorin and Sestrin were less than 2-fold downregulated by Epo/SCF
and inhibition of PI3K had no effect on the expression of these genes (Figure
4.2B). Notably, expression of Cited2 was upregulated by Epo and by Epo plus
SCF (2-fold). Inhibition of PI3K did not affect Epo-induced upregulation of Cited2,
but further increased Epo/SCF-induced expression of Cited2 (>4-fold). 
Finally, we determined expression of the selected cluster A and D target
genes during erythroid differentiation. Previously we showed that Foxo3a
expression increases during erythroid differentiation, whereas PKB activity and
Foxo3a phosphorylation decrease. Consequently, expression of Btg1 and p27KIP
sharply increase from the moment unphosphorylated Foxo3a accumulates in
differentiating erythroblasts (Figure 4.2C; (4). Transcription of the cluster A genes
Cyclin G2 and Ulk1 similarly increased 48h after differentiation induction
(between 5-and 10-fold as previously observed for Btg1). However, none of the
cluster D genes was significantly upregulated during differentiation (Figure 4.2C
lower panels).
In conclusion, transcription of Btg1, Cyclin G2, and Ulk1 (and p27KIP; 4)
is clearly repressed by Epo and SCF via a PI3K-dependent pathway and is
induced in differentiation. In contrast, the transcription of Decorin, Sestrin, and
Cited2 is not or hardly affected by the PI3K/PKB pathway in response to factor-
deprivation and restimulation by Epo/SCF, and is also not stimulated during
differentiation. Since Foxo's have been shown to cooperate with multiple
transcription factors, these data suggest that Foxo3a may function within distinct
transcriptional complexes to enhance expression of cluster A and D targets.
Differential regulation of Foxo3a targets in erythropoiesis
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Epo induces Foxo3a/Stat5 complex formation
The association of Foxo3a with additional transcription factors may conceal the
normal regulation of Foxo3a by phosphorylation. To examine this possibility we
investigated Epo- and Foxo3a-induced expression of Cited2 as an example.
Cited2 is known to be a cytokine- and growth factor inducible gene, that is
transcriptionally controlled in a Jak/Stat dependent manner (51). In addition,
Cited2 was also found as a potential Foxo1 target (45). This suggests that Cited2
expression may be regulated by the cooperate action of the Foxo and Jak/Stat
pathways, similar to the reported association and cooperation of Foxo1 and
Stat3, in response to IL-6 stimulation, on transcriptional activation of the α2-
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Figure 4.2. Expression of FoxO3a target genes in response to growth factors and during differentiation of
erythroid progenitors. (A) Two independent Foxo3a(A3):ER overexpressing clones, and a control clone were
treated with 50 nM 4OHT for 2h. Expression of selected target genes indicated at the left side of the panels was
compared between the Foxo3a(A3):ER clones F17 and F18 and the control clone. (B) I/11 cells were factor
deprived, and subsequently stimulated for 6h with Epo, SCF, or Epo plus SCF, in the presence or absence of the
PI3K inhibitor LY294002 (15 µM). Expression of selected targets was compared between the various conditions and
unstimulated cells. Ratio's are given as 2log-values. (C) I/11 cells were differentiated and samples were taken every
12 h, until the end of erythroid differentiation (72 h). Transcript levels from the selected genes were compared
between the start of the differentiation experiment and ensuing time points. In all experiments transcript levels were
determined using poly-A mRNA and real-time PCR.
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macroglobulin promoter (34). 
Because Stat5, but not Stat3, is robustly activated by Epo in
erythroblasts, we examined a possible association between endogenous Foxo3a
and Stat5 in response to Epo and SCF stimulation. I/11 cells were factor deprived
and stimulated with Epo, SCF and Epo plus SCF (Figure 4.3A). In agreement
with previous data (4) Epo stimulation resulted in modest Foxo phosphorylation,
whereas SCF phosphorylated almost all Foxo3a. In contrast, Stat5 is
phosphorylated exclusively by Epo, not by SCF (56). Thus, all combinations of
predominantly phosphorylated and unphosphorylated Foxo3a and Stat5 are
represented by these conditions. Phosphorylated Foxo3a was prominently
present in Stat5 immunoprecipitates of unstimulated and Epo-stimulated cells,
although most Foxo3a is unphosphorylated under these conditions (Figure 4.3A).
This suggests that Stat5 associates more efficiently, but not exclusively, with
phosphorylated Foxo3a. In addition, association of Foxo3a with Stat5 increased
upon Epo-stimulation. However, in the presence of Epo plus SCF both Foxo3a
and Stat5 are phosphorylated, but less Foxo3a was present in the Stat5
immunoprecipitates. This suggests that the phosphorylation status of Foxo3a
and Stat5 is not be the major determinant of Foxo3a/Stat5 association.
Compartmentalization may be a second determinant of Foxo3a/Stat5
association. Maximally phosphorylated Foxo3a is located in the cytoplasm,
whereas phosphorylated Stat5 is located in the nucleus.
To investigate the role of compartmentalization, we analyzed
Foxo3a/Stat5 association in cytoplasmic and nuclear cell fractions under various
conditions. The colocalisation of phosphorylated Stat5 with unphosphorylated
Foxo3a in the nucleus of Epo stimulated cells induced a much more prominent
co-immunoprecipitation than the colocalisation of unphosphorylated Stat5 with
phosphorylated Foxo3a in the cytoplasm induced by SCF (Figure 3B). The
nuclear fractions were not contaminated with cytoplasmic proteins, since Stat3,
which is always cytoplasmic in erythroid progenitors grown under serum-free
conditions (4), was restricted to the cytoplasmic fraction (Figure 4.3C). Therefore
the data indicate that colocalization of Stat5 and Foxo3a in the nucleus enhances
the Foxo3a/Stat5 interaction. The interaction is not completely dependent on
phosphorylation, which is demonstrated by the interaction of unphosphorylated,
cytoplasmic Stat3 with unphosphorylated Foxo3a (Figure 4.3B lower panel). 
To examine the role of compartmentalization in more detail, we assessed
the cellular location of Foxo3a complexes in response to Epo and Epo plus SCF
over time. In I/11 cells, both Epo and SCF induced transient translocation of
Foxo3a from the nucleus to the cytoplasm. Epo induced partial phosphorylation
of Foxo3a and by consequence also partial exclusion of Foxo3a from the
nucleus. In the presence of Epo plus SCF, both phosphorylation and nuclear
exclusion of Foxo3a were almost complete (Figure 4.3C). In cytoplasmic
fractions of Epo-induced I/11 cells, Foxo3a always co-immunoprecipitated with
Stat5 (Figure 4.3D), which is abundantly present in the cytoplasm of these cells.
In contrast to its abundant presence in the cytoplasm, nuclear Stat5 was hardly
detectable in factor-deprived cells and only induced in response to Epo.
Nevertheless, low levels of a nuclear Foxo3a/Stat5 complex was precipitated
from factor deprived cells. Upon Epo stimulation this complex first disappeared,
Differential regulation of Foxo3a targets in erythropoiesis
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then reappeared as nuclear Stat5 increases (Figure 4.3D). The same pattern was
observed in three independent experiments (it has to be noted that the exposure
of the cytoplasmic and nuclear panels can not be compared). Apparently a
nuclear Foxo3a/Stat5 complex can be formed when Foxo3a or Stat5 is
abundantly present in the nucleus. 
In conclusion, the assumed proliferation-inhibiting factor Foxo3a and
proliferation-promoting Stat5 associate to regulate common target genes such as
Cited2. The association of Foxo3a and Stat5 is not strictly dependent on
phosphorylation of either Foxo3a or Stat5, but phosphorylation of Stat5 and
nuclear co-localization of Stat5 and Foxo3a in presence of Epo enhances
Foxo3a/Stat5 complex formation, whereas increased phosphorylation of both
proteins in response to Epo plus SCF results in nuclear exclusion of Foxo3a and
decreased Foxo3a/Stat5 complex formation. This suggests that association with
Stat5 is not sufficient to retain phosphorylated Foxo3a in the nucleus.
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Figure 4.3. Epo induces Foxo3a Stat5
complex formation. (A/B)  I/11 erythroblasts
were factor deprived (4h) and restimulated with
Epo (E; 20' 5 U/ml), SCF (S; 20' 200 ng/ml) or
both (ES) as indicated below the blots. (A) Total
cell extracts (tcl) and Stat5 immunoprecipitates
(IP:Stat5) were stained for Foxo3a. Lower blot
presents Stat5 backstaining. (B) Foxo3a/Stat5
interaction was tested in nuclear and
cytoplasmic fractions of erythroblasts. Stat3
and Stat5 immunoprecipitates were stained for
Foxo3a. (C/D) I/11 erythroblasts were factor
deprived and restimulated with Epo (E) or with
Epo plus SCF (ES) for the indicated time (min).
(C) Total cytoplasmic (C) and nuclear (N)
extracts were stained for Foxo3a. (D) Stat5
immunoprecipitates from cytoplasmic (C) or
nuclear (N) fractions of Epo-stimulated cells
were stained for Foxo3a and Stat5. In various
panels the low mobility phosphorylated form (p-
Foxo3a) and faster mobility unphosphorylated
form (Foxo3a) of Foxo3a are indicated.
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Transcriptional activation of Cited2 by the Foxo3a/Stat5 complex
We next examined how the Foxo3a/Stat5 complex regulates Cited2 gene
expression. The sequence of a genomic mouse fragment, encompassing the
-1128/+238 promoter region identified previously (NT039491) (39), was aligned
with the human CITED2 promoter (AF129290). Although 22 putative monomeric
Stat binding sites have been reported for the human promoter based on the 
5'-TTNNNNNAA-3' sequence (39), alignment of the human and murine Cited2
promoter did not reveal clear Stat5 binding sites. Two Foxo binding sites (DBE
for Daf-16 binding element) were identified in the murine Cited2 promoter, one of
which was identical between mouse and human. This DBE is located in a highly
conserved promoter region at position -872 (Figure 4.4A).
To analyze whether a Foxo3a/Stat5 complex binds to the DBE, nuclear
extracts were incubated with wild-type or mutated DBE oligonucleotide probes in
EMSA assays. One protein complex specifically associated with the wild-type
Cited2 oligo, suggesting its dependence on an intact DBE (Figure 4.4B).
However, Epo induction did not enhance binding, and this complex could not be
supershifted by a Stat5 antibody. Epo did induce Stat5 DNA-binding in these
lysates, since an Epo-dependent complex was binding to a classical Stat5-probe
(β-casein; Figure 4.4C) and this complex could be supershifted with anti-Stat5.
These data suggest that Epo-induced induction of the Cited2 promoter activity by
the Foxo3a/Stat5 complex does not require the DBE at -872.
Differential regulation of Foxo3a targets in erythropoiesis
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Figure 4.4. Analysis of conserved DBE in Cited2 promoter. (A) Allignment of the
mouse (upper line ) and human (lower line) Cited2 promoter. The Daf-16 binding
element (DBE) is shown in bold. The position of the DBE, as indicated in the figure, is
based on analysis of the human CITED2 promoter (39). The line under the sequence
containing the DBA indicates the oligonucleotide probe used in the EMSA assay. (B)
Gel retardation assays using Cited2 oligonucleotide probes comprising the DBE
element. Probes with a wt or mutated DBE were incubated with nuclear extracts from
I/11 erythroblasts that were factor deprived for 4 hours (0') and restimulated with Epo
for 10'. The arrow indicates the complex specifically binding the DBE. Lane 5 - 8
contain competition experiments with 100-fold excess unlabeled probe (mutated and
wt). In lane 9 - 10 anti-Stat3 and anti-Stat5 were added. (C) The same nuclear extracts
were also incubated with a b-casein probe, to test for Stat5 activation. Anti-Stat3 (lane
3), and anti-Stat5 (lane 4) were added as a control for the experiment shown in (B).
Epo induced Stat5 complexes are are indicated by arrows.
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To test the regulation of the entire -1128/+238 promoter fragment by Foxo3a and
Stat5, the fragment was cloned into a luciferase reporter construct and tested in
Ba/F3 cells. The Cited2 promoter stimulated luciferase activity 40-fold (Figure
4.5A), indicating basic promoter activity. To express and control Foxo3a and
Stat5 in Ba/F3 cells, Foxo3a transfected cells were cultured in presence of SCF,
which prevents activation of wt Foxo3a, and subsequently cells were left
untreated or treated with combinations of IL-3 and LY294002 (LY), to induce
nuclear localization of Stat5 and Foxo3a respectively (Figure 5B). In the absence
of active Foxo3a (no LY), IL-3 stimulation only modestly increased promoter
activity. In contrast, active Foxo3a (plus LY) induced Cited2 promoter activity 
4-fold, which was enhanced to 9-fold upon stimulation with IL-3 (Figure 4.5B). To
examine whether the observed IL-3 stimulation of Foxo3a was dependent on
Stat5, Ba/F3 cells were transfected with the Cited2 promoter together with wt
Foxo3a and/or dominant negative Stat5. Reproducibly, IL-3 cooperated with
Foxo3a to stimulate Cited2 promoter activity, which was inhibited in the presence
of dominant negative Stat5 (Figure 4.5C). Together these experiments indicate
that Foxo3a-induced Cited2 induction is Stat5-dependent.
To investigate whether a Foxo3a/Stat5 complex could act through the
consensus DBE, the core sequence TGTT was mutated to AAAT (26). The wild-
type and DBE mutated Cited2 promoter had similar promoter activity in Ba/F3
cells (Figure 4.5D). The DBE-mutant and wt reporter construct were similarly
responsive to Foxo3a and Stat5 activation (Figure 4.5E), which indicates that the
Foxo3a/Stat5 complex does not bind a consensus DBE. This is in agreement with
the failure to detect a Foxo3a/Stat5 complex bound to the DBE in a bandshift
assay (Figure 4.4B) and suggests that the Foxo3a/Stat5 complex does not act
through a classical DBE. This also predicts that Foxo3a/Stat5 complexes do not
regulate classical Foxo target genes such as present in cluster A. To confirm this
prediction, regulation of the Cited2 promoter was compared with regulation of the
Btg1 promoter, cloned previously (4). Whereas IL-3 stimulation of Ba/F3 cells
activated the Cited2 promoter, it repressed Btg1 promoter activity more than two
fold (Figure 4.5F). In addition, inhibition of PI3K induced the Btg1 promoter, but
did not affect the activity of the Cited2 promoter (Figure 4.5G). These data
confirm the differential promoter regulation of the cluster A target Btg1 and the
cluster D target Cited2 in response to factor stimulation and deprivation.
Differential regulation of Foxo3a targets in erythropoiesis
109
Chapter-4.qxd  24-Nov-04  14:52  Page 109
Chapter 4
110

 1


 
!
"
#$
%






 


 
!
2"
#
$%







 



 
!
"
#$
%
/ 3
    /
0#





3
	



 
!
"
#$
%


0#
      4
  
   








5 
 '
"
6
-#
(
#
"
7
8

#
'






 '
"
6
-#
(
#
"
7
8

#
'

/ 35




 '
"
6
-#
(
#
"
7
8

#
'

  4

0#
39#
 






   
   
Figure 4.5. Foxo3a and Stat5 cooperate to induce Cited2 promoter activity. For promoter studies, Ba/F3 cells
were electroporated with Cited2-luciferase constructs (-1128/+238 of the Cited2 promoter) and a β-galactosidase
construct to correct for transfection efficiency. Luciferase activity is expressed as arbitrary units (a.u.) (A) The pGL3
vector without (EV) or with Cited2 promoter sequence (Cited2) were examined for basal promoter activity in Ba/F3
cells. After electroporation cells were grown overnight in the presence of IL-3. (B) Ba/F3 were transfected with the
Cited2-reporter construct together with wt Foxo3a, where indicated, were grown overnight in presence of SCF.
Subsequently cells were treated (7 h) with combinations of IL-3 and the PI3K inhibitor LY (15 µM). Luciferase activity
is presented as fold induction, calculated compared with Cited2 promoter activity obtained after 24 h of culture in
presence of SCF only. (C) Ba/F3 cells were transfected with combinations of the Cited2 promoter, Foxo3a and
dominant negative Stat5 (DN-Stat5). Cells were allowed to recover from electroporation for 2 hours, and
subsequently incubated overnight in the presence or absence of IL-3. (D) Basal pomoter activity was compared
between the wild-type (wt) and the DBE mutated (DBEm) Cited2 promoter. Electroporated Ba/F3 cells were grown
overnight in the presence of IL-3. (E) The wt and DBE-mutated (DBEm) reporter constructs were transfected into
Ba/F3 cells with or without Foxo3a. After 16 h cells were left untreated or were stimulated with IL-3 for 7 h. Fold
induction indicates the luciferase ratio +/- IL-3. (F/G) The Cited2 and Btg1 reporter constructs were transfected into
Ba/F3 cells and the ratio of luciferase activity was determined +/- IL-3 (F) or +/- LY294002 (15 µM)(G). 
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Discussion
In this study we identified Foxo3a target genes in erythroid progenitors and
investigated their regulation by factor deprivation and Epo/SCF restimulation.
Hierarchical clustering identified 5 major clusters of Foxo3a target genes. Of 69
putative Foxo3a-upregulated target genes, only 22 were downregulated by
signaling as expected (cluster A), whereas 42 were not regulated (cluster D), and
5 were upregulated by signaling (cluster E). Of 229 putative target genes
downregulated by Foxo3aa, only 38 were upregulated by signaling (cluster C),
whereas the majority was not regulated by signaling (cluster B). The low
response to factor deprivation and restimulation of Foxo3a upregulated target
genes suggested that these targets may require cooperation of Foxo3a with
additional transcription factors. Stat5 appeared to be one such a transcription
factor binding to Foxo3a to alter the expected expression of the Foxo3a target
gene Cited2. Foxo3a/Stat5 complex formation is not strictly dependent on
phosphorylation of Stat5 and Foxo3a, but co-localization of Stat5 and Foxo3a in
the nucleus enhanced Cited2 expression. This co-localization was optimal in
presence of Epo, which potently phosphorylates Stat5 resulting in nuclear
translocation and which only partially phosphorylates Foxo3a, allowing Foxo3a to
remain in the nucleus. Foxo3a-induced expression of Cited2 depends on Stat5
and is independent of a classical Foxo-binding site. Thus, we identified a novel
mechanism of Foxo-dependent gene regulation through the cooperation of an
assumed growth inhibitory (Foxo3a) and growth promoting (Stat5) transcription
factor.
Differential regulation of Foxo3a targets in response to stress conditions
Because phosphorylation of Foxo3a by PKB is supposed to diminish DNA
binding and retain the protein in the cytoplasm (54), expression of Foxo3a target
genes was expected to be dependent on SCF-induced PI3K activity. Moreover,
we previously showed a strong upregulation of Foxo3a during erythroid
differentiation (4) and expected a general upregulation of Foxo3a target genes
during differentiation as observed for Btg1, Cyclin G2, Ulk1 and other genes
listed as cluster A. However, the majority of Foxo3a targets did not show this
expected expression pattern (e.g. cluster D). Because we performed single
hybridizations, we cannot be sure that all putative target genes are reliable.
However, there is large consistency between the array data of Epo, SCF,
Epo/SCF, Epo/SCF/Dex and Epo/SCF/ZK hybridizations (32). Moreover, we
validated several selected target genes from cluster A and D in distinct
Foxo3a(A3):ER expressing clones. Together the data suggest that cluster D
targets are not involved in a cellular response to factor deprivation. Foxo's
activate gene expression in response to various stress situations including
oxidative stress, DNA damage, and growth factor depletion (16, 54). These
various stress conditions all result in inhibition of cell growth and Foxo's are
involved in these processes via regulation of distinct target genes; p27KIP and Bim
are upregulated in response to factor deprivation, whereas Gadd45 is induced in
response to DNA damage and oxidative stress (14, 18, 25, 33, 43, 53). Recently,
it was shown that oxidative stress induces acetylation of Foxo on five different
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lysine residues and phosphorylation on eight serine/threonine residues,
concomitant with nuclear localization (14). Oxidative stress induced association
of Foxo's with the acetylase p300/CBP-associated factor (PCAF), possibly
responsible for stress-induced acetylation on five lysines. This subsequently
induced the association with the deacetylase Sirt1, whereas it decreases
interaction of Foxo with p300 (14, 54). Interestingly, interaction of Foxo with Sirt-
1 was shown to repress Foxo-induced expression of Bim, p27KIP, PECK, and
IGFBP1 (14, 46), but appeared to induce expression of Gadd45 (14). As a result,
Sirt-1 deacetylation of Foxo's enhanced cell cycle arrest and replicative
senescence, and suppressed apoptosis (14). These data indicate how Foxo
protein modifications in response to distinct stimuli may specify Foxo target gene
activation. In addition, these data may also explain how forced activation of
Foxo3a(A3):ER can activate Foxo targets that are normally induced in response
to oxidative stress but fail to be activated by factor deprivation. 
Role of target genes in cell fate determination
As the Foxo3a target genes can be divided into genes activated by factor
deprivation or stress conditions, these target genes may be involved in distinct
cellular processes. From the 14 genes with a known function that are up-
regulated by factor deprivation, at least 8 have a function late in erythroid
differentiation, or in mature erythrocytes. We previously showed p27KIP and Btg1
to be transcriptionally activated late in differentiation. We now show the same for
the antiproliferative Cyclin G2 , for the serine/threonine kinase Ulk1 and for
p130Rb2, which has a similar role in inhibition of the cell cycle as p27KIP (16). Also
phosphoglucomutases (Pgm2l1), adenosine monophosphate deaminase 2
(Ampd2) and carnitine palmitoyltransferase I (Cpt1a) are abundant proteins in
mature erythrocytes (1, 3, 6), regulating glucose metabolism (Pgm2l1), the
affinity of hemoglobin to bind oxygen (Ampd2) and membrane stability (Cpt1a; 3,
6). Failure to induce these target genes may contribute to the compensated
anemia observed in Foxo3a-deficient mice (17). In contrast, from 24 genes with
a known function that were hardly regulated by factor deprivation only the
common IL3-receptor β-chain was found to be upregulated in differentiation (~30-
fold). We found no genes with an obvious function in late differentiation in this
group. Instead 6 putative target genes function in a response to oxidative stress:
a thioredoxin-related membrane protein (Txndc1), selenoprotein P (Sepp1, 2x),
arginase1 (Arg1; depletes cells of arginine to inhibit mRNA translation and induce
senescence; 23), homeodomain-interacting protein kinase (Hipk1; upregulates
the Daxx, Ask1, Jnk pathway in an oxidative stress response; 21, 50), Sestrin1
(Ses1; regenerates thioredoxin, 15) and NAD(P)H:menadione oxidoreductase 1
(Nqo2, deficient mice show a prominent bone marrow hyperplasia; 41). In
addition, 9 putative target genes control signal transduction, including the IGF-I
receptor and protein geranylgeranyltransferase Ib (Pggt1b; the enzyme
transferring a membrane anchor to Ras). Enhanced IGF-I receptor signaling and
sustained Ras/Mek/Erk activation are hallmarks of cell senescence. Finally it is
noteworthy that cluster D contains at least two prominent tumor suppressor
genes: NF2/Merlin (31) and Copeb/Klf6 (22, 47). In conclusion, cluster D seems
to contain genes that control the induction of senescence. Notably, mitotic
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hematopoietic progenitors cannot execute a senescence program similar to e.g.
fibroblasts. Instead, activation of a senescence program including stabilization of
p53 seems to enhance differentiation. These targets may, therefore, still
contribute to the observed enhanced differentiation in response to Foxo3a
activation (4). 
Regulation of Cited2 expression by Foxo3a and Stat5
Differential activation of target genes by Foxo's in response to different stimuli
can be established through differential cooperation with other transcription
factors. At present Foxo is known to mediate transcription via interaction with a
large variety of transcription factors (9, 54). Complex formation with other
transcription factors also explains how a mutant Foxo1, incapable of DNA
binding, retains the ability to regulate expression of part of its target genes (49).
This mutant lost the ability to induce apoptosis but was still able to cause a G1-
arrest (49), underscoring that different mechanisms of target gene activation are
associated with distinct cellular responses.
We showed that an Epo induced Foxo3a/Stat5 complex regulates Cited2
expression. Epo induced Cited2 expression was not affected by the PI3K
inhibitor LY294002 (Figure 2B). This is not surprising since Epo strongly induces
Stat5 activation, whereas it only causes weak Foxo3a phosphorylation (Figure
4.3A, C). SCF repressed Cited2 expression in a PI3K-dependent way, both in
presence and absence of Epo, although less pronounced than the repression of
genes in cluster A. The data show that a Foxo3a/Stat5 complex can be formed
when either Foxo3a or Stat5 is abundantly present in the nucleus, i.e. upon factor
deprivation and Epo/SCF stimulation respectively. However, induction of Stat5 in
absence of Foxo3a phosphorylation favors Foxo3a/Stat5 interaction and Cited2
expression. 
The observation that a complex is binding specifically to the DBE of the
Cited2 promoter in an EMSA assay, although the DBE seems not to be required
for Foxo3a-induced up-regulation of Cited2, raises a question as to the identity
of the DBE-binding complex. Unfortunately, the Foxo3a antibodies are unable to
supershift Foxo3a-containing complexes, not even on a proper DBE in e.g. the
Btg1 promoter. Therefore, we cannot be sure that the complex binding the DBE
contains Foxo3a. Possibly, a different Foxo3a-containing complex binds to the
DBE to promote Cited2 expression in response to other signals. The observation
that the Foxo3a/Stat5 complex activates Cited2 independent of the DBE is not
surprising, since the specific function of this complex is likely to require a specific
DNA-binding site, otherwise all Foxo3a target genes would be subject to Stat5
regulation. This is very unlikely since genes in cluster A are predominantly
repressed in response to Epo stimulation (Table I). The fact that Cited2 transcript
levels are strongly and rapidly increased by growth factor or cytokine stimulation
(51), and by Foxo3a activation supports the hypothesis of direct transcriptional
control through the Foxo3a/Stat5 complex. Interestingly, the Il-6 induced
cooperation of the Foxo1/Stat3 complex on the α-2-macroglobulin promoter was
suggested to act via two Stat3 elements present in the promoter (34). Also the
glucocorticoid receptor induced Stat3 transcriptional activation of the α-2-
macroglobulin promoter by enhanced recruitment other transcriptional
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components, independent of DNA binding (38). Therefore it seems likely that
Foxo3a enhances Cited2 transcription via association with a Stat5 containing
complex, possibly acting through an unidentified Stat5 promoter element.
Another interesting observation is the cytoplasmic interaction between Stat3 or
Stat5 and Foxo3a, which may be part of the reported statosome protein
complexes (48). However, the function of the cytosolic Foxo/Stat interaction
remains unclear.
Our data implicate that differential binding of Foxo's to cooperating
transcription factors results in a distinct response to growth factors. Genes
encoding Riken clone 2010005O13, EST AW146242 and Cpeb4 (cytoplasmic
polyadenylation element binding protein 4) are among the targets in cluster D
that are regulated similarly to Cited2, being upregulated by Epo and
downregulated by SCF (Table II). These genes are likely candidates to be
regulated by the Foxo3a/Stat5 complex as well. Notably, neither Cited2 nor
Cpeb4 proteins are associated with inhibition of growth, but rather with
developmental processes. Cited2 is a chromodomain protein that interacts with
the transcriptional co-activator p300/CBP to alter its interaction with transcription
factors among which HIF1a (7). Among the genes positively regulated by Cited2
are the polycomb proteins Bmi-1 and Mel-18 (35). Cpeb binds to the cytoplasmic
polyadenylation element (CPE) to regulate polyadenylation and translation in
response to activation of PKA and CaMKII (44, 52).
Other Foxo target genes such as Ptpns1 (protein tyrosine phosphatase,
non-receptor type substrate 1) and P2ry14 (purinergic receptor P2Y14) are
upregulated by both Epo and SCF and may be regulated by yet another complex
of transcription factors activated by mitogenic signals and Foxo's.
We did not observe a marked regulation of Cited2 during differentiation.
Notably, Stat5 is expressed early but not late in differentiation, whereas Foxo3a
expression increases from the start of differentiation induction to reach maximal
levels 48 h after differentiation induction when Stat5 expression becomes
undetectable (4, 20). Both Foxo3a and Stat5 are required for terminal
differentiation. The cooperation between the two factors apparently ensures
ongoing Cited2 transcription during differentiation, either through a Foxo3a/Stat5
complex early in differentiation or later by Foxo3a alone.
In conclusion, we identified putative Foxo3a target genes that were assigned to
different clusters based on their regulation by Epo and SCF signal transduction.
We analyzed some genes in more detail that belonged to cluster A, being
upregulated by factor-deprivation and repressed by SCF-induced PI3K activity, or
cluster D, not prominently controlled by factor deprivation and SCF restimulation.
We do not propose that the latter group is regulated independent of PKB-
mediated phosphorylation of Foxo transcription factors. Rather we propose that
this group of genes requires further modification of Foxo proteins e.g. by
acetylation and phosphorylation in response to a specific stimulus, or requires
cooperation with other transcription factors. As an example we describe a novel
mechanism for Foxo3a-mediated control of gene expression. A Foxo3a/Stat5
complex controls expression of genes such as Cited2 independent from a
classical Foxo-binding element (DBE). The data strengthen the notion that
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Foxo's function at the heart of signal dependent gene-regulation and in
complexes that integrate multiple signals to decide between cell death or survival
and senescence.
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Materials and Methods
Cells and reagents
BA/F3 were cultured in RPMI 1640 (Invitrogen) supplemented with 10% FCS
(Hyclone, PerBio) and 10 ng/ml murine IL-3 (supernatant). The erythroid cell line
I/11 was cultured in Stempro medium (Invitrogen) supplemented with 0.5 U/ml
Epo (kind gift of Ortho-Biotech, Tilburg, The Netherlands), 100 ng/ml SCF
(supernatant) and 1mM dexamethasone (Sigma-Aldrich) (56). To activate
Foxo3aa(A3):ER 50 nM 4-hydroxytamoxifen (4OHT; Sigma-Aldrich) was added
to these expansion conditions. For stimulation, I/11 cells were incubated for 4h in
plain IMDM (Invitrogen) and stimulated at 37°C with 200 ng/ml SCF or 5 U/ml
Epo. Reactions were stopped by addition of ice-cold PBS. Stable
FOXO3a(A3):ER expressing  I/11 clones were generated using the retroviral
expression vector pBabe as described previously (4). LY294002 was obtained
from Alexis (Schwitzerland).
cDNA array hybridisations and analysis
Total RNA was generated from cells treated with or without 4OHT. Dual labelling
was used to hybridise the cDNAs pairwise to custom made EST micro-array
containing 17.000 cDNAs (17K). For MIAME-compliant description of the
procedures, see on-line supplement (32). Hierarchically clustering of data was
performed and visualised with the Spotfire application, using Euclidean distance
and average linkage to assess distance.
Real-time quantitative PCR 
cDNA synthesis and quantitative RT-PCR were performed using Taqman
technology and Sybr-green detection (Applied Biosystems) of dsDNA as
described. (32) Murine primer sequences used:
Btg1: forward 5'-GCAGGAGCTGCTGGCAG-3',
reverse 5'-TGCTACCTC CTGCTGGTG A-3'.
Ccng2: forward 5'-TGAAACCGAAACACCTGTCC,
reversed 5'-TCGAGTTTATCGAGGCTGAGA.
Ulk-1: forward 5'-TACCAGAATGTTCTCAGTGG,
reverse 5'-TGCTCCATGAGGGTCTCC.
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Sesn1: forward 5'- TCTGATGTGACAAGGTGACA,
reverse 5'-TGTTACCGCCAACACGGTC.
Dcn: forward 5'-TGGGCGGCAACCCACTG,
reverse 5'-TCAGGCTGGGTGCATCAAC.
Cited2: forward 5'-TGAACCACGGGCGCTTCC,
reverse 5'-TGGCGTGCCTGATGCCGC.
Ribonuclease inhibitor: forward 5'-TCC AGT GTG AGC AGC TGA G-3',
reverse 5'-TGC AGG CAC TGA AGC ACC A-3'.
The CT-values of Rnase Inhibitor were used for normalisation.
Western blotting and antibodies
Cell lysis, immunoprecipitation, SDS-polyacrylamide gel electrophoresis and
Western blotting were performed as described previously (55). Nuclear and
cytoplasmic extracts were prepared as described previously (2). Lysate of
20x106 cells was used for one immunoprecipitation. Antibodies used in this study
were: anti-FOXO3a (#06-951) from Upstate Biotechnology, anti-Stat3 (C-20),
anti-Stat5 (N-20) from Santa Cruz. Concentrated aliquots of the Stat3 (C-20;
Santa Cruz) and Stat5 (L-20; Santa Cruz) antibodies were used for EMSA. 
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described (2), Oligonucleotide probes were
end-labelled with 32P and EMSA were performed as described (27). The
following oligonucleotide probes were used:
wt-Cited2 5'-GCTGATCGCTGAGTTTGTTTACAGAGCAGGGAC,
DBE-mutated Cited2 5'-AGCTGATCGCTGAGTTTAAATACAGAGCAGGGAC-3'.
A standard ß-casein oligonucleotide (5'-AGATTTCTAGGAATTCAATCC) binding
Stat5 and Stat1 (57) was used as a positive control. 
Cloning of the Cited2 promoter and Luciferase Reporter assays
The mouse Cited2 promoter was cloned in pGL3-basic (Promega) using the
following primers: forward 5'-CCTATTGCTCCACTGAACAAT-3', reverse 5'-
CTCACCTTCCGTCTTTGCGATTTC-3', and the Expand High Fidelity PCR
System (Roche). Promoter alignment between human (AF129290) and murine
Cited2 (NT039491) was performed using the DNAMAN program, version 5.2.9.
The position of the identified Foxo promoter element was based on the cloned
human CITED2 promoter (39). The AAAT mutation in the DBE of the Cited2
promoter was made using the Quickchange Site Directed Mutagenesis kit
(Stratagene) according to the manufacturers protocol, using the primers: forward
5'-GATCGCTGAGTTTAAATACAGAGCAGGGAC-3', and the opposite strand for
the reverse primer. For reporter assays, 10 x 106 Ba/F3 cells were electroporated
(0.28 kV, capacitance 960 µFD) with maximum 20 mg of DNA. After recovery for
several hours in normal media, cells were washed and grown overnight in the
presence or absence of IL-3 and SCF, or cells were IL-3 deprived overnight and
next day stimulated for 7 h with IL-3. Luciferase activity was measured using the
Steady-Glo system (Promega). Transfection efficiency was determined by
cotransfecting lacZ and analyzing β-galactosidase activity.
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General Discussion
1. Overview
This thesis describes the role of Forkhead transcription factor Foxo3a in
erythropoiesis. We observed a strong increase in Foxo3a activity during erythroid
differentiation through up-regulation of Foxo3a with concomitant loss of PKB
activity, suggesting a role for Foxo3a in the control of gene expression in terminal
differentiation. This was confirmed by the observation that activation of Foxo3a
accelerated terminal erythroid differentiation (Chapter 2). Expression profiling
studies performed on erythroid specific and general cDNA arrays enabled the
identification of Foxo3a regulated genes. A subset of the Foxo3a target genes
was indeed up-regulated during late differentiation (Chapter 2 and 4). Among
these targets we could identify genes that play a role in red cell function and cell
cycle arrest, but also novel genes for which a function in erythropoiesis was
unknown. Of the latter targets, the role of the anti-proliferative gene Btg1 was
investigated. Expression of Btg1 is regulated both by Foxo3a binding to the DBE
(Chapter 2), and by the cAMP pathway via a CRE in the Btg1 promoter (Chapter
3). Both sites are required for optimal expression of Btg1. Increased intracellulair
cAMP, and phosphorylated CREB/ATF1 levels at terminal stages of
differentiation indicate involvement of the cAMP pathway in erythroid maturation.
Stimulation of the cAMP enhanced Foxo3a-induced differentiation (Chapter 3),
showing cooperation of these pathways in regulating erythroid differentiation.
One of the functions of Btg1 is regulation of the protein arginine methyl
transferase-1 (Prmt1). We found that Btg1 repressed erythroid colony growth
dependent on the domain interacting with Prmt1. This indicated protein arginine
methylation as a novel mechanism regulating the balance between erythroid
expansion and differentiation (Chapter 2).
Because PKB regulates the function of Foxo proteins, we expected the
identified Foxo3a targets to be regulated by factor deprivation and Epo/SCF re-
stimulation. Although this was true for the genes regulated during differentiation,
it was not the case for about 70% of the Foxo3a regulated genes. From this we
concluded that a minority of the Foxo3a regulated sequences is controlled upon
down-regulation of the PI3K pathway, whereas the other sequences may be
regulated in response to stimuli such as DNA damage and oxidative stress.
Notably, one subset of Foxo3a up-regulated genes encodes proteins able to
protect against oxidative stress, a cellular mechanism regulated by Foxo proteins
(Chapter 4). Interestingly, The CRE site in the Btg1 promoter bound both cAMP
responsive transcription factors CREB/ATF1, which are activated during
differentiation, and a cJun/ATF2 complex, which is activated by JNK in response
to DNA damage and oxidative stress. Thus Foxo-induced expression of Btg1 is
enforced via the CRE both in differentiation and possibly also under stress
conditions (Chapter 3).
To examine how Foxo target genes can escape control by factor
deprivation and restimulation, we studied expression regulation of the
transcriptional co-regulator Cited2. This demonstrated that Foxo3a associates
with Stat5, an association that is enhanced upon stimulation with Epo, which is
consistent with Epo induced up-regulation of Cited2. The Foxo3a/Stat5 complex
Chapter 5
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does not act via a regular Foxo3a or Stat5 binding sites, but may act via a
specific, so far unidentified binding site in the Cited2 promoter. The
transcriptional regulation of Cited2 exemplifies how Foxo's are able to integrate
multiple signals to the transcriptional machinery.
2. The erythroblast cell line I/11 - A relevant model to study erythropoiesis
Normal hematopoiesis requires a tight balance between progenitor expansion
and differentiation, which is regulated by the concerted action of extra cellular
factors regulating the signaling network and transcription factors (99). The
analysis of SCF-induced signaling pathways that regulate expansion and
differentiation of erythroid progenitors, requires the use of a proper cell model.
Although erythroid progenitors can be expanded to large numbers from umbilical
cord blood (114), bone marrow (114), and day E12-E14 murine fetal livers (113)
in the presence of Epo, SCF and Dex (in serum free media), these progenitors
have a limited life-span due to spontaneous differentiation. However, immortal
cultures can be established reproducibly from fetal livers and bone marrow of
p53-deficient mice. These cultures retain their dependence on Epo, SCF and
Dex, as well as their ability to differentiate synchronously to enucleated
erythrocytes in the presence of Epo. This permits factor-dependent expansion to
numbers that allow large scale molecular and biochemical analysis of
mechanisms regulating erythroid expansion versus differentiation. Unlike the in
vivo situation, other erythroid-leukemic cell lines (HCD57 (52), AS-E2 (103),
K562 (34), UT-7 (45, 59)) depend only on Epo for expansion and display an
incomplete differentiation, which is in some cases artificially induced upon
addition of DMSO or factor deprivation. Therefore, a clonal cell line derived from
a p53-/- fetal liver cells (I/11 cells) is used for most studies in this thesis, because
it most faithfully mimics the expansion/differentiation aspects of in vivo
erythropoiesis.
3. The role of the PI3K/PKB/Foxo3a pathway in erythropoiesis
3.1. The PI3K/PKB pathway is not restricted to regulation of apoptosis
In previous studies it was shown that the PI3K and not the MAPK pathway
controls erythroid expansion versus differentiation (113). Although these
experiments were performed using the I/11 model, they have been consolidated
in primary cells. Treatment of human primary erythroblasts with 7.5-15 mM
LY294002 resulted in an acceleration of erythroid differentiation (Figure 5.1), but
did not affect the survival of these cells (determined by cell morphology, Figure
5.1, and TUNEL assay, not shown). In addition, 24 h activation of the active
Foxo3a in the erythroblasts clones also did not increase the apoptotic index
(Chapter 2). Contradictory results come from several reports that did link the
PI3K pathway primarily to regulation survival and apoptosis of erythroblast.
However, these studies use high concentrations of PI3K inhibitors (> 50 µM
LY294002; > 1 µM wortmannin; 44, 73, 92, 93, 105) resulting in inhibition of
additional pathways (92, 107, 112). For instance, we have reported that a
concentration of 30 µM LY294002 in erythroblasts significantly inhibits tyrosine
phosphorylation of the EpoR, Jak2, Gab-1, PKC, and Erk, whereas a LY294002
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concentration of 7,5 µM completely blocks PKB activation but hardly affects the
phosphorylation of these proteins (107, 112) Furthermore, 0.5 µM wortmannin
not only blocked PI3K activity but also Erk activation (92). Other studies are
performed in differentiation-incompetent cell lines and cells that attempt to
differentiate may enter a conflict situation resulting in apoptosis (52, 103).
Therefore these and our data are not in conflict but we reach different
conclusions. In granulopoiesis, inhibition of the PI3K/PKB pathway also does not
result in cell death. Umbilical cord blood derived CD34+ cells that were
differentiated towards the eosinophilic lineage did not show increased apoptosis
upon PKB or mTOR inhibition (16). Only inhibition of PI3K activity using 20 µM
LY294002, a concentration that affects other pathways as well, did increase the
apoptotic rate during eosinophilic differentiation (16).
These data indicate that inactivation of PI3K/PKB pathway in
hematopoietic cells does not automatically result in apoptosis and may regulate
other cellular endpoints as well.
3.2. The PI3K/PKB pathway controls the balance between erythroid
expansion and differentiation
The PI3K family contains a large number of highly related lipid kinases. The role
of each of these kinases in regulation of hematopoietic development is only
beginning to be understood. Mice lacking the P110γ catalytic subunit of PI3K
display impaired T-cell development (88), p110δ appeared to be essential for
allergic reactions initiated by mast cells (3), and mice lacking p85α, the
regulatory subunit of class 1 PI3K show a block in B-cell development at the pro-
B cell stage (35). Mice lacking PKBα only show an increased apoptosis in the
thymus (104), whereas mice lacking both PKBα and PKBß have defects in
multiple tissues (78). Although erythropoiesis has not been studied in detail in
most of these models, mice lacking P110γ have reduced numbers of BFUE and
CFUE. The various models show that signaling through PI3K/PKB defines cell
survival in some cells and in some stages of development, whereas it is involved
in control of proliferation and differentiation in other cells. This has recently been
confirmed for the eosinophilic lineage. CD34+ cells derived from umbilical cord
blood that were differentiated to the eosinophilic lineage showed dramatically
enhanced differentiation upon PKB or mTOR inhibition, whereas activation of
PKB in these cells resulted in inhibition of eosinophilic differentiation (16).
Strikingly, activation of PKB in these CD34+ cells enhanced neutrophilic
differentiation, showing an important role for PKB in myeloid lineage
determination (16). In addition to hematopoietic cells, PKB promotes neuronal
differentiation(111), and PKBβ but not PKBα, enhanced myoblast  differentiation
(55, 109). To test the role of PKB in erythropoiesis we tried to overexpress PKB
and PKB mutants in the erythroid cell line I/11, but stable clones could not be
obtained suggesting tight regulation of PKB in erythropoiesis. However, inhibition
of PI3K using low LY294002 concentrations, did not result apoptosis but induced
differentiation (Figure 5.1; 113). This shows that PKB is implicated in regulation
of erythoid proliferation and differentiation instead of apoptosis.
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4. The role of Foxo3a in erythropoiesis
4.1. Foxo3a and regulation of hematopoietic differentiation
Initially the role of Foxo proteins in the hematopoietic system was thought to be
regulation of blood cell turnover (17) because overexpression in hematopoietic
cell lines (Jurkat cells, 14; Ba/F3 cells, 29) induced apoptosis. However, these
studies often suffered from the same deficits as studies on the role of PI3K in
hematopoiesis; they were performed in differentiation incompetent cells.
Therefore, a potential Foxo-induced cell cycle arrest may not lead to
differentiation but results in a conflict situation leading to apoptosis. We showed
that Foxo3a is markedly increased late in erythroid differentiation. Activation of an
active Foxo3a mutant at the onset of differentiation accelerated the differentiation
process but did not induce apoptosis (Chapter 2 and 3). To confirm the control of
erythopoiesis by the PI3K/Foxo3a pathway in primary cells, murine primary cells
were differentiated in the presence of Epo, and expression kinetics of PKB,
Foxo3a and p27KIP were examined by western blot (Figure 5.2). These kinetics
were similar as observed in differentiating erythroblasts from the I/11 cell line
(Chapter 2), suggesting an identical role for the PI3K/Foxo3a pathway in the
control of erythropoiesis in primary cells. A role for Foxo3a in regulation of
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Figure 5.1. The level of PI3K activity controls the balance
between erythroid expansion and differen-tiation of
primary human erythroid progenitors. Erythroid progenitors
were seeded in differentiation medium containing Epo (E; 2
U/ml), with and without SCF (S; 100 ng/ml) and the PI3K
inhibitor LY294002 (15 µM). ). (A) After 4 days, cytospins were
stained using Benzidine, which stains hemoglobinized cells
orange-brown (here shown as small, dark cells). Addition of
SCF delays Epo induced differentiation, which can be
reversed upon inhibition of PI3K activity. (B) Growth curve of
the cultures. In the presence of Epo alone, cells divide 3-4 times and than terminally differentiate. SCF significantly
enhances the expansion capacity of these cells. This effect was abrogated when PI3K was inhibited, showing the
importance of PI3K for expansion. (C) Hemoglobin levels were determined during the assay as a measure for
differentiation. Primary erythroid cells cultured in the presence of Epo plus SCF showed a significantly delayed
hemoglobinization compared with Epo induced differentiation. However, addition of the PI3K inhibitor LY294002 to
Epo/SCF cultures fully restored hemoglobinization. Notably, addition of the MEK inhibitor PD98059 only slightly
reduced the proliferation but did not alter the balance between expansion and differentiation (not shown).
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erythropoiesis is furthermore supported by the fact that Foxo3a null mice suffer,
among other abnormalities, from a mild compensated anemia with reticulocytosis
showing that Foxo3a is required for the generation of stable erythrocytes (18).
Foxo proteins regulate differentiation in other cell types as well. In
thymocytes, endogenous Foxo1 is expressed in parallel with differentiation
markers, and ectopic expression of a dominant negative Foxo1 mutant reduced
cell numbers, without affecting the apoptotic rate of these cells (62). The
commitment of myeloid progenitors to either eosinophilic or neutrophilic
granulocytes which is controlled by PKB (previous paragraph) is at least in part
mediated by Foxo's through transcriptional repression of the helix-loop-helix
transcription factor Id1 (16). Furthermore, Foxo1 is involved in differentiation of
myoblasts. Although Foxo1 activation induced differentiation of primary
myoblasts (11), Foxo1 had to be inactivated to induce differentiation of the
myoblast cell line C2C12 (47). These seemingly contradictory results may point
to cell type specific differences (2).
4.2. Overlap between Foxo3a and Epo/SCF regulated targets 
To identify the mechanisms via which Foxo3a mediated accelerated erythroid
differentiation, mRNA expression profiling studies were performed to screen for
Foxo3a targets, using erythroid clones expressing an inducible, active Foxo3a
mutant. Because the Foxo forkhead transcription factors are defined as
PI3K/PKB targets, we assumed that Foxo up-regulate genes would be repressed
by SCF-induced PI3K activity. Vice versa we expected Foxo's to mediate SCF-
induced repression of target genes. Therefore, we assessed how Foxo3a
regulated sequences were controlled by Epo/SCF. Clustering of array-data
revealed Foxo3a up- and down-regulated clusters, which were differentially
regulated by Epo/SCF signaling (Chapter 4). Surprisingly, about 70% of the
Foxo3a regulated sequences, are not regulated in a starvation/stimulation
experiment (Figure 5.3 and Chapter 4). When selected for Foxo3a and Epo/SCF
regulated sequences with a threshold of a factor 1.75, only 13% of the Foxo3a
regulated sequences were regulated by Epo/SCF stimulation. Similarly, 588 out
of 11585 sequences were regulated by Epo/SCF of which 80% is not regulated
by Foxo3a. Notably, these data clearly show that only a minor subset of Foxo3a
targets are regulated upon factor deprivation. and suggest that a majority of the
Foxo3a targets is controlled via alternative mechanisms (see paragraph 4.4).
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Figure 5.2. Regulation of PKB,
Foxo3a, and p27KIP in murine
primary erythroblast differentia-
tion. Erythroid progenitors derived
from murine fetal livers were
differentiated in the presence of Epo
(20 U/ml). Cell lysates were
harvested every 8 hours and
proteins were separated performing
SDS-PAGE. Blots were stained for
total levels of Foxo3a, PKB, and
p27KIP as indicated. Total Erk was
used as a loading control.
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4.3. Foxo3a targets and their role in differentiation
In addition to the mRNA profiling studies described in this thesis, we have also
performed profiling analysis on differentiating erythroblast cells using affymetrix
cDNA arrays (manuscript in preparation). Combining the results of both studies
allows the characterization of Foxo3a controlled gene expression in
differentiation. The differentiation studies were performed using the p53-deficient
erythroblast cell lines I/11 and R10 (the R10 cell line is derived from p53-/- mice
with a different genetic background). Because the 17K EST array and the
affymetrix array have a different background, only ~50% of the Foxo3a controlled
genes could be traced back on the affymetrix arrays. These overlapping Foxo3a
targets (130) were clustered with the differentiation data (Figure 5.4). Because
Foxo3a activity increases in differentiation, Foxo3a-regulated genes identified on
the 17K array were expected to be regulated in differentiation. The Foxo3a
regulated sequences showing this consistent regulation are show in Table 5.1
and some of them are discussed below.
This procedure confirmed the up-regulation of some Foxo3a induced
genes already identified in Chapter 4 such as Btg1, Cdkn1b (p27KIP) and Ccng2
(Cyclin G2), and identified additional targets up-regulated during differentiation.
Core promoter element binding protein (Copeb), also known as Krüppel like
factor-6 (KLF6) is a transcription factor that functions as a tumor suppressor. A
Copeb mutant was cloned from a B-cell chronic lymphocytic leukemia patient and
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Figure 5.3. Analysis of target gene regulation by Foxo3a and
Epo/SCF (E/S) stimulation as detected using the 17K EST
cDNA array. For the analysis presented in this figure, we
discarded all sequences that showed a 'bad' signal in the Foxo3a
or Epo/SCF hybridization and all sequences that were regulated
by 4OHT in the control clone (ev) more than 1.4 fold (2log >0.49
or < -0.49), This yielded a selection of 11585 sequences which
are presented in (A). The X-coordinate of each gene presents
the fold regulation by Epo/SCF stimulation over starvation, and
the Y-coordinate presents the fold regulation by Foxo3a (4-
hydroxy-tamoxifen  stimulated over non-stimulated Foxo3a
clones). Fold regulation for both axis are presented as 2log
ratio's. (B) Out of 11585 sequences, 238 were regulated by
Foxo3a with a 2log ratio of >0.81 or <-0.81 (factor 1.75 up- or
down-regulated). The fold Foxo3a regulation is plotted against
their fold regulation by E/S stimulation. Using MS-access, we
found 74% of the Foxo3a regulated sequences not to be
regulated by E/S stimulation (non-regulation is defined as less
than 1.4 fold. (C) The reversed analysis as shown in B: 588
sequences are regulated by E/S (factor 1.75 up- or down-
regulated), of which 80% is not regulated by Foxo3a (factor
regulation < 1.4). These data show that the majority of the
Foxo3a sequences are not regulated by factor depletion and re-
stimulation experiments, and that about 80% of the Epo/SCF
regulates sequences are not regulated by Foxo3a.
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exhibited transforming capacity (31). Furthermore, Copeb is frequently mutated
human prostate cancer (74). Its late up-regulation in differentiation probably
contributes to terminal G1-arrest since Cdkn1a (p21CIP1) was found as a Copeb
target (74). Another differentiation upregulated Foxo3 target is Selenoprotein P
plasma 1 (Sepp1). Selenium has been shown to play a role in oxidant defense
(122). Sepp1 functions as a heparin-binding protein associated with endothelial
cells and has been implicated as an oxidant defense in the extracellular space
(123). Exportin 7 is a Ran-binding protein involved in nuclear transport, and was
identified from the t(5;14) translocation that is found in acute lymphoblastic
leukaemia suggesting loss of growth suppression through inactivation (57).
The list of Foxo3a-induced genes outlined above underlines the growth-
suppressing role of Foxo3a in differentiation (Chapter 2). Transcriptional
induction of cell the cycle inhibitors Cdkn1b, Ccng2, Btg1, and Rbl2 (p130Rb;
Chapter 2 and 4) is probably part of the mechanism via which Foxo3a controls
differentiation. This is underlined by the fact that Foxo3a activity is induced after
completion of the 3 - 4 differentiation-divisions when cells terminally arrest in G1
(113). The importance of a terminal cell cycle arrest in erythroid differentiation is
suggested by Rb null mice which display a differentiation defect,(51) and by a
block of erythroid differentiation resulting from GATA1 overexpression which is
also thought to occur through deregulation of the cell cycle (118). Furthermore,
cell cycle inhibition is believed to be a general mechanism involved in regulation
of the terminal differentiation of hematopoietic cells (36).
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Figure 5.4. Regulation of Foxo3a
targets in differentia-tion.
Clustering of Foxo3a up-regulated
targets (right column, grey bars) and
down-regulated genes (right
column, white bars) in terminal
erythroid differentiation (non-
regulated sequences are shown in
black). This analysis was performed
by linking Foxo3a regulated genes
identified on the general 17K EST
cDNA array with differentiation
profiling studies performed on
affymetrix gene chips, using the
erythroblast cell lines I/11 and R10.
From the 299 Foxo3a regulated
genes identified with the 17K EST
chip (fold regulation > 1.75), 130
genes could be traced back in the
affymetrix hybridization and are
presented in this graph. Differentia-
tion expression profiling studies
were performed for the following
timepoints: 0 h, 6 h, 22 h, 46 h, and
60 h. Duplicate hybridizations were
performed for each cell line at each
timepoint (except for 6 h I/11: one
hyb.).
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Complementary to the induction of growth inhibitory genes, Foxo3a may
also accelerate differentiation through down-regulation of target genes (Figure
5.3; table 5.1). Other profiling studies aimed to identify Foxo3a target genes also
revealed clusters of down-regulated genes (31, 81). A subset of genes was
down-regulated both by Foxo3a and in differentiation (Table). In general, these
targets can be linked to expansion: DEAD/H Box 18 (Ddx18), is a putative ATP-
dependent RNA helicase. Ddx18 expression is induced by the Myc-Max
transcriptional complex, after proliferative stimulation of primary human
fibroblasts and B cells, and is down-regulated during terminal differentiation of
HL60 leukemia cells and primary keratinocytes consistent with the
disappearance of c-Myc RNA (41). Chondroitin sulfate proteoglycan (Cspg6),
causes transformation when overexpressed, and is frequently found to be
induced in human and murine tumors (39). The zinc finger protein 292 (Zfp292)
is involved in transcriptional activation of growth hormone (108), and the Renela
cell carcinoma, papillary (Prcc) gene was identified from a translocation occurring
in papillary renal cell carcinoma (117). Finally, the growth factor Erv1 (Gfer) is
essential for cell cycle progression in yeast (65) and plays a role in liver
regeneration (33).
Tabel 5.1. Foxo3a regulated genes with consistent regulation in erythroid differentiation
Foxo3a upregulated genes, upregulated in differentiation
unigene # gene name gene function
Mm .333738 acidic ribosomal phosphoprotein P0 unknown 
Mm .254297 ATPase, Cu++ transporting, alpha polypeptide (Atp7a ) transport
Mm .152987 Exportin 7 (Xpo7 ) transport
Mm .3527 Cyclin G2 (Ccng2 ) nuclear transport
Mm .24642 hypothetical protein cell cycle regulation
Mm .275036 Core promoter element binding protein (Copeb ) transcription
Mm .1940 Colony stimulating factor 2 receptor, beta 2 chain (Csf2rb ) Signalling
Mm .22699 Selenoprotein P, plasma, 1 (Sepp1 ) oxidant defense
Mm .2958 p27KIP (Cdkn1b ) cell cyle regulation
Mm .305438 B-cell translocation gene 1 (Btg1 ) arginine methylation
Foxo3a downregulated genes downregulated in differentiation
unigene # gene name gene function
Mm .44219 DEAD/H BOX 18; (Ddx18) proliferation
Mm .26392 THUMP domain containing 1 (Thumpd1 ) unknown 
Mm .321440 2010309E21Rik unknown 
Rn .11074 Chondroitin sulfate proteoglycan 6 (Cspg6 ) induces proliferation
Mm .38193 zinc finger protein 292 (Zfp292 ) transcription 
Mm.35089 Renela cell carcinoma, papillary (Prcc ) unknown 
Mm .41555 member RAS oncogene family (Rab28 ) embryogenesis
Mm.24117 DNA segment, Chr 8, ERATO Doi 319, expressed unknown 
Mm .2756 non-histone chromosomal protein HMG-14 unknown 
Mm .28124 growth factor, erv1 (Gfer ) proliferation
Mm .12459 ankyrin repeat domain 10 unknown 
Mm .27131 Ribonuclease P 21 subunit (human) (Rpp21 ) mRNA regulation
Mm .512 WW domain binding protein 5 (Wbp5 ) unknown 
Mm .2478 splicing factor, arginine/serine-rich 4 (Sfrs4 ) pre-mRNA splicing
Mm .343230 Similar to protein translocation complex beta protein transport
Mm .24643 centrin 2 (Cetn2 ) calcium binding protein 
Mm .28392 Deformed epidermal autoregulatory factor 1 (Deaf1 ) transcription, growht suppression
Mm .52583 putative protein unknown 
Foxo3a targets were accepted as regulated when 4 or more out of 8 hybridizations from the later
timepoints (46, 60h) showed regulation. Fold regulation Foxo3 clone > 1.75 (ev < 1.3).
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The fact that these genes all support proliferation suggest that their
suppression by Foxo3a may present a complementary mechanism via which
Foxo3a controls erythropoiesis. Such a mechanisms has recently been proposed
for eosinophilic differentiation. It was suggested that Foxo3a transcriptional
repression of the helix-loop-helix protein Id1 is required for execution of the
differentiation program (16). Whether Foxo3a regulates Id1 in erythroid cells is
not known. However, Id1 expression is potently induced upon cytokine
stimulation myeloid cells (24), and ectopic expression of Id1 in erythroid cells
blocks erythroid differentiation (66, 67).
4.4. Foxo3a may play diverse functions in erythroid cells
Foxo proteins are not only activated upon down-regulation of the PI3K pathway,
but also in response to genotoxic stress, oxidative stress, and stimulation of the
cAMP pathway (15, 21, 71, 102). Oxidative stress induces Foxo3a acetylation on
multiple lysine residues as well as phosphorylation of serine/threonine residues
(15), causing differential co-regulator binding (15), and target gene activation (15,
71), which resulted in cell cycle arrest and replicative senescence rather than
apoptosis (15). From the studies described in this thesis it can be hypothesized
that Foxo3a plays diverse function in erythroid cells as well. This is suggested by
the fact that some targets regulate levels of reactive oxygen species (Chapter 4).
Whereas genotoxic stress is able to induce Foxo3a activity, other transcription
factors induced by genotoxic stress may cooperate with Foxo3a to control a
specific set of target genes as demonstrated by the Foxo3a target gene Btg1.
Genotoxic stress induces Btg1 expression (25) and we describe it as a Foxo3a
target gene. Interestingly, Foxo3a seems to cooperate with the DNA damage
inducible cJun/ATF2 complex, which was found to associate with the CRE
present close to the DBE in the Btg1 promoter (Chapter 3). However, further
investigation is required to establish the function of Btg1 in response to DNA
damage.
It becomes increasingly clear that both factor deprivation and stress
factors (DNA damage, oxidative stress) induce Foxo's and that the cellular
response to Foxo activation may vary from differentiation to cell cycle arrest,
senescence or apoptosis, depending on the stress factor but probably also on
the strength of the stress-induced signal (15). Modification and regulation of
Foxo's seem to be crucial in the regulation of Foxo-function. Not only PKB, also
Casein kinase 1 (CK1), SGK1, IκB Kinase (IKK) and Dyrk1 phosphorylate
Foxo's. CK1 and SGK1 induce Foxo phosphorylation in response to genotoxic
stress, whereas IKK and Dyrk1a phosphorylate Foxo's independent from the
PI3K pathway (28, 43, 87, 119). Furthermore, Foxo3a is also acetylated on
multiple lysine residues in response to oxidative stress (15).
In conclusion, these data suggest that Foxo's function at the heart of
signaling controlled gene expression and exert multiple functions. Stimulus-
specific Foxo protein modification and (subsequent) co-factor binding are
fundamental in their selective activation of target genes, determining cell fate.
Future investigation is necessary to establish the different roles for Foxo
transcription factors in erythroid cells. 
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4.5. Cooperation of Foxo3a with co-regulators in regulation of
erythropoiesis As indicated above, these different Foxo functions may be
mediated by differential activation of gene expression resulting from protein
modifications and subsequent distinct co-regulator binding. The importance of
Foxo co-regulators is exemplified by a Foxo1 mutant, which lost its DNA-binding
capacity. This mutant is still able to mediate gene expression and inhibit cell cycle
progression, whereas its ability to induce apoptosis was diminished (81).
Nowadays, numerous co-regulators have been identified (9, 106). The
ATF1/CREB and ATF2/cJun complexes binding to the CRE in the Btg1 promoter
may comprise novel Foxo co-regulators, suggested by the close proximity of only
7 basepairs between the DBE and CRE (Chapter 3). However, an association
between Foxo3a and CREB (or CREM) could not be detected in overexpression
studies (not shown). However, an interaction with the CREB family member ATF1
was not tested. The binding of both Foxo3a and CREB/ATF1 to the Btg1
promoter may enhance the recruitment of other transcriptional components and
lead to the cooperative induction of Btg1 transcription as suggested in Chapter
3. A similar cooperation between Foxo1 proteins and the cAMP pathway was
shown on transcriptional activation of the prolactin in human ES cells (21).
The interaction of Foxo transcription factors with nuclear hormone
receptors is also of interest in erythropoiesis. Expansion of erythroid progenitors
is dependent on glucocorticoids, whereas retinoic acid and thyroid hormone
induce differentiation (61). Transient transfection of FKHR into mammalian cells
represses transcription mediated by the glucocorticoid and progesterone
receptors and stimulates retinoic acid and thyroid hormone receptor-mediated
transactivation (121). Thus, activation of Foxo's could suppress GR function and
thereby suppress erythroid expansion. However, we observed cooperation on
gene transcription between Foxo3a and the GR. The Foxo3a target gene Btg1
has also been identified as a GR induced gene (58). In addition, other genes
such as Glcci1 and Zfp36 also showed induction both by Foxo3a and the GR
(Figure 4.1). Since glucocorticoids have a growth suppressive function in e.g.
macrophages and lymphocytes, cooperation of Foxo's and the GR in the
abrogation of cell proliferation in general seems plausible. However, the role of
glucocorticoids may be different in erythropoiesis and in granulopoiesis.
The importance of Foxo transcriptional co-regulators was clearly shown
by the interaction between Foxo3a and Stat5 (Chapter 4). This interaction was
Epo-induced and could be abrogated by co-stimulation with SCF, resulting in a
decreased binding of these proteins because of subcellular separation: SCF
induced an almost exclusive cytoplasmic localization of Foxo3a, and Epo
induced predominantly nuclear localized Stat5. In absence of SCF, Epo
stimulation only modestly affects Foxo3a nuclear export and resulted in an
enhanced nuclear interaction between Foxo3a and Stat5. A similar mechanism
has been observed for Foxo1 and Stat3 in liver cells. Stimulation of HepG2 liver
cells with IL-6 induced interaction between Stat3 and Foxo1, which could be
reversed by co-stimulation with insulin (60), the main activator of the PI3K
pathway in liver cells. Interestingly, Foxo1 and Stat5 did not interact in these cells,
suggesting that there may be cell specific interactions between Foxo and Stat
proteins. It is most likely that the Foxo3a/Stat5 complex directly binds the Cited2
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promoter resulting in Cited2 expression. This is suggested by the findings that
Cited2 transcript levels are strongly increased after 1 hour of growth
factor/cytokine stimulation in a variety of cells (95). Notably, this induction
depended on activation of the Jak/Stat pathway (95). We observed increased
Cited2 transcript levels after 2 hours of Foxo3a activation in the presence of Epo
(Chapter 4). Although we identified a conserved DBE in the Cited2 promoter,
deletion of this site did not alter the cytokine response of the promoter suggesting
that another regulatory element is required for activation of the promoter by the
Foxo3a/Stat5 complex. This is plausible since Epo does not induce all other
identified Foxo targets. This hypothesis is supported by the cytokine induced
cooperation between Foxo1/Stat3 on induction of α-2-macroglobulin, an inhibitor
of many proteases, including trypsin, thrombin and collagenase (7).Two Stat3
binding sites are essential for the Stat3 response (63). Increasing amounts of
Foxo1 did enhance the promoter activity only in the presence of activated Stat3
suggesting that this occurs via Stat3 binding sites (60). Furthermore, optimal
transcriptional activation of the α-2-macroglobulin is dependent on the
cooperation between Stat3 and the GR. Interestingly, in this cooperation the GR
does not bind directly to the DNA whereas Stat3 does (63). The cooperative
activation of the promoter was caused by a more efficient recruitment of a large
transcriptional complex called the enhanceosome (63). Similarly, Stat5 may bind
to the Cited2 promoter to a yet unidentified element, whereas Foxo3a may act in
a DNA-binding independent manner. This may result in the more efficient
recruitment of other transcriptional complexes like the enhanceosome. Since
Foxo1 did not enhance the transcriptional activity of Stat3 itself, and also did not
affect cellular distribution of Stat3 (60), recruitment of other transcriptional
components to the promoter is probably the mechanisms via which Foxo and Stat
proteins cooperate on transcriptional activation of genes. In support of this
hypothesis it will be necessary to identify a Stat5 promoter element in the Cited2
promoter.
We also noticed a cytoplasmic interaction between Foxo3a and Stat3 or
Stat5. Since Foxo1 cellular transport did not alter Stat3 cellular localization in liver
cells, it was suggested that this interaction does not affect the transcriptional
activity of both proteins and may serve a different function. Notably, large
cytosolic protein complexes of 200 - 400 kD and 1 - 2 mD were described in
which both non-tyrosine phosphorylated and tyrosine phosphorylated Stat
proteins are present (75). The functions of these Statosomes are yet unknown.
However our data suggests that Foxo proteins could be part of the Statosome
complexes. Possibly, these protein complexes may function as large cytosolic
anchoring sites for both Stat and Foxo proteins.
5. Regulation of protein arginine methylation as a novel cellular mechanism
that controls erythropoiesis From the data described in this thesis it can be
hypothesized that Foxo3a controls erythropoiesis by multiple mechanisms. As
described in Chapter 2 and 4, Foxo3a induces genes that stimulate growth arrest
and maturation of these cells, and down-regulate growth promoting genes, as
outlined in 4.3. Another mechanism via which Foxo3a may control erythropoiesis
is via regulation of protein arginine methylation. This is mediated via up-
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regulation of Btg1. Btg1 is a member of the antiproliferative (Apro) gene family.
The Apro family consists of six members that are labile and share an Apro-
homology domain consisting of two highly conserved boxes (A and B) separated
by a non-conserved spacer region (69). Family members function as regulators
of cell growth, differentiation and DNA-repair (69, 101). In addition, Btg1 and its
closest homologue Btg2 share an additional conserved domain termed box C (8),
suggesting a different function for these proteins. Btg1 and 2 are both expressed
in quiescent cells and during the G1 phase of the cell cycle (83, 85).
Overexpression of Btg1 suppresses growth and is negatively correlated with
proliferation in a variety of cell types, such as T-lymphocytes, fibroblasts,
macrophages, and during testis development (80, 85, 94). However, the
mechanisms involved in the antiproliferative effect of this gene family are largely
unsolved (69, 101), and can only be implied from their interaction partners.
Btg1 and Btg2 have been shown to interact with the transcription factor
carbon catabolite repressor protein (CCR4)-associated factor 1 (Caf-1; 10, 49,
84, 30). This interaction occurs via box-B (85) suggesting that it is a common
binding partner among the family members. Caf-1 is part of a transcriptional
regulatory complex and is also part of the major cytoplasmic mRNA deadenylase
complex in yeast (104). Caf-1 is involved in transcriptional regulation of a variety
of targets that regulates chromatin structure, and interacts with the cell cycle
regulated protein Dbf2 in yeast (68). Caf-1 also regulates expression of Rad51,
a gene involved in DNA repair (89). These data suggest an interesting link
between the Btg1/CCR4 complex, cell cycle regulation and DNA damage
response. Interestingly, both Btg2 (42) and Foxo1 (81) suppress transcription of
D-type cyclins. This suggests that Foxo induced growth suppression may in part
be performed via Btg1 mediated transcriptional downmodulation of D-type
cyclins.
Another Btg1 interacting protein is protein arginine N-methyltransferase
(Prmt1). Since the box-C domain is responsible for this interaction (8), Prmt1 only
associates to Btg1 and Btg2. Type I arginine N-methyltransferase produces ω-
monomethylarginine and asymetric ω-NG, NG-dimethylarginine. Interestingly,
Prmt1 null mice die during development (77), and arginine methylation by type I
arginine N-methyltransferase is a common post-translational protein modification
that seems to be catalyzed predominantly by Prmt1 (38, 77, 96, 97). Btg1 and
Btg2 have both been shown to stimulate arginine methylation activity of Prmt1
(64). Although the function of type I protein arginine methylation is unknown, it
has been suggested to mediate transcriptional regulation (19), protein shuttling
(90), and RNA processing (38). Interestingly, Prmt1 has been shown to associate
to the Ifnαr-1 chain of the interferon type 1 receptor and contributes to the growth
arrest induced by this receptor via methylation of Stat1 (1, 72). Other targets of
Prmt1 are Interleukin-enhanced-binding factor 3 (97), poly-A-binding protein II
(5), hnRNP A2 (76), Fibroblast growth factor-2 (56), and histones (70).
We showed that Btg1 suppressed colony formation of murine bone
marrow cells, which could be reversed upon deletion of box-C. Therefore,
association of Btg1 with Prmt1 seems to be responsible for the Btg1 growth
suppression. Prmt1 is expressed throughout the differentiation process, but the
expression of Btg1 late in differentiation may activate Prmt1 during terminal
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differentiation or recruit it to a different set of target proteins. The observations
that (1) arginine methylation of a number of unknown proteins was increased
during differentiation and (2) a global inhibitor of methylation blocked erythroid
differentiation (Chapter 2), supports a role for Prmt1 during terminal erythroid
differentiation. Interestingly, overexpression of the box-C peptide, which inhibits
Prmt1, blocked neuronal differentiation in PC12 cells (8), and NGF-induced
PC12 differentiation could be inhibited by an global inhibitor of methylation (22).
Therefore, Btg1 mediated arginine methylation could serve as a general
mechanism that regulates differentiation. This is supported by the finding that
Btg1 and Btg2 regulate not only erythroid differentiation but also neuronal (12)
and myoblast differentiation (82).
6. Foxo activation versus other mechanisms
Inactivation of Foxo3a by PKB presents one mechanism via which the PI3K/PKB
pathway controls erythropoiesis. Another mechanism important for the expansion
of erythroid progenitors is the activation of the translation machinery. PKB
phosphorylates and activates the mTOR kinase, which results in phosphorylation
of the translation elongation and initiation factor 4E (eIF4E) binding protein
(4EBP) leading to its dissociation from eIF4E (40). The level of free eIF4E is
particularly important for the translation of structured mRNAs. Interestingly,
inactivation mutations in the C. elegans homologue of mTOR (CeTOR) result in
dauer formation (53) similar to what was observed for Daf-16 activation.
Activation of the PKB/eIF4E pathway leads to cell growth. This is clearly shown
by the role of this pathway in tumorigenesis in various tissues (86, 110, 116). To
investigate the role of the PKB mediated translation in erythroid cells, we
constructed eIF4E overexpressing I/11 clones. Notably, constitutive eIF4E
expression induced erythroid expansion and delayed erythroid differentiaton (M.
Blázquez-Domingo and G. Grech, manuscript in preparation). Currently,
Epo/SCF-induced translationally regulated targets are under investigation (G.
Grech). Interestingly, Drosophila dFOXO induces expression of the translation
inhibitor d4EBP (79). However, in erythroid cells, activation of Foxo3a does not
affect 4EBP transcription (unpublished observations).
We observed that overexpression of eIF4E abrogates the requirement
for PI3K activation during expansion of erythroid progenitors, whereas
experiments presented in this thesis argue that PI3K activity is required to
suppress activation of Foxo3a. Although one may argue that it should be one or
the other mechanism that is important, the data are complementary (Figure 5.5).
If PI3K is activated, mRNA translation is promoted and Foxo activity is
suppressed. When PI3K activity is abrogated, translation of structured mRNA
ceases and the differentiation program is actively induced by enhanced Foxo
activity.
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7. Future directions
7.1. Foxo transcription factors and cancer
It has been suggested that Foxo proteins may function as tumor suppressor
genes, however, up to date, this remains to be established. Despite some
interesting observations concerning the identification of FOXO genes from
translocations involved in tumorigenesis (27, 37) and the association of
tumorigenesis and poor breast cancer survival with FOXO inactivation (48), their
role as tumor suppressor genes is still unclear. So far, Foxo knock-out mice have
not shown any evidence for increased tumor risk (18, 46). However, this may be
caused by complementary functions for the three most homologous Foxo
proteins (Foxo1, Foxo3a, Foxo4). Studies on Foxo target genes have revealed
the regulation of a common set of targets, suggesting overlap in function of the
Foxo members. This could explain why Foxo4 null mice do not shown any
abnormalities (46). The observation that only Foxo3a null mice display disturbed
erythropoiesis (18) may be due to the fact that Foxo3a, but not Foxo4 or Foxo1,
plays a role in terminal erythroid differentiation. Therefore, the contribution of
Foxo proteins to cancer has to be tested in double or triple knock out mice, or via
simultaneous knock down of their mRNA's using siRNAs. Until then their role in
tumorigenesis remains to be established.
7.2. Regulation of Foxo function
Foxo proteins can be activated in response to DNA damage, oxidative stress,
growth factor depletion and stimulation of the cAMP pathway (15, 21, 71, 102).
So far, several stimulus specific target genes have been identified. Further
identification of these stimuli specific targets will help to understand the different
cellular functions of Foxo proteins. One way via which Foxo stimuli specific
targets may be identified is by performing mRNA profiling experiments to detect
the changes in gene expression induced by sublethal DNA damage or oxidative
stress, in the absence or presence of the described Foxo3a specific siRNA
(Chapter 2). A detailed analysis of these Foxo mediated mechanisms may give
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Figure 5.5. PKB regulates the balance
between erythroid expansion and
differentiation by control of Foxo3a and
eIF4e activity. Potent activation of PI3K/PKB
by Epo/SCF results in an complete Foxo3a
inactivation and a strong activation of
eukaryotic translation initiation factor 4E
(eIF4e). These events support erythroid
expansion. Epo induced activation of the
PI3K/PKB pathway only results in minor
inactivation of Foxo3a (thin arrow) and low
activation of eIF4e. The majority of the Foxo3a
proteins are activated and accelerate
differentiation. The activity of the PI3K/PKB
pathway thus controls erythropoiesis. This is
obtained via complementary mechanisms of
PKB induced eIF4e activation and inhibition of
Foxo3a.
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important clues with respect to the relation between oxidative stress, DNA repair
and human cancer, as well as other degenerative diseases of aging (4).
Another important question concerning Foxo proteins is what triggers
Foxo activation in response to the different Foxo activating stimuli, and which
Foxo modifiers may be involved in regulation of target specificity. A powerful
screening method that I plan to use in the near future to isolate Foxo modifier
genes is the genetic Drosophila P-element screen. In this method, transgenic
Drosophila lines are used in which overexpression of dFOXO is specifically
targeted to the eye, which prevents intervention with early development (13), and
results in a 'small eye phenotype' (54). Crossing of these flies with an library of
1600 mutant fly lines in which single genes are disrupted by P-element
integration (91) will allow the identification of genes that alter the degenerate eye
phenotype imposed by dFOXO. Using this method, putative modifiers of dFOXO
can be identified and potential Foxo modiers can be rapidly tested that either
positively or negatively change Foxo3a function. The Foxo3a transcriptional co-
regulator Stat5 may present a co-regulator that alters Foxo function because it
may tip Foxo-induced growth arrest towards growth stimulation via transcriptional
up-regulation of Cited2.
7.3. Foxo transcription factors and regulation of hematopoietic quiescence
A role for Foxo transcription factors in regulation of cellular quiescence was
initially suggested from studies in C. elegans (see 8.1 of Chapter 1). In these
worms, activation of the Foxo transcription Daf16 induces a temporal
developmental arrest that results in an increased life span. This is at least
partially obtained via lowering of the metabolism (100), and possibly through
increased protection against oxidative stress (98). The role of Foxo proteins in
regulation of cellular quiescence and protection from oxidative stress has been
confirmed in mammalian cells (17) and is underscored by several in vivo
observations. Foxo3a knock-out mice exhibited ovarian follicle activation that
may result from loss of quiescence (18). In addition, in vivo overexpression of a
dominant negative Foxo1 mutant in the T-cell lineage resulted in increased
thymocyte proliferation (62), suggesting a role for Foxo1 in maintaining a
quiescent state in resting T-cells (23, 120).
Because quiescence is a characteristic of hematopoietic stem cells,
Foxo proteins may be implicated in regulation of stem cell quiescence. For
example, the cell cycle inhibitor p21CIP regulates the quiescent state of
hematopoietic stem cells. Mice deficient for p21CIP show increased cycling and
exhaustion of hematopoietic stem cells (20). In addition, p27KIP also stimulates
the quiescence of hematopoietic stem cells (26, 32). Foxo's may thus contribute
to hematopoietic stem cell quiescence by regulating the cell cycle. Strikingly,
protection against oxidative stress is also important for hematopoietic stem cell
maintenance (50), and may present another mechanism via which Foxo's
regulate quiescence of hematopoietic stem cells. To decipher the role of Foxo
proteins in hematopoietic stem cell maintenance, bone marrow cells from
Foxo3a-deficient mice could be used in transplantation experiments. 
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7.4. Btg and arginine methylation
Protein arginine methylation is nowadays believed to be a common protein
modification that regulates a variety of cellular processes such as signaling, RNA
processing and chromatin remodeling and transcription (6, 70). The recent
cloning of peptidylarginine deiminase 4 (Pad4), a protein which exhibits arginine-
demethylation activity (115), underscores the dynamic character of protein
arginine methylation. Since we proposed protein arginine methylation as a novel
cellular mechanism regulating the balance between erythroid expansion and
differentiation, as also shown in neuronal cells, the identification of arginine
methylated proteins will be required to unravel the underlying mechanisms. This
may be performed by analysis of arginine methylated proteins, using the
antibodies described in this Chapter 2, and comparing conditions with or without
Btg1 overexpression. Differentially methylated proteins may be identified using
mass spectrometry. Because Prmt1 deficient mice are lethal (22, 77), erythroid
specific Prmt1 null mice should be constructed to determine whether protein
arginine methylation is essential for erythropoiesis.
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Inleiding op, en overzicht van de behaalde resultaten
Een mens is opgebouwd uit miljarden cellen. Al deze cellen zijn onder te
verdelen in verschillende typen cellen. Zo zijn er o.a. spiercellen, hersencellen,
huidcellen, botcellen, bloedcellen, en zenuwcellen. Deze verschillende cellen
ontstaan uit slechts één enkele embryonale 'stamcel' via een complex proces dat
differentiatie wordt genoemd. Een soort gelijk differentiatie proces vindt ook
plaats bij het aanmaken van bloedcellen. Vanuit de 'bloedstamcel' kunnen zich
rode bloedcellen, bloedplaatjes of witte bloedcellen (de overige bloedcellen)
ontwikkelen (Figuur 1). Witte bloedcellen beschermen ons lichaam tegen
indringers zoals virussen en bacteriën. Bloedplaatjes zijn noodzakelijk voor het
stollen van bloed wanneer er een bloeding optreedt. Rode bloedcellen
transporteren zuurstof (O2) van de longen naar de weefsels, en koolstofdioxide
(CO2) vanuit de weefsels naar de longen. Een andere onderverdeling van
bloedcellen kan worden gemaakt op basis van de plaats waar de bloedcel
gemaakt wordt. Bloedcellen die uitrijpen in het beenmerg behoren tot de
myeloïde reeks, terwijl bloedcellen die uitrijpen in de lymfklieren behoren tot de
lymfoïde reeks.
Het proces waarbij de verschillende bloedcellen ontstaan vanuit de
bloed-stamcel wordt hemopoïese genoemd. De differentiatie van een stamcel
naar de functionele bloedcellen is een proces dat verloopt via zogenaamde
voorlopercellen. Naarmate voorlopercellen verder gedifferentieerd zijn kunnen ze
minder rijpe bloedcellen produceren. Zo kan een vroege voorloper-rode bloedcel
(BFU; Figuur 1) zo'n 5*103 rode bloedcellen produceren, terwijl een meer
gedifferentieerde voorloper-rode bloedcel (CFU) nog maar enkele tientallen rode
bloedcellen kan produceren. Differentiatie wordt voor een belangrijk deel
geregeld door groeifactoren. Sommigen groeifactoren kunnen er voor zorgen dat
een voorlopercel zich gaat delen in plaats van te differentiëren. Hierdoor zal het
aantal rijpe bloedcellen dat de voorlopercel kan voortbrengen toenemen. Dit
proces wordt expansie genoemd. Andere groeifactoren ondersteunen juist alleen
de differentiatie van een bepaalde voorlopercel. Op een zelfde manier kan de
aanwezigheid van een bepaalde 'groeifactormix' er voor zorgen dat er op een
bepaald moment meer rode bloedcellen gemaakt worden, of juist een bepaald
type witte bloedcel.
Het doel van dit proefschrift was te onderzoeken of en op welke manier
bepaalde eiwitten een rol spelen in de vorming van rode bloedcellen
(erythropoïese). Eiwitten spelen een cruciale rol in het functioneren van een cel
en kunnen gezien worden als de robotten, of robotonderdelen van de cel. Voor
een aantal eiwitten is onderzocht of en hoe zij de balans tussen erythroïde
expansie en differentiatie bepalen. Een beter begrip van erythropoïese mogelijk
leiden tot een betere behandeling van bepaalde typen anemie (te kort aan rode
bloedcellen) en bloedkanker. Voordat ik de resultaten van mijn studie beschrijf wil
ik eerst kort uiteenzetten hoe een cel 'opgebouwd' is, hoe eiwitten gemaakt
worden en op welke wijze eiwitten de deling van een cel kunnen reguleren.
NL
146
nl-samenv.qxd  29-Nov-04  11:05  Page 146
Inleiding op, en samenvatting van de behaalde resultaten
147
	




 	
	




		

	

	

	


 !
" 
 !#$%
" 
 &#%#'#$(  $#)#!
*+ "+
,*
*+	
-.
 "#'#$$
-.




	
	
	/	0
 "#%
/1
	0
,
, 
	0
*+,*
,*
,*
 '+,*
,*
,*+ "
*+" 
*+ $#&#'*+,*+,*
 $#"#&#$$
" +*
,*+ "
 "#'#$$
-.
,*
 "#%
 "+,*
,*
*

1
	
/

2			/
3			
/

	
01/


00

/





00

/




04		//
//
2
	00/
511
	0

/	

	

	/
	1//	/
/2/		//
/0

2#/
	00/
602/4/
Figuur 1. Schematische weergaven van de bloedcel vorming (hematopoïese). Stamcellen zijn zeldzaam en
kunnen door deling van de cel of zichzelf dupliceren/vernieuwen, of differentiëren in een myeloïde or lymfoïde
voorloper cel. Differentiatie van voorloper cellen kan alleen plaats vinden in de aangegeven richting van de pijlen.
Des te verder een voorloper cel in het differentiatieproces gevorderd is, des te minder bloedcellen de voorloper cel
kan produceren. Uit een stamcel kunnen zo verschillende typen bloedcellen ontstaan met ieder hun eigen functie.
De groei en differentiatie van de hematopoietische voorloper cellen vereist de aanwezigheid van bepaalde
groeifactoren zoals aangegeven bij de pijlen. De volledige namen van deze groeifactoren zijn: SCF (Stem cell
factor), IL3 (Interleukin 3), FLT3L (FMS-like tyrosine kinase 3 ligand), Epo (erythropoietin), GM-CSF
(granulocyte/macrophage-colony stimulating factor), G-CSF (granulocyte -colony stimulating factor), TPO
(thrombopoietin). De volledige naam van weergegeven voorloper cellen is: CFU-GEMM (colony forming unit-
granulocyte-erythroid-monocyte-megakaryocyte), CFU-Eo(colony forming unit-eosinophilic-granulocyte), BFU-MK
(burst forming unit-megakaryocyte), BFU-E (burst forming unit-erythroid). CFU-GM (colony forming unit-
granulocyte-macrophage).
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Moleculaire mechanismen betrokken bij de regulatie van celgroei
Een cel wordt begrensd door een celmembraan (Figuur 2). In deze membraan
bevinden zich kanalen die nodig zijn voor uitwisseling van zouten en water met
het medium buiten de cel. Ook bevinden zich in de celmembraan receptoren
voor groeifactoren en hormonen die het functioneren van de cel reguleren. In de
cel bevinden zich onder andere mitochondriën, dit zijn de energiefabriekjes van
de cel. Ribosomen zijn verantwoordelijk voor de productie van eiwitten. Het
endoplasmatisch reticulum en Golgi systeem modificeren en sorteren de eiwitten
voor gebruik in of buiten de cel. Endozomen transporteren eiwitten van en naar
de celmembraan, en in de lysozomen worden eiwitten afgebroken. In de celkern
bevindt zich het erfelijk materiaal (DNA) .
Omdat eiwitten slijten, of alleen tijdelijk nodig zijn, moet de productie van
eiwitten goed gereguleerd zijn. Eiwitten worden gecodeerd door het DNA (deoxy-
nucleïne zuur (acid)) dat zich in de celkern bevindt en ook wel de 'blauwdruk van
het leven' wordt genoemd (Figuur 3). DNA bestaat uit twee lange aan elkaar
gekoppelde strengen. Deze strengen zijn opgebouwd uit 4 verschillende
moleculen die basen worden genoemd: adenine (A), guanine (G), cytosine (C),
en thymine (T). Hierbij is een A (of T) uit de ene streng altijd gekoppeld aan een
T (of A) uit de andere streng. Hetzelfde geldt voor G en C. Omdat de twee
strengen van het DNA een spiraal-vorm hebben wordt de ruimtelijke structuur
van het DNA ook wel vergeleken met een wenteltrap waarbij de verbindingen
tussen de basen A-T en G-C de treden vormen. Iedere cel van het menselijk
lichaam bevat 23 paar chromosomen die opgebouwd zijn uit dit DNA. Een gen is
een stuk DNA dat alle informatie bevat voor het maken van een specifiek eiwit.
In 2001 werd een eerste ruwe versie van de totale basenvolgorde van het
menselijke DNA bekend (alle chromosomen = het genoom), en op dit moment
wordt het totale aantal genen van de mens geschat op zo'n 20.000 - 25.000.
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Figuur 2. Schematische weergave van de
cel. De celmembraan vormt een fysieke
barrière tussen de omgeving en de cel-
inhoud. In het cytoplasma bevinden zich de
volgende cel-compartimenten: de celkern
(bevat het erfelijk materiaal (DNA)), het
endoplasmatisch reticulum met de
ribosomen (waar een groot deel van de eiwit
synthese plaatsvindt), het Golgi-apparaat
(waar de in het ER gesynthetiseerde
eiwitten modificaties ondergaan wat gevolg
heeft voor hun functie en transport, en de
mitochondriën (energie produktie).
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Een volgende belangrijke vraag is hoe een gen nu 'vertaald' kan worden in een
eiwit. Allereerst wordt er een kopie (mRNA) van het gen gemaakt (Figuur 4). Dit
proces heet transcriptie en wordt uitgevoerd door eiwitten genaamd transcriptie
factoren. Een complex van transcriptie factoren bindt aan een specifieke
bindingsplaats in het DNA die naast het gen ligt (promoter DNA). Het transcriptie
complex leest het gen af en maakt een kopie (mRNA) van het gen. Alle gedeelten
in het mRNA die geen informatie bevatten worden verwijderd, en het resterende
mRNA wordt omgezet in een eiwit. Dit proces heet translatie. Translatie wordt
uitgevoerd door de in het cytoplasma gelegen ribosomen. In het translatie-proces
codeert iedere set van drie basen (codon) voor een bepaald aminozuur. Zo
codeert de basenvolgorde ATG-AAA-TCC- voor een keten van de aminozuren
methionine-lysine-serine. In totaal kunnen de vier verschillende basen 64
verschillende codons vormen die coderen voor de 20 verschillende aminozuren.
Op deze manier kan de grote verscheidenheid aan genen vertaald worden in een
minstens zo grote verscheidenheid aan eiwitten.
Specifieke eiwitsynthese
Zoals gezegd heeft de cel niet alle eiwitten tegelijkertijd nodig. Sommige eiwitten
bevorderen de celdeling terwijl andere deze juist remmen. Tijdens de celdeling
moeten de eiwitten van de laatste categorie dus niet gemaakt worden. Daarnaast
zijn er eiwitten die juist wel of juist niet in een bepaald celtype voorkomen. Zo
wordt het zuurstof bindende eiwit hemoglobine uitsluitend in rode bloedcellen
Inleiding op, en samenvatting van de behaalde resultaten
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Figuur 3.  Weergave van het DNA. In iedere cel van het menselijk lichaam bevindt zich in de celkern een kopie
van het menselijk genoom (het totaal van alle 46 chromosomen). DNA is opgebouwd uit twee complementaire
strengen van aan elkaar geschakelde basen adenine (A), thymine (T), guanine (G), en cytosine (C). Hierbij kunnen
uitsluitend de basen A en T een verbinding aangaan (hetzelfde geldt voor G en C). De ruimtelijke structuur van het
DNA is een wenteltrap, waarbij de verbindingen tussen de basen (A met T, en G met C) de treden vormen.
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Figuur 4. Schematische weergave van het vertalen van
een gen in een eiwit. Transcriptie factoren maken een
kopie van het gen (mRNA) door specifiek te binding aan
het promoter DNA van een gen (stuk DNA gelegen vóór
het coderende DNA van een gen dat nodig is voor de
activativering van transcriptie). Vervolgens wordt het DNA
afgelezen waarbij gelijktijdig het mRNA gemaakt wordt
(transcriptie). Na synthese wordt het mRNA de kern uit
getransporteerd naar het cytoplasma waar het als
blauwdruk dient voor de synthese van het eiwit. Dit proces
wordt translatie genoemd en wordt uitgevoerd door
ribosomen.
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gemaakt. Iedere situatie in ieder celtype vereist zo een specifieke set van
eiwitten. Een belangrijke vraag binnen de moleculaire biologie is hoe deze
specificiteit in eiwitsynthese gerealiseerd wordt.
Eiwit-synthese is gekoppeld aan de signalen van buiten de cel. Een cel
is namelijk niet autonoom maar werkt samen met andere cellen in het uitoefenen
van een bepaalde functie in een organisme. Signalen zoals bijvoorbeeld
groeifactoren, kunnen binden aan receptoren in de celmembraan. Vanaf de
celmembraan wordt het signaal door eiwitten doorgegeven naar de celkern, waar
transcriptie factoren de mRNA’s maken van de eiwitten die nodig zijn voor dit
specifieke signaal. Een cel heeft verschillende signaal routes, waardoor
specifieke signalen van buiten de cel kunnen leiden tot de aanmaak van een
specifieke set mRNA’s. 
Een voorbeeld van een signaal route is de Epo signaal route. Epo is een
groeifactor voor rode bloedcellen (Epo) die verhoogd wordt uitgescheiden door
de nieren bij een tekort aan zuurstof in het lichaam. Epo stimuleert de groei van
voorloper-rode bloedcellen door aan de in de celmembraan aanwezige Epo-
receptor te binden (Figuur 5). Dit resulteert in de 'activatie' van het aan de Epo-
receptor gekoppelde kinase-eiwit Jak2, een eiwit dat fosfaatgroepen koppelt aan
de receptor (fosforylatie). Aan deze fosfaatgroepen kunnen vervolgens weer
allerlei andere eiwitten binden die op hun beurt ook door Jak2 gefosforyleerd
worden. Stat5 is een transcriptie factor die op de wijze door Jak2 geactiveerd
wordt. Hierdoor wordt Stat5 naar de kern getransporteerd waar het de
transcriptie van Stat5 target genen stimuleert.
Model en Vraagstelling
Regulatie van rode bloedcel productie (erythropoïese) is afhankelijk van Epo,
stamcel factor (SCF) en corticosteroïden (een bepaald type hormoon). SCF bindt
en activeert zijn specifieke receptor (c-Kit) zoals Epo bindt aan de Epo-receptor.
Corticosteroïden binden een receptor die zich in de cel bevindt en niet aan de
membraan. De activering van alledrie de signaal routes (Epo, SCF, Dex) is
vereist om erythroblasten (voorloper-rode bloedcellen) tot expansie te aan te
zetten (Figuur 6). In de aanwezigheid van alleen Epo rijpen de erythroblasten uit
in functionele rode bloedcellen. Ondanks dat de factoren die erythropoïese
reguleren bekend zijn, is het grotendeels onduidelijk welke moleculaire
mechanismen hierbij betrokken zijn. Het in dit proefschrift beschreven onderzoek
heeft tot doel deze mechanismen te identificeren.
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Figuur 5. Voorbeeld van signaaltransductie in
voorloper-rode bloedcellen (erythroblasten). De
groeifactor Epo bindt aan zijn receptor, waarna de kinase
Jak2 geactiveert wordt om fosfaatgroepen te koppelen
(fosforylering) aan de receptor. Hierdoor kunnen er
verschillende eiwitten aan de receptor binden waaronder
de transcriptie factor Stat5. Stat5 wordt vervolgens ook
gefosforyleerd door Jak2. Fosforylering van stat5 leidt tot
activering van Stat5 waardoor Stat5 naar de kern
getransporteerd wordt en het betrokken is bij transcriptie
van specifieke genen (genen die een Stat5-
bindingsplaats in de promoter hebben). Op deze manier
kunnen signalen van buiten de cel de activiteit en
synthese van eiwitten reguleren.
nl-samenv.qxd  29-Nov-04  11:05  Page 150
Resultaten
De PI3K signaal route voorkomt erythroïde differentiatie
Twee bekende signaal routes die een rol spelen in erythropoïese zijn de
Ras/Raf/MEK/Erk, en de PI3K/PKB signaal routes. Beide worden zowel door
Epo als door SCF geactiveerd. De activatie van deze signaal routes door SCF is
echter het sterkst. Om de bijdrage van deze signaal routes aan erythropoïese te
analyseren is er gebruik gemaakt van moleculen die specifiek de activiteit van de
MEK of de PI3K signaal route blokkeren. Toevoeging van deze remmers aan
erythroblasten die gekweekt worden in de aanwezigheid van Epo en SCF
resulteert voor de Erk remmer in een onderdruking van celdeling, terwijl remming
van PI3K niet alleen resulteert in een geremde expansie maar ook in een
stimulatie van de  differentiatie. De PI3K signaal route is dus een belangrijke
route die de blans tussen expansie en differentiatie van rode bloedcellen regelt.
Foxo transcriptie factoren worden door de PI3K/PKB signaal route
gereguleerd. In de afwezigheid van Epo en SCF zijn Foxo's  actief en bevorderen
ze de aanmaak van eiwitten die het delen van een cel remmen. Activatie van de
PI3K/PKB signaal route door Epo en SCF resulteert in inactivering van de Foxo
transcriptie factoren zoals aangegeven in Figuur 7. Om te bepalen of Foxo's
mogelijk een rol spelen in het door PI3K/PKB gereguleerde proces van
erythropoïese is de hoeveelheid eiwit van Foxo1, Foxo3a en Foxo4 bepaald in
expansie en differentiatie van voorloper cellen. Terwijl de eiwit hoeveelheid van
Foxo1 en Foxo4 snel afneemt in differentiatie, neemt het van Foxo3a juist toe
(Hoofdstuk 2). Dit suggereert dat de versnelde differentiatie door remming van
PI3K mogelijk ten dele wordt veroorzaakt door activatie van Foxo3a. Om te
testen of Foxo3a inderdaad de differentiatie van rode bloedcellen kan stimuleren
werd er in voorloper-rode bloedcellen een gen ingebracht dat codeert voor een
actieve mutant van Foxo3a. Deze mutant kan niet meer door PKB geremd
worden. Ook is deze mutant gefuseerd met een gedeelte van de estrogeen
receptor (ER) waardoor de Foxo3a mutant (Foxo3a(A3):ER) specifiek te
activeren is door toevoeging van 4-hydroxy-tamoxifen (4OHT) aan de cellen.
Toevoeging van 4OHT resulteert inderdaad in een door Foxo3a versnelde
differentiatie, en een reductie van het aantal celdelingen tijdens de differentiatie
(Hoofdstuk 2). Concluderend: inactivatie van Foxo3a door de PI3K/PKB signaal
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Figuur 6. Regulatie van rode bloedcel vorming. De expansie van voorloper-rode
bloedcellen wordt gestimuleerd door de samenwerking van de groeifactoren:
Erythropoietin (Epo), Stamcel factor (SCF), en corticosteroïden (waarvan
Dexamethasone (Dex) een synthetische variant is). Als de voorlopercellen in de
aanwezigheid van alleen Epo worden gekweekt, differentiëren ze uit tot functionele
rode bloedcellen.
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route is een mechanisme waarmee SCF de differentiatie van erythroblasten
uitstelt en daardoor de expansie mogelijk maakt.
Identificatie van Foxo3a target genen
Vervolgens willen we weten via regulatie van welke genen Foxo3a de rode
bloedcel differentiaie stimuleert. Hiervoor hebben we de zogenaamde DNA-chip
technologie gebruikt. Op deze chips bevinden zich DNA fragmenten van zo'n
10.000 verschillende genen. We hebben mRNA geïsoleerd uit cellen waarin
Foxo3a(A3):ER aanwezig is en waarin deze Foxo3a mutant wel of niet
geactiveerd is met 4OHT. Het mRNA uit cellen waarin Foxo3a(A3):ER gedurende
6 uur geactiveerd is, is met een rood fluorescerend molecuul gemarkeerd, het
mRNA uit cellen die niet met 4OHT zijn behandeld met een groen fluorescerend
molecuul. Het enkelstrengs mRNA bindt op de DNA-chip heel specifiek alleen
aan het (enkelstrengs) DNA van het gen waarvan het een kopie is. Door te
registreren welke spots op de DNA chip rood, groen of geel fluoresceren, weten
we welke mRNA synthese wel of niet door Foxo3a wordt gereguleerd. Op een
vergelijkbare manier is ook bepaald van welke genen Epo en SCF de mRNA
synthese reguleren. Omdat Epo en SCF de PI3K signaal route  activeren, en dus
Foxo’s inactiveren (Figuur 7), zouden genen waarvan Foxo3a de mRNA
synthese activeert ‘uitgezet’ moeten worden na behandeling van de cellen met
Epo en SCF (en vice versa).
Btg1
Er werd inderdaad een serie genen gevonden waarvan Foxo3a de transcriptie
stimuleert en Epo en SCF de transcriptie remmen. Tot deze groep behoren Btg1,
p27KIP, Ulk-1, en Cyclin-G2). De hoeveelheid mRNA’s van deze genen neemt
sterk toe tijdens differentiatie van rode bloedcellen, overeenkomend met de
verhoogde Foxo3a activiteit tijdens differentiatie. Van een aantal van deze
eiwitten is bekend dat ze de celdeling remmen. Remming van celdeling is dus
waarschijnlijk een belangrijke mechanisme waarmee Foxo3a de differentiatie
van rode bloedcellen stimuleert. Van deze geïdentificeerde Foxo3a target genen
is Btg1 is uitgekozen voor verdere analyse.
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Figuur 7. Activatie van de PI3K signaal route
inactiveert de activiteit van Foxo transcriptie
factoren. Binding van Stamcel factor (SCF) aan
zijn receptor-kinase (c-Kit) resulteert in de
fosforylatie van (en door) de receptor
(weergegeven door een 'F'). PI3K bindt aan zo'n
receptor-gekoppelde fosfaat groep en wordt
vervolgens ook door de receptor gefosforyleerd.
Actief PI3K fosforyleert vervolgens moleculen aan
de membraan (PIP: fosfo-Inositol-fosfaat
moleculen). Aan deze fosfo-moleculen binden o.a.
Pdk1 en PKB. PKB wordt vervolgens geactiveerd
(gefosforyleerd) door Pdk1 waarna transport naar
de celkern plaatsvindt. In de kern fosforyleert PKB
de Foxo transcriptie factoren. Deze fosforylering
resulteert in de inactivatie van Foxo's door
disruptie van DNA binding, transport uit de kern
gevolgt door cytoplasmatische verankering aan
14-3-3 eiwitten.
nl-samenv.qxd  29-Nov-04  11:05  Page 152
Allereerst is onderzocht of Foxo3a direct aan het promoter-DNA van Btg1 bindt.
Het is bekend dat Foxo3a specifiek bindt aan de basenvolgorde TTGTTTAC.
Deze basenvolgorde was ook aanwezig in Btg1 promoter. Deletie van deze
bindingsplaats is voldoende om transcriptie van Btg1 door Foxo3a te voorkomen
(Hoofdstuk 2). Behalve een Foxo3a bindingsplaats, bevat de Btg1 promoter ook
een bindingsplaats voor transcriptie factoren van de CREB familie. Inderdaad
kon binding van de transcriptie factoren CREB/ATF1 aan de Btg1 promoter
worden aangetoond (Hoofdstuk 3). Transcriptie factoren van de CREB familie
worden geactiveerd via de cyclisch-AMP (cAMP) signaal route: binding van
hormonen aan zogenaamde G-gekoppelde receptoren zorgt voor toename van
de stof cAMP in de cel. Deze toename van cAMP activeert de kinase PKA, die
naar de kern getransporteerd wordt en door fosforylatie het CREB/ATF1
transcriptie complex activeert. Om te onderzoeken of cAMP bijdraagt aan
transcriptie van Btg1 in differentiatie is eerst de activiteit van de cAMP route in
differentiatie getest. Dit is gedaan door de hoeveelheid cAMP en gefosforyleerd
CREB/ATF1 te meten. Beide namen toe in differentiatie, gelijktijdig met de
toename van het Btg1 mRNA (Hoofdstuk 3). Stimulatie van erythroblasten met
cAMP bleek inderdaad de transcriptie van Btg1 te stimuleren. Mogelijk leidt
stimulatie van de cAMP signaal route tot een versnelde differentiatie via
transcriptie van Btg1, zoals voor Foxo3a en Btg1 wordt verondersteld. Omdat
verondersteld wordt dat Foxo3a de differentiatie versneld via transcriptie van
Btg1, is hetzelfde te verwachten voor de cAMP signaal route. Echter, stimulatie
van alleen de cAMP signaal route resulteerde in een nauwelijks toegenomen
differentiatie, terwijl activatie van de cAMP route wel de Foxo3a versnelde
differentiatie stimuleerde (Hoofdstuk 3). Foxo3a en de cAMP signaal route
werken dus samen in het stimuleren van rode bloedcel differentiatie,
waarschijnlijk via gezamenlijke stimulatie Btg1 mRNA synthese.
Btg1 is ook wel bekend als anti-proliferatief eiwit 2 (Apro2). Om het effect
van Btg1 op rode bloedcel-vorming te testen is het Btg1 gen ingebracht in muize-
beenmergcellen. De ontwikkeling van deze cellen is vervolgens getest in een
zogenaamde kolonie-assay waarmee de groei van voorlopercellen te bestuderen
is. Terwijl zich in een controle experiment kolonies van rode bloedcellen
ontwikkelen, is deze kolonie-vorming sterk geremd in de aanwezigheid van Btg1
(Hoofdstuk 2). Van Btg1 is verder bekend dat het arginine-methylering van
eiwitten stimuleert (het koppelen van methyl groepen aan het amonizuur arginine
in eiwitten). Dit gebeurt door binding van Btg1 aan, en stimulatie van de arginine-
methylase Prmt1. Een Btg1 mutant die niet instaat is om Prmt1 te binden
vertoont de reductie in kolonie-vorming van rode bloedcellen niet (Hoofdstuk 2).
Regulatie van eiwit methylering door Btg1 speelt dus een belangrijke rol in de
differentiatie van rode bloedcellen. Omdat de totale Btg1 activiteit sterk verhoogd
is tijdens de differentiatie, is er met een antilichaam dat arginine-gemethyleerde
eiwitten herkent gekeken of er een toename is in de methylering van eiwtten. Een
aantal eiwitten waarvan de identiteit nog onbekend is vertoonen inderdaad een
toenemende arginine-methylatie in differentiatie (Hoofdstuk 2). Toekomstig
onderzoek moet uitwijzen welke eiwitten dit zijn.
Inleiding op, en samenvatting van de behaalde resultaten
153
nl-samenv.qxd  29-Nov-04  11:05  Page 153
Cited2
In tegenstelling tot Btg1 behoren Cited2, Decorin en Sestrin tot een groep genen
waarvan de mRNA synthese wel door Foxo3a gestimuleerd wordt, maar die niet
of nauwelijks geremd wordt door Epo en SCF (Hoofdstuk 4). Blijkbaar activeert
Foxo3a deze genen in respons op een andere stress-factor. Uit ander onderzoek
bleek inderdaad dat Foxo's niet alleen geactiveerd worden in de afwezigheid van
groeifactoren, maar ook door het optreden van DNA schade en oxidatieve stress
(schade aan cellen door bij-effecten van zuurstof). Inderdaad bevat de Cited2
groep van Foxo3a targets een aantal genen waarvan bekend is dat ze een rol
spelen in de bescherming tegen oxidatieve stress (Hoofdstuk 4). De regulatie
van deze genen door Foxo3a in respons op deze stress-factor zal echter nog
bewezen moeten worden.
Een andere opmerkelijke observatie was dat de mRNA synthese van
weer een ander aantal andere genen binnen de Cited2 groep gestimuleerd wordt
door Epo. Deze observatie is bovendien opmerkelijk omdat Epo Foxo's remt door
activatie van PI3K/PKB signaal route. Echter, we hebben aangetoond dat deze
remming niet totaal is zoals dit bij SCF wel het geval is. Dit heeft tot gevolg dat
een gedeelte van de Foxo3a eiwitten nog steeds actief is in de aanwezigheid van
Epo (Hoofdstuk 4). Van Cited2 was verder bekend dat de transcriptie door
verschillende hemopoïetische groeifactoren gestimuleerd wordt via activatie van
Stat transcriptie factoren. Foxo3a en Stat5, de Stat transcriptie factor die door
Epo gestimuleerd wordt in erythroïde cellen (Figuur 5), werken dus mogelijk
samen in de transcriptie van Cited2. We konden inderdaad aantonen dat Foxo3a
en Stat5 een gezamenlijk transcriptioneel complex vormen na behandeling van
de cellen met Epo (Hoofdstuk 4). Ook werd aangetoond dat gelijktijdige activatie
van Stat5 en Foxo3a een maximale transcriptie geeft van het Cited2 gen
(Hoofdstuk 4). Zowel Epo behandeling van voorloper-rode bloedcellen als
activatie van Foxo3a, laten binnen korte tijd (2 uur) een verhoogde mRNA
synthese van Cited2 zien. Daarom denken we dat het Stat5/Foxo3a complex de
mRNA synthese van Cited2 stimuleert door direct aan de Cited2 promoter te
binden. Verder onderzoek moet uitwijzen of deze hypothese juist is en welk DNA
element in de Cited2 promoter hierbij betrokken is.
Conclusies
De PI3K/PKB/Foxo3a signaal route speelt een belangrijke rol in de regulatie van
de balans tussen expansie en differentiatie van voorloper-rode bloedcellen.
Tijdens expansie wordt Foxo3a geïnactiveerd door maximale activatie van de
PI3K/PKB signaal route door de aanwezigheid van Epo en SCF. Tijdens
differentiatie neemt de activiteit van de PI3K/PKB route af doordat alleen Epo
aanwezig is. Dit heeft tot gevolg dat Foxo3a geactiveerd wordt. Foxo3a versnelt
vervolgens de differentiatie door stimulatie van eiwit methylering via transcriptie
van Btg1, maar ook door het remmen van de celdeling via transcriptie van p27KIP
en Cyclin G2. Ook is er bewijs gevonden dat Foxo3a transcriptie van een aantal
genen stimuleert in samenwerking met Stat5. Dit gebeurt in de aanwezigheid van
Epo en is aangetoond voor het Foxo3a/Sta5 target gen Cited2. De functionele rol
van de transcriptionele cooperatie van Foxo3a en Stat5 is echter nog onbekend.
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Verklarende woordenlijst
Hemopoïese ontstaan van alle bloedcellen uit de bloed stamcel
Erythropoïese ontstaan van rode bloedcellen uit de voorloper-rode bloedcel
Erythroblast voorloper-rode bloedcel
Differentiëren uitrijpen van een voorlopercel (uiteindelijk in een functionele 
bloedcel)
Erythroïde expansie vermeerdering van voorloper-rode bloedcellen
Epo (Erythropoïetin) groeifactor specifiek voor de rode bloedcellen
SCF (Stamcel factor) algemene groeifactor, ook voor rode bloedcellen
Corticosteroïden bepaald type hormoon waarvan bekend is dat het de expansie
van erythroblasten stimuleren
Ribosomen eiwitcomplex dat zorgt voor de synthese van eiwitten
Cytoplasma cel-inhoud (zonder de celkern)
Genoom al het DNA in de celkern
DNA erfelijk materiaal, aanwezig in de celkern
Basen Bouwstenen van het DNA (ATGC)
Gen DNA dat informatie bevat voor een eiwit
promoter DNA DNA gelegen vóór het coderende DNA van een gen (nodig 
voor de activativering van transcriptie)
mRNA kopie van gen dat nodig is voor de synthese van het eiwit
Transcriptie kopiëren van gen in mRNA
Transcriptiefactor eiwit betrokken bij de transcriptie van een gen 
Translatie Synthetiseren van een specifiek eiwit aan de hand van een 
specifiek mRNA
Kinase eiwit dat fosfaatgroepen koppelt aan andere eiwitten
Fosforylatie het proces waarbij een kinase een fosfaatgroep koppelt aan 
een ander eiwit
Receptor eiwit dat door de celmembraan heen, contact heeft met de 
omgeving buiten de cel
Signaal route het omzetten van een signaal afkomstig van buiten de cel, in 
een cellulaire respons (signaal wordt doorgegeven m.b.v. 
eiwitten).
Btg1 (cursief) hiermee wordt het Btg1 gen bedoeld
Btg1 (niet-cursief) hiermee wordt het Btg1 eiwit bedoeld
Inleiding op, en samenvatting van de behaalde resultaten
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Abbreviations
Abbreviations
1 h 1 hour
1' one minute
1" 1 second
4OHT 4-hydroxy-tamoxifen
aa amino acids
Apro2 Antiproliferative protein 2
ATF1 Activating transcription factor 1
BFUE Burst forming unit-erythroid
bp base pair
Btg1 B-cell translocation gene 1
cAMP Cyclic-adenosine-monophosphate
CBP CREB-binding protein
CFUE Colony forming unit-erythroid
CFUS Colony forming Unit-spleen assay
Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2
CREB Cyclic AMP response element binding protein
Dex Dexamethasone
DNA Deoxyribonucleic acid
eIF4E Eukaryotic initiation factor 4E
Epo Erythropoietin
EpoR Epo-receptor
Foxo Forkhead transcription factors subclass O
Gab-1 Grb-2 associated binding protein-1 
Jak Janus kinase
kD kilo dalton
MTA 5'-deoxy-5'-methylthioadenosine
PDK1 Phosphoinositide-dependent kinase-1
PH pleckstrin homology
PI3K phosphatidylinositol-3-kinase
PIP3 PI-3,4,5-phosphate
PKA Protein kinase A
PKB Protein kinase B
PTEN Phosphatase and tensin homolog
SCF Stem cell factor
SD standard deviation
SH2 Src homology 2
SHIP SH2-domain-containing inositol phosphatases
SOCS Suppressor of cytokine signaling
Stat Signal transducer and activator of transcription
wt wild-type
abbr-cv-pub-dank.qxd  29-Nov-04  11:09  Page 156
Curriculum vitae
The author of this thesis was born on the 4th of February 1976 in Delft, The
Netherlands. In 1993 he graduated from high school (HAVO) at the
"Gereformeerde Scholengemeenschap" in Rotterdam. The same year he started
his training as a technician in biotechnology at the Hoger Laboratorium Onderwijs
in Delft. He received his degree in 1998 after completing a graduation project on
biochemical analysis of cross talk between the Rac and Rho pathways. This
research was performed under the supervision of Dr. Frank van Leeuwen in the
group of John Collard at the Netherlands Cancer Institute. In 1997 he joined the
post-HBO program for Biology at the University of Leiden were he specialized on
Molecular/Cellular Biology. During this period, he constructed and analyzed a
heme-deficient yeast strain with the aim to screen for anaerobic regulated genes
in the yeast Saccharomyces cerevisiae under supervision of Drs. José ter Linde
in the lab of Dr.ir. Yde Steensma at the Institute of Molecular Plant Sciences,
University of Leiden. Another research study involved the isolation of Manganese
oxidizing proteins, a project supervised by Drs. Geert-Jan Brouwers in the lab of
Prof.dr. Peter Westbroek at the Gorlaeus Laboratory, section of Geobiochemistry,
at the University of Leiden. After obtaining his master of science degree in
Molecular/Cellular Biology at the University of Leiden, he continued to work at the
Geobiochemistry section were he participated in a project funded by industry to
perform large scale isolation of iron-oxidizing protein complexes from the fresh-
water bacterium Leptothrix discophora. This project was performed under
supervision of Dr. Elizabeth de Vrind-de Jong. In arpil 2000 he started the
research described in this thesis. This research was performed at the department
of Hematology of the Erasmus Medical Center in the lab of Prof.dr. Bob
Löwenberg and supervised by Dr. Marieke von Lindern.
157
Curriculum vitae
abbr-cv-pub-dank.qxd  29-Nov-04  11:09  Page 157
Publication list
Kolbus A, Blazquez-Domingo M, Carotta S, Bakker WJ, Luedemann S, von Lindern M, Steinlein P,
Beug H. Cooperative signaling between cytokine receptors and the glucocorticoid receptor in the
expansion of erythroid progenitors: molecular analysis by expression profiling. Blood. 2003;102:3136-
3146
Bakker WJ, Blazquez-Domingo M, Kolbus A, Besooyen J, Steinlein P, Beug H, Coffer PJ, Lowenberg
B, Von Lindern M, Van Dijk TB. Foxo3a regulates erythroid differentiation and induces BTG1, an
activator of protein arginine methyl transferase 1. J Cell Biol. 2004;164:175-184
Bakker WJ, Martine Parren-van Amelsvoort, Andrea Kolbus, Peter Steinlein, Hartmut Beug, Bob
Löwenberg, Marieke von Lindern. Regulation of Foxo3 target genes in erythropoiesis: cooperation of
Foxo3a with Stat5 in the regulation of cited2 expression. In preparation. 
Bakker WJ., van Dijk T, Parren-Van Amelsvoort M, von Lindern M. FoxO3a and the cyclic AMP
pathway regulate BTG1 expression in erythroid differentiation. Submitted.
Bakker, W. J. and Marieke von Lindern. Control of Erythropoiesis by the PI3K/PKB pathway. Review.
In preparation (contains parts of the Introduction and General Discussion).
Publication list
158
abbr-cv-pub-dank.qxd  29-Nov-04  11:09  Page 158
Dankwoord
Zo'n vier-en-een-half-jaar heb ik met heel veel plezier op de afdeling
Hematologie gewerkt. Omdat daar met dit proefschrift een einde aan komt wil ik
eigenlijk iedereen bedanken voor de prettige werksfeer op de afdeling. De
openheid en behulpzaamheid heb ik erg gewaardeerd.
Een aantal mensen wil ik graag in het bijzonder bedanken. Allereerst
natuurlijk Marieke. Bedankt voor je enthousiasme, betrokkenheid, positiviteit en
het feit dat ik altijd bij je kon komen binnen lopen. Ik heb veel geleerd. Niet alleen
over erythropoïese, maar ook van de periode in Wenen, het EU-
trainingsnetwerk, het schrijven van aanvragen en dat samenwerken loont.
Bedankt voor de waardevolle tijd!
Ook wil ik mijn promoter Bob Löwenberg bedanken. Met name voor het
promoten van het afronden van het proefschrift, maar ook voor de getoonde
belangstelling gedurende het project. Naast mijn promotoren wil ik de overige
leden van de kleine commissie, Ivo Touw, Sjaak Philipsen en Paul Coffer
bedanken voor de tijd die zij hebben vrijgemaakt voor het beoordelen van het
proefschrift, zoals ook de overige commissie leden, Ruud Delwel, Hartmut Beug
en Jan Trapman. Ivo, bovendien bedankt voor je waardevolle kritieken waardoor
aanvragen, papers en presentaties scherper werden. Also Paul and Hartmut for
the possibility to use their valuable tools (Foxo3a(A3):ER and gene-array
facilities, respectively).
Thamar, samen zijn we begonnen aan het Foxo-project wat misschien
niet altijd even vlot verliep maar wel tot leuke resultaten heeft geleid. Mede door
jou kennis en Utrecht verleden, waardoor we telkens weer de nieuwste Foxo
constructen voorradig hadden, zijn er leuke dingen uitgerold. Bedankt! Mede
lotgenoot Emile bedankt voor de collegialiteit. Het was plezierig samenwerken,
mede door de voor een AIO broodnodige ontspanning in de vorm van Binas-
quizen, ijsbrekers en hele flauwe grappen. Martine, bedankt voor je inzet
gedurende de anderhalf jaar dat we samenwerkten. Door jouw ervaring kon
hoofdstuk vier echt goed geworden. Die nauwgezetheid zal mij de 19e met jou als
paranimf ook goed van pas komen. I also want to thank the translation team.
Montse, your RNA handling and QPCR skills were really helpful. Godfrey, Good
luck with your translation targets. I hope you will survive the wintertime in your
SHIP3. Lambo, bedankt voor je pirouettes aan de Von Lindern Boulevard. 
Ook de Touw-groep (Gert-Jan (GJ), Marijke, Stefan (ook voor de leuke
rondreis in Californië), Alexandra, Onno, Judith, Astrid, Claudia, Karishma, Bart
en Mahban) wil ik bedanken voor hun prettige rol als 'buren', het snoep, maar ook
voor de werkbesprekingen met af en toe taart.
De zeer gewaardeerde kamergasten Bart en Roel, bedankt voor de
koffie-praat. Bart speciaal voor zijn levens- en labwijsheid, Roel voor rustieke
muziek en het af en toe mogen zitten op de gouden stoel. Ook de muzikale
uitspattingen met de 'boys from next door' (Erik en GJ) waren goed.
I also appreciated the soccer games and tournements with the
bloodsoccers a lot. This is for sure one of the things I am going to miss. Thanks
guys!
159
Dankwoord
abbr-cv-pub-dank.qxd  29-Nov-04  11:09  Page 159
Roy, het was een leuke tijd in Wenen die ook goede resultaten heeft opgeleverd.
Het mag een wonder heten dat we niks over hebben gehouden aan het met de
hand corrigeren van een veelvoud van 17K spots!
FANX as well:
GJ, Meri, Karola en Elwin for help during the preparation of the thesis.
Ruud en Lianne voor het vormen van een leuke labdag-commissie.
Peter, Ivo, Bob, Ruud en Marieke het supporten van aanvragen.
Freek voor het vinden van een potentiële Stat5 site in de Cited2 promoter.
Johan voor het produceren van een drietal geweldige covers! Kunnen we nu toch
spreken van een eerste bureau BAkkerman produktie.
Antonie, dat jij paranimf wilt zijn is voor mij een bevestiging van onze chronische
vriendschap die ik nog altijd zeer waardeer! We moeten nog maar eens een
plaatje draaien onder het genot van een wijntje.
En al was de Frisse lucht de eerste keren even wennen, het Ardennen weekend
staat inmiddels bovenaan als het gaat om de jaarlijkse festiviteiten lijst. Het is
ieder jaar weer feest om het werkleven te verruilen voor de jungle die de
Ardennen heet. Ik (we)  zal (zullen) dat/jullie zeker missen!
De afgelopen jaren maak ik ook op bescheiden wijze deel uit van de Kwanten-
mechanica. Het was altijd jammer om de buitenrust-gezelligheid achter te
moeten laten en weer terug te reizen naar de betonnen stad, al was het wel altijd
met frisse tegenzin. Bedankt voor de pret en goede zorgen!
Pa en Ma, jullie bedanken is onbegonnen werk. Het lijkt gewoon maar jullie
meeleven, betrokkenheid is toch wel bijzonder. Ook de afgelopen jaren waren
daarop geen uitzondering, en dat zal nog wel even zo blijven denk ik. Dank
daarvoor! (Pa ook nog voor het fungeren als proefkonijn voor het testen van de
leesbaarheid van de NL samenvatting). Aafke, Martijn, Rianne, Juul, Jappert, Lau
en Wouter, ik hoop jullie de komende jaren zo af en toe te blijven zien. We zien
wel hoe.
Ten slotte Frederike. Trouwen met jou blijft absoluut mijn allerbeste resultaat. Ik
heb veel van je geleerd en je bent al vanaf het begin onmisbaar! Je hebt me
regelmatig moeten afstaan aan het werk, die ruimte en je steun heb ik erg
gewaardeerd. Net zoals je doortastendheid als het gaat om het regelen van onze
Canada plannen. Ik heb veel zin om ons gezamenlijke avontuur in Toronto voort
te zetten!
Walbert
160
Dankwoord
abbr-cv-pub-dank.qxd  29-Nov-04  11:09  Page 160
